# 2025年12月18日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. IMPROVE-DiCE：一项两部分、开放标签、2a期临床试验，评估Ninerafaxstat在心脏代谢综合征患者中的安全性和有效性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41410037)
**期刊：** Circulation
**PMID：** 41410037
**DOI：** 10.1161/CIRCULATIONAHA.125.074041

### 第一部分 原文与翻译

**英文原标题：** IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.

> **英文摘要：**
> BACKGROUND: We report IMPROVE-DiCE (Improve Diabetic Cardiac Energetics), a 2-part open-label, phase 2a trial evaluating the safety and effectiveness of ninerafaxstat, a novel therapeutic designed to enhance cardiac energetics. Between May and September 2021, part 1 enrolled patients with type 2 diabetes and obesity without heart failure with preserved ejection fraction (HFpEF). Between January 2023 and June 2024, part 2 enrolled patients with type 2 diabetes, obesity, and HFpEF.
> 
> METHODS: Forty-two participants received 200 mg ninerafaxstat twice daily (part 1, n=21, 43% women, 72±0.5 years of age, 4-8 weeks; part 2, n=21, 29% women, 71±6 years of age, 12 weeks). Myocardial energetics (phosphocreatine-to-ATP ratio [PCr/ATP], primary outcome) and function (rest and dobutamine stress) were assessed before and after treatment using magnetic resonance imaging, P- and H magnetic resonance spectroscopy. In part 1, hyperpolarized [1-C]pyruvate magnetic resonance spectroscopy to assess in vivo pyruvate dehydrogenase flux (n=9) and plasma metabolomics and proteomics were also performed.
> 
> RESULTS: In part 1, in patients with diabetes and obesity but without HFpEF, the heart was characterized by impaired pyruvate dehydrogenase flux, reduced PCr/ATP, triglyceride deposition, and diastolic impairment. Treatment with ninerafaxstat was associated with improved PCr/ATP (+0.39±0.49 [95% CI, 0.16-0.62]; Cohen's , 0.79; =0.002) and lower myocardial triglyceride (by 34%, =0.03). In part 2, in patients with diabetes, obesity, and symptomatic HFpEF, the heart was characterized by reduced PCr/ATP, diastolic impairment, and failure of systolic augmentation to exercise. Consistently, treatment with ninerafaxstat was associated with improvement in PCr/ATP (+0.15±0.25 [95% CI, 0.03-0.26]; Cohen's , 0.60; =0.02), improved systolic augmentation to exercise (+1.4 L/min, =0.04), improved exercise capacity (6-minute walk distance +16 m, =0.02), and improved New York Heart Association class symptom burden.
> 
> CONCLUSIONS: These mechanistic phase 2a study results show that ninerafaxstat is safely tolerated and improves myocardial energetics in participants with obesity and diabetes without or with clinically manifest HFpEF.
> 
> REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT04826159.
> DOI: 10.1161/CIRCULATIONAHA.125.074041

> **中文摘要：**
> 背景：本研究报告IMPROVE-DiCE（改善糖尿病心肌能量代谢）试验结果。这是一项分为两部分的开放标签2a期临床试验，旨在评估旨在增强心肌能量代谢的新型治疗药物Ninerafaxstat的安全性和有效性。2021年5月至9月，第1部分纳入患有2型糖尿病和肥胖但无射血分数保留型心力衰竭（HFpEF）的患者。2023年1月至2024年6月，第2部分纳入患有2型糖尿病、肥胖及伴随HFpEF的患者。
> 
> 方法：共42名受试者每日两次口服200 mg Ninerafaxstat（第1部分n=21，女性43%，年龄72±0.5岁，疗程4–8周；第2部分n=21，女性29%，年龄71±6岁，疗程12周）。在治疗前后，通过磁共振成像及磷、氢磁共振波谱评估心肌能量状态（磷酸肌酸/ATP比值[PCr/ATP]，主要终点）及心肌功能（静息及多巴酚丁胺负荷）。第1部分中，还采用高极化[1-C]丙酮酸磁共振波谱评估体内丙酮酸脱氢酶通量（n=9），并进行血浆代谢组学与蛋白质组学分析。
> 
> 结果：在第1部分（糖尿病与肥胖但无HFpEF的患者）中，心脏表现为丙酮酸脱氢酶通量受损、PCr/ATP降低、三酰甘油沉积及舒张功能障碍。Ninerafaxstat治疗与PCr/ATP改善相关（+0.39±0.49 [95% CI, 0.16–0.62]; Cohen’s d=0.79; p=0.002），并伴随心肌三酰甘油显著降低（降低34%；p=0.03）。在第2部分（糖尿病、肥胖及有症状性HFpEF患者）中，心脏表现为PCr/ATP降低、舒张功能障碍及运动时收缩储备不足。Ninerafaxstat治疗同样与PCr/ATP改善相关（+0.15±0.25 [95% CI, 0.03–0.26]; Cohen’s d=0.60; p=0.02），并改善运动时收缩反应（+1.4 L/min; p=0.04）、提高运动耐力（6分钟步行距离+16 m; p=0.02），且改善纽约心脏病学会分级症状负担。
> 
> 结论：这项机制学2a期研究结果显示，Ninerafaxstat耐受性良好，能够改善糖尿病与肥胖患者（无论是否伴随HFpEF）心肌能量代谢功能。
> 
> 注册信息：URL：https://clinicaltrials.gov；注册号：NCT04826159。

### 第二部分 AI 大师评价

该研究是一项分为两阶段的机制学2a期临床试验，系统评估了Ninerafaxstat在糖尿病伴肥胖及伴或不伴HFpEF患者中的安全性与疗效。研究采用磁共振能谱学、多巴酚丁胺负荷及代谢组学综合评估心肌能量状态与功能，显示Ninerafaxstat可显著改善PCr/ATP比值、减少心肌脂质沉积并提升运动能力。其创新性在于明确揭示了药物调节心肌能量代谢的潜力。尽管样本量较小且随访时间有限，但结果为代谢性心肌功能障碍的新型治疗策略提供了重要依据。

---

## 2. 内皮转录因子EB可防止多柔比星诱导的内皮毒性及心脏功能障碍

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41410033)
**期刊：** Circulation
**PMID：** 41410033
**DOI：** 10.1161/CIRCULATIONAHA.124.071774

### 第一部分 原文与翻译

**英文原标题：** Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction.

> **英文摘要：**
> BACKGROUND: Doxorubicin (DOX), an effective chemotherapeutic drug for various cancers, has been demonstrated to induce cardiovascular toxicity in cancer survivors. Endothelial cell (EC) dysfunction is recognized to play a critical role in the onset and severity of cardiotoxicity associated with DOX. TFEB (transcription factor EB), a master regulator of autophagy and lysosome biogenesis, regulates cardiovascular homeostasis. In the present study, we aimed to test whether endothelial TFEB protects against EC damage and alleviates cardiac dysfunction induced by DOX treatment.
> 
> METHODS: EC-specific TFEB transgenic mice, EC-specific TFEB knockout mice, and their corresponding littermate controls were administered DOX intravenously. Survival curves were generated, and cardiac functions were measured in mice. The effects of TFEB on mitochondrial reactive oxygen species production, autophagic flux, and apoptosis were evaluated in human and mouse cardiac microvascular ECs treated with DOX. RNA sequencing, single-cell RNA sequencing, and chromatin immunoprecipitation with quantitative polymerase chain reaction was performed to dissect molecular mechanisms in DOX-treated ECs in vitro and in vivo. Mice with endothelium-specific deficiency of DAB adaptor protein 2 () were subjected to measurement of cardiac function and fibrosarcoma growth under DOX treatment.
> 
> RESULTS: EC-specific TFEB transgenic mice showed significantly reduced mortality and improved cardiac function, together with attenuation of perivascular fibrosis after DOX treatment. By contrast, EC-specific TFEB knockout exacerbated DOX-induced cardiac dysfunction in mice. Furthermore, we observed that TFEB enhanced autophagy and reduced oxidative stress in cardiac microvascular ECs treated with DOX. In addition, TFEB preserved EC barrier integrity, alleviated proinflammatory cytokine release from cardiac microvascular ECs, and maintained the EC-cardiomyocyte communication, contributing to the protective effects of EC TFEB on cardiomyocyte function. Mechanistically, DAB2, a clathrin- and cargo-binding endocytic adaptor protein, was identified as a TFEB target gene in ECs. Accordingly, DAB2 knockdown attenuated the inhibitory effects of TFEB on apoptosis and the secretion of proinflammatory cytokines from cardiac microvascular ECs. In vivo, EC-specific  deficiency abolished the protective effect of EC TFEB on DOX-induced cardiac dysfunction.
> 
> CONCLUSIONS: Taken together, endothelial TFEB protects against EC damage and cardiac dysfunction, constituting a potential target for treating cardiotoxicity induced by DOX. Our study provides new mechanistic insights into cardiotoxicity associated with chemotherapy.

> **中文摘要：**
> 背景：多柔比星（DOX）是一种对多种癌症具有疗效的化疗药物，但已被证实可在癌症幸存者中诱发心血管毒性。内皮细胞（EC）功能障碍被认为在DOX相关心脏毒性的发生和严重程度中起关键作用。TFEB（转录因子EB）作为自噬和溶酶体生物发生的主调控因子，可调节心血管稳态。本研究旨在探讨内皮TFEB是否可防止EC损伤并减轻DOX治疗引起的心脏功能障碍。
> 
> 方法：研究中采用了内皮特异性TFEB转基因小鼠、内皮特异性TFEB敲除小鼠及相应同窝对照小鼠，并通过静脉注射给予DOX。绘制生存曲线并测定小鼠的心脏功能。在经DOX处理的人及小鼠心脏微血管内皮细胞中，评估TFEB对线粒体活性氧生成、自噬通量及细胞凋亡的影响。通过RNA测序、单细胞RNA测序及染色质免疫沉淀结合定量PCR分析DOX处理后EC体内外的分子机制。对于内皮特异性缺失DAB衔接蛋白2的小鼠，在DOX治疗下评估其心脏功能及纤维肉瘤生长。
> 
> 结果：内皮特异性TFEB转基因小鼠在DOX治疗后显示显著降低的死亡率和改善的心脏功能，同时伴随血管周围纤维化的减轻。相反，内皮特异性TFEB敲除加重了小鼠的DOX诱导心脏功能障碍。此外，研究发现TFEB在DOX处理的心脏微血管内皮细胞中增强了自噬并减少了氧化应激。同时，TFEB维持了EC屏障完整性，缓解了心脏微血管内皮细胞的促炎细胞因子释放，并保持了EC与心肌细胞间的通讯，从而促进EC-TFEB对心肌细胞功能的保护作用。在机制上，DAB2（一种能够结合网格蛋白及货物的内吞衔接蛋白）被确认为TFEB在内皮细胞中的下游靶基因。相应地，DAB2的敲低削弱了TFEB在心脏微血管内皮细胞中对凋亡及促炎细胞因子分泌的抑制作用。体内实验中，内皮特异性DAB2缺失消除了EC-TFEB对DOX诱导心脏功能障碍的保护作用。
> 
> 结论：综上所述，内皮TFEB可防止内皮细胞损伤及心脏功能障碍，构成治疗DOX诱导心脏毒性的潜在靶点。本研究为化疗相关心脏毒性提供了新的机制性见解。

### 第二部分 AI 大师评价

该研究聚焦于转录因子TFEB在防护多柔比星（DOX）诱导心血管毒性中的作用。研究者通过内皮特异性转基因与敲除小鼠模型、细胞及分子层面的多维度实验，揭示了TFEB通过增强自噬、抑制氧化应激和炎症反应从而维持心脏微环境稳定。发现DAB2为TFEB新颖的下游靶基因，深化了对化疗相关心肌损伤机制的理解。该研究创新性地指出内皮TFEB-自噬轴在抗心脏毒性中的关键作用，但未来仍需评估其在人类中的可转化潜力。

---

## 3. 放射增强剂NBTXR3：连接物理与生物学以改善放射治疗效果并激发抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408568)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41408568
**DOI：** 10.1186/s13046-025-03579-1

### 第一部分 原文与翻译

**英文原标题：** The radioenhancer NBTXR3: bridging physics and biology to improve radiotherapy outcomes and prime anti-tumor immunity.

> **英文摘要：**
> Radiotherapy remains a cornerstone in cancer treatment, used in over 50% of cases. It employs ionizing radiation, primarily X-rays, to target and destroy tumors through direct DNA damage and indirect effects via reactive oxygen species. Despite technological advancements improving precision of the delivered dose to the tumor, radiotherapy faces critical challenges, particularly damage to healthy tissues, which limits the maximum safe dose. Recent years have seen significant improvements in radiation delivery, including advanced imaging for real-time tumor tracking and combinations with immunotherapy. However, the need for innovative strategies to enhance radiotherapy's therapeutic index remains essential. The radioenhancer NBTXR3 could represent a solution in addressing these limitations. This nanotechnology has been designed to amplify radiotherapy's effects within tumors without increasing toxicity in non-injected adjacent healthy tissues. Beyond better cancer cell destruction and tumor control, radiotherapy-activated NBTXR3 nanoparticles can also stimulate systemic antitumor immune responses in preclinical models. This review aims to provide a comprehensive analysis of preclinical research on NBTXR3, focusing on its mechanism of action and role in initiating and enhancing antitumor immune responses.

> **中文摘要：**
> 放射治疗仍然是癌症治疗的基石，应用于超过50%的病例中。它利用电离辐射，主要是X射线，通过直接的DNA损伤以及活性氧物质的间接效应来靶向并摧毁肿瘤。尽管技术进步提高了放射剂量递送到肿瘤的精确性，但放疗仍面临重要挑战，特别是对健康组织的损伤，这限制了可安全使用的最大剂量。近年来，放射递送技术取得了显著进步，包括用于实时肿瘤追踪的先进成像技术，以及与免疫治疗的联合应用。然而，提高放疗治疗指数的创新策略仍然是必需的。放射增强剂NBTXR3可能在解决这些局限性方面提供一种解决方案。这项纳米技术旨在增强放疗在肿瘤内的作用，而不会增加未注射的邻近健康组织的毒性。除了更有效地破坏癌细胞和控制肿瘤外，经放疗激活的NBTXR3纳米颗粒还能够在临床前模型中刺激系统性抗肿瘤免疫反应。本综述旨在全面分析NBTXR3的临床前研究，重点关注其作用机制及其在启动和增强抗肿瘤免疫反应中的作用。

### 第二部分 AI 大师评价

本文综述探索了纳米放射增强剂NBTXR3在放射治疗中的机制及其免疫激活潜力。研究聚焦于该材料如何在肿瘤局部放疗时增强效应，同时维持健康组织安全性。该综述的创新点在于将物理能量放大与免疫调控结合，为放疗与免疫治疗的协同提供新思路。尽管临床前结果令人鼓舞，但未来仍需验证其在不同肿瘤类型和临床环境中的长期疗效与安全性。

---

## 4. Raptor 和 GLI1 作为 USP37 底物的鉴定揭示其在髓母细胞瘤细胞中的情境特异性功能。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408466)
**期刊：** Oncogene
**PMID：** 41408466
**DOI：** 10.1038/s41388-025-03651-2

### 第一部分 原文与翻译

**英文原标题：** Identification of Raptor and GLI1 as USP37 substrates highlight its context-specific function in medulloblastoma cells.

> **英文摘要：**
> The USP37 gene encodes a deubiquitylase (DUB), which catalyzes the proteolytic removal of ubiquitin moieties from proteins to modulate their stability, cellular localization or activity. Its expression is downregulated in a subgroup of medulloblastomas driven by constitutive activation of sonic hedgehog (SHH) signaling. Patients with SHH-driven medulloblastomas with elevated expression of the RE1 silencing transcription factor (REST) and reduced expression of USP37 have poor outcomes. In previous studies, we showed sustained proliferation of SHH-medulloblastoma cells due to blockade of terminal cell cycle exit and neuronal differentiation stemming from a failure in USP37-dependent stabilization of its target, the cyclin-dependent kinase inhibitor (CDKI)-p27. This finding suggested a tumor suppressive function for USP37. Interestingly, the current study also uncovered Raptor, a component of the mTORC1 complex, as a novel target of USP37. Under conditions of low-USP37 expression, reduced Raptor stability and mTORC1 activity caused a decline in phosphorylation of 4E-binding protein 1 (4EBP1) and increased its interaction with eukaryotic elongation factor 4E (eIF4E), which is known to inhibit CAP-dependent translation initiation. Surprisingly, a subset of patients with SHH-driven medulloblastomas with elevated expression of USP37 and the Glioma-associated Oncogene 1 (GLI1), also exhibited poor outcomes. Using genetic and biochemical analyses, we showed that USP37-mediated stabilization of GLI1, a terminal effector of SHH signaling, increases pathway activity and upregulates expression of its target oncogene product, CCND1, to drive cell proliferation. These data indicate that USP37 elevation in SHH-driven medulloblastomas has the potential to promote non-canonical activation of SHH signaling. Overall, our findings suggest that USP37 may have context-specific oncogenic and tumor suppressive roles in medulloblastoma cells.

> **中文摘要：**
> USP37 基因编码一种去泛素化酶（DUB），该酶可催化从蛋白质上去除泛素基团，从而调节其稳定性、细胞定位或活性。在由声波刺猬（SHH）信号持续激活驱动的髓母细胞瘤亚群中，其表达被下调。在具有高表达 RE1 沉默转录因子（REST）且 USP37 表达降低的 SHH 驱动型髓母细胞瘤患者中，预后较差。在以往研究中，我们发现 SHH 型髓母细胞瘤细胞由于阻断末端细胞周期退出及神经分化，而出现持续增殖，该现象源于 USP37 依赖性靶蛋白——细胞周期依赖性激酶抑制因子（CDKI）p27 稳定化失败。该结果提示 USP37 具有抑瘤功能。有趣的是，本研究进一步发现了 Raptor（mTORC1 复合物的组成部分）是 USP37 的新靶蛋白。在低 USP37 表达条件下，Raptor 稳定性及 mTORC1 活性降低，导致 4E 结合蛋白 1（4EBP1）磷酸化水平下降，并增强其与真核延伸因子 4E（eIF4E）的结合，从而抑制 CAP 依赖性翻译起始。令人意外的是，在另一部分 SHH 驱动的髓母细胞瘤患者中，USP37 与胶质瘤相关癌基因 1（GLI1）高表达也与不良预后相关。通过遗传学与生化分析，我们发现 USP37 介导的 GLI1（SHH 信号的末端效应因子）稳定化可增强通路活性，并上调其靶癌基因产物 CCND1 的表达，从而促进细胞增殖。这些数据表明，在 SHH 驱动的髓母细胞瘤中，USP37 的升高可能促进 SHH 信号的非经典激活。总体而言，我们的研究结果提示 USP37 在髓母细胞瘤细胞中可能同时具有情境特异性的促癌与抑癌作用。

### 第二部分 AI 大师评价

本研究聚焦于去泛素化酶 USP37 在髓母细胞瘤中的双重功能，通过整合遗传与生化实验，阐明其在不同分子背景下可分别稳定 p27 或 GLI1，从而呈现抑瘤或促瘤作用。作者首次鉴定 Raptor 为 USP37 新底物，提示其可通过调控 mTORC1 活性影响蛋白合成。研究揭示了 USP37 表达水平与 SHH 信号通路组分的复杂交互，具有重要理论与潜在治疗意义。其局限在于主要依赖细胞与模型系统验证，临床转化仍需进一步研究。

---

## 5. KRT81 通过作为 ezrin 的蛋白支架促进结直肠癌转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408465)
**期刊：** Oncogene
**PMID：** 41408465
**DOI：** 10.1038/s41388-025-03665-w

### 第一部分 原文与翻译

**英文原标题：** KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin.

> **英文摘要：**
> Metastasis to distant organs represents the most fatal prognostic factor for colorectal cancer (CRC). The distant metastasis of tumor cells results from the collaborative effort of multiple subcellular structures, with dynamic cytoskeletal remodeling underlying this entire process. Here, we found that knockdown of KRT81 expression (shKRT81) inhibited the proliferation, invasion, and migration, while ectopic overexpression of KRT81 enhanced the CRC cells migration. Furthermore, we identified a potential downstream effector of KRT81, ezrin, a member of the ezrin/radixin/moesin (ERM) protein family that regulates cell morphology and motility. Phenotypically, the shKRT81 attenuated ezrin protein expression and reduced the number and length of filopodia in CRC cells, which were restored when KRT81 was re-overexpressed. Mechanistically, KRT81 formed a complex with ezrin, and recruitment of ezrin to the membrane and phosphorylation at the Thr567 residue were significantly abolished in shKRT81 cells. Interestingly, we found that Myosin 1B (MYO1B) might provide the driving force for the recruitment of ezrin. Notably, combinatorial inhibition (shKRT81 + ezrin-specific inhibitor) exerted significantly greater suppression of CRC cell migration and invasion than either intervention alone. Consistently, KRT81 expression was increased in CRC, and relatively high expression of KRT81 was associated with a poor prognosis. In summary, we identified a novel regulatory axis that involves KRT81, MYO1B, and ezrin, which regulates filopodia formation and migration behavior in CRC. Therefore, KRT81 may serve as a therapeutic target for CRC.

> **中文摘要：**
> 远处器官的转移是结直肠癌（CRC）最致命的预后因素。肿瘤细胞的远处转移源于多种亚细胞结构的协同作用，而动态的细胞骨架重塑贯穿于整个过程。在本研究中，我们发现敲低 KRT81 表达（shKRT81）可抑制 CRC 细胞的增殖、侵袭和迁移，而异位过表达 KRT81 则增强了 CRC 细胞的迁移能力。此外，我们鉴定出 KRT81 的一个潜在下游效应分子 ezrin，它是调节细胞形态和运动的 ezrin/radixin/moesin (ERM) 蛋白家族成员。从表型上看，shKRT81 可减弱 ezrin 蛋白表达，并降低 CRC 细胞中丝状伪足的数量和长度，而当 KRT81 被重新过表达时，这些表型得以恢复。从机制上讲，KRT81 与 ezrin 形成复合物，此外，shKRT81 细胞中 ezrin 向膜的募集及其在 Thr567 残基处的磷酸化显著被抑制。有趣的是，我们发现肌球蛋白 1B（MYO1B）可能为 ezrin 的募集提供驱动力。值得注意的是，联合抑制（shKRT81 + ezrin 特异性抑制剂）对 CRC 细胞迁移和侵袭的抑制作用显著强于单独干预。与此一致，CRC 中 KRT81 表达水平升高，且高表达 KRT81 与较差的预后相关。总之，我们鉴定出一个包含 KRT81、MYO1B 和 ezrin 的新的调控轴，该轴调节 CRC 中丝状伪足的形成和迁移行为。因此，KRT81 可能成为 CRC 的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究旨在阐明 KRT81 在结直肠癌转移过程中的功能及其分子机制。研究通过基因敲低和过表达实验，结合表型观察与蛋白互作分析，揭示 KRT81 通过作为 ezrin 的蛋白支架促进细胞迁移与伪足形成。进一步发现 MYO1B 参与 ezrin 的募集，为该信号轴的动力提供支持。其创新点在于发现了 KRT81–MYO1B–ezrin 这一新的调控轴，为结直肠癌转移的分子机制提供了新见解，并提示 KRT81 可能成为潜在治疗靶标。研究局限在于机制验证主要基于细胞实验，临床样本和动物验证尚有限。

---

## 6. MDC1 抑制复制叉反转并介导 BRCA1/2 缺陷肿瘤的化疗敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408464)
**期刊：** Oncogene
**PMID：** 41408464
**DOI：** 10.1038/s41388-025-03659-8

### 第一部分 原文与翻译

**英文原标题：** MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors.

> **英文摘要：**
> MDC1 is a key protein in DNA damage signaling. When DNA double-strand breaks (DSBs) occur, MDC1 localizes to the sites of DNA damage to promote the recruitment of other factors, including the 53BP1-mediated DSB repair pathway. By studying mechanisms of poly (ADP-ribose) polymerase inhibitor (PARPi) resistance in BRCA2; p53-deficient mouse mammary tumors, we identified a thus far unknown role of MDC1 in replication fork biology. Our results show that MDC1 localizes at active replication forks during normal DNA replication and regulates replication fork progression. It suppresses spontaneous fork reversal and regulates fork nucleolytic processing thereby promoting sensitivity to PARPi and cisplatin. In this way, MDC1 loss improves DNA damage tolerance and causes chemoresistance in BRCA1/2-deficient cells. We demonstrate that limiting MRE11 activity abolishes the reduced fork speed while MRE11 inhibition/depletion overcomes PARPi resistance in these cells. Overall, our data provides new insights into the role of MDC1 in replication fork progression that mediates PARPi- and cisplatin-induced DNA damage, in addition to its role in DSB repair.

> **中文摘要：**
> MDC1 是 DNA 损伤信号传导中的关键蛋白。当 DNA 双链断裂（DSBs）发生时，MDC1 定位于损伤位点，以促进包括 53BP1 介导的 DSB 修复通路在内的其他因子的募集。通过研究 BRCA2 及 p53 缺陷小鼠乳腺肿瘤中多聚（ADP-核糖）聚合酶抑制剂（PARPi）耐药机制，我们发现了 MDC1 在复制叉生物学中的一个此前未知的作用。结果显示，MDC1 在正常 DNA 复制过程中定位于活跃的复制叉，并调控复制叉的延伸。它能抑制自发性的复制叉反转，并调节复制叉的核酸酶处理，从而促进对 PARPi 和顺铂的敏感性。由此，MDC1 的缺失增强了 DNA 损伤耐受性，并导致 BRCA1/2 缺陷细胞的化疗耐药。我们证明，通过限制 MRE11 的活性可以消除复制叉速度降低的现象，而抑制或去除 MRE11 可克服这些细胞对 PARPi 的耐药性。总体而言，我们的数据为 MDC1 在复制叉进程中所发挥的作用提供了新的见解，该作用不仅涉及 PARPi 和顺铂诱导的 DNA 损伤调控，也拓展了其在 DSB 修复中的已知功能。

### 第二部分 AI 大师评价

本研究揭示了 MDC1 在复制叉稳定性调控中的新功能，并阐明其在 BRCA1/2 缺陷肿瘤化疗敏感性中的关键作用。研究者通过小鼠模型解析 PARPi 耐药机制，发现 MDC1 可防止复制叉反转、调控核酸酶介导的加工，从而维持复制叉完整性。MDC1 缺失增强了 DNA 损伤耐受性，导致顺铂和 PARPi 的耐药，而抑制 MRE11 可逆转此效应。该研究创新性地扩展了 MDC1 在 DNA 修复网络中的生物学内涵，但仍需进一步研究其在临床耐药肿瘤中的普适性。

---

## 7. 释放在癌症中靶向血管紧张素 II 1 型受体的潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408463)
**期刊：** Oncogene
**PMID：** 41408463
**DOI：** 10.1038/s41388-025-03666-9

### 第一部分 原文与翻译

**英文原标题：** Unlocking the potential of targeting the angiotensin II type 1 receptor in cancer.

> **英文摘要：**
> The renin-angiotensin system is a key regulator of blood pressure homeostasis, with its primary effector, the angiotensin II type 1 receptor (AT1R), mediating vasoconstriction and processes fundamental to cancer progression, including proliferation, angiogenesis, and metastasis. Elevated AT1R expression is consistently linked to poor prognosis and therapeutic resistance across various malignancies. Preclinical studies provide compelling evidence that AT1R activation drives key cancer related processes, while its inhibition by angiotensin receptor blockers (ARBs) suppresses tumour growth, induces apoptosis, reduces angiogenesis, and inhibits metastasis across a wide range of cancer models. Critically, ARBs effectively modulate the tumour microenvironment (TME), alleviating fibrosis, promoting anti-tumour immune cell phenotypes, and enhancing the efficacy of targeted therapies, chemotherapies, and immunotherapies. Despite this strong preclinical evidence and supporting retrospective population studies, clinical translation of ARBs in oncology remains inconsistent, with trials often limited by design, patient heterogeneity, and supra-therapeutic ARB dosages required for acute anti-cancer effects. This review seeks to summarise the current understanding of AT1R's role in cancer, highlight preclinical and clinical investigations of targeting RAS, and suggest further strategies to unlock its therapeutic potential. Realising the full therapeutic promise of AT1R targeting in oncology requires a multifaceted approach, including the development of innovative delivery systems, such as TME-activated ARBs, and the exploration of advanced therapeutic modalities, such as antibody based AT1R inhibitors. Rigorously designed clinical trials that include biomarker-driven patient stratification to identify responsive cohorts are crucial to define the context-dependent role of AT1R and conclusively establish its clinical utility as a combinatorial strategy to enhance patient outcomes.

> **中文摘要：**
> 肾素-血管紧张素系统是血压稳态的关键调节者，其主要效应分子血管紧张素 II 1 型受体（AT1R）介导血管收缩以及对癌症进展至关重要的多种过程，包括增殖、血管生成和转移。AT1R 表达升高与多种恶性肿瘤的不良预后和治疗耐受性密切相关。临床前研究提供了有力证据，表明 AT1R 的激活推动与癌症相关的关键生物过程，而通过血管紧张素受体阻滞剂（ARBs）抑制 AT1R 则可抑制肿瘤生长、诱导凋亡、减少血管生成并抑制多种癌症模型中的转移。关键的是，ARBs 能有效调节肿瘤微环境（TME），缓解纤维化，促进抗肿瘤免疫细胞表型，并增强靶向治疗、化疗和免疫治疗的疗效。尽管有强有力的临床前证据以及回顾性人群研究支持，但 ARBs 在肿瘤学中的临床转化仍然不一致，临床试验常受到设计、患者异质性以及实现急性抗癌效应所需超治疗剂量的限制。本综述旨在总结当前对 AT1R 在癌症中作用的理解，突出针对肾素-血管紧张素系统（RAS）的临床前与临床研究，并提出进一步释放其治疗潜力的策略。要充分实现 AT1R 靶向治疗在肿瘤学中的潜能，需要多层次的综合方法，包括开发创新的药物递送系统（如肿瘤微环境激活的 ARBs）以及探索先进的治疗模式（如基于抗体的 AT1R 抑制剂）。同时，严格设计的临床试验，特别是通过生物标志物驱动的患者分层以识别响应性人群，对于明确 AT1R 的情境依赖性作用并确立其作为联合治疗策略以改善患者预后的临床价值至关重要。

### 第二部分 AI 大师评价

本文综述系统阐述了血管紧张素 II 1 型受体在癌症发生发展中的作用机制及治疗潜力，整合了大量临床前证据表明 ARBs 在多种癌症模型中具有抗肿瘤作用。作者还评估了肿瘤微环境调控、药物递送创新及抗体疗法等新方向的可行性，并指出当前临床转化受限于试验设计和异质性问题。该综述为今后基于生物标志物的精确分层治疗提供了重要思路，但其临床验证尚需高质量随机对照试验支持。

---

## 8. 用于卵巢癌的双靶点CAR-T疗法：协同靶向MSLN和B7H3增强抗肿瘤效应并克服抗原异质性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408462)
**期刊：** Oncogene
**PMID：** 41408462
**DOI：** 10.1038/s41388-025-03663-y

### 第一部分 原文与翻译

**英文原标题：** Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.

> **英文摘要：**
> Ovarian cancer (OC) remains a lethal malignancy with limited treatment options owing to antigen heterogeneity and an immunosuppressive tumor microenvironment (TME). Here, we designed a unique chimeric Antigen Receptor T-Cell (CAR-T) construct (B4M3) that integrates an anti-MSLN scFv linked to the CD3ζ activation domain and an anti-B7H3 scFv linked to the 4-1BB co-stimulatory domain. In vitro, B4M3 CAR-T cells exhibited robust cytotoxicity against OC cell lines with enhanced degranulation (CD107a) and efficient tumor cell killing, even at low effector-to-target ratios. In vivo, B4M3 CAR-T cells significantly inhibited tumor growth and prolonged survival and demonstrated superior tumor infiltration and persistence in OC xenograft models. Imaging mass cytometry (IMC) revealed that B4M3 treatment reshaped the TME, increased cytotoxic T lymphocyte (CTL) infiltration, and reduced regulatory T cells (Tregs). Mechanistically, B4M3 therapy upregulated TGF-β, promoting Th17 differentiation and CTL recruitment, thereby enhancing anti-tumor immunity. Our findings demonstrate that B4M3 CAR-T cells effectively address antigen heterogeneity and enhance therapeutic efficacy in OC, thereby offering a promising strategy for solid tumor immunotherapy.

> **中文摘要：**
> 卵巢癌（OC）由于抗原异质性和免疫抑制性肿瘤微环境（TME），仍是一种致命的恶性肿瘤，且治疗手段有限。在本研究中，我们设计了一种独特的嵌合抗原受体T细胞（CAR-T）构建体（B4M3），该构建体将抗MSLN的单链可变片段（scFv）与CD3ζ活化结构域连接，并将抗B7H3的scFv与4-1BB共刺激结构域连接。在体外实验中，B4M3 CAR-T细胞对卵巢癌细胞系表现出强烈的细胞毒性，伴随增强的脱颗粒作用（CD107a表达增加）和高效的肿瘤细胞杀伤作用，即使在低效靶比下亦能维持效应。在体内实验中，B4M3 CAR-T细胞显著抑制肿瘤生长并延长生存期，同时在卵巢癌异种移植模型中表现出更强的肿瘤浸润能力和持久性。成像质谱流式细胞术（IMC）显示，B4M3治疗可重塑肿瘤微环境，增加细胞毒性T淋巴细胞（CTL）浸润，降低调节性T细胞（Tregs）比例。在机制上，B4M3治疗上调TGF-β表达，促进Th17细胞分化及CTL募集，从而增强抗肿瘤免疫反应。我们的研究结果表明，B4M3 CAR-T细胞可有效应对抗原异质性并显著提升卵巢癌治疗效能，为实体瘤免疫治疗提供了有前景的策略。

### 第二部分 AI 大师评价

该研究通过构建双靶点CAR-T细胞（B4M3），协同靶向MSLN与B7H3，旨在克服卵巢癌的抗原异质性与免疫抑制微环境。体内外实验验证了B4M3的强效细胞毒性与持久抗肿瘤活性，并证实其可显著改善肿瘤浸润与免疫环境。机制研究揭示了B4M3通过TGF-β上调促进Th17分化与CTL募集，从而增强抗肿瘤免疫应答。该研究在实体瘤CAR-T治疗领域具有创新性，但仍需在临床前安全性与长期持续性方面进一步验证。

---

## 9. 银屑病的遗传易感性可预测疾病的严重结局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408349)
**期刊：** Genome medicine
**PMID：** 41408349
**DOI：** 10.1186/s13073-025-01561-2

### 第一部分 原文与翻译

**英文原标题：** Genetic liability to psoriasis predicts severe disease outcomes.

> **英文摘要：**
> BACKGROUND: Psoriasis is a common inflammatory skin disease with heterogeneous presentation. Up to 30% of individuals have severe disease with a greater surface area of skin involvement, co-morbidity burden and impact on quality of life. Prognostic biomarkers of psoriasis severity could improve allocation of clinical resources and enable earlier intervention to prevent disease progression, and a genetic biomarker would be cost-effective, stable over time, and unaffected by treatment or comorbidity.
> 
> METHODS: Psoriasis severity was studied in four European population-based biobanks (Estonian Biobank, HUNT, FinnGen, UK Biobank) and classified based on level of clinical intervention received, with criteria for severe disease including hospitalisation due to psoriasis, use of systemic immunomodulating therapy or phototherapy. Common genetic variants, polygenic risk scores and traditional epidemiological risk factors were tested for association with severe psoriasis in each of the constituent biobanks and combined through meta-analysis. The distribution of psoriasis polygenic risk was also evaluated in a cohort of 4151 participants in the UK-based severe psoriasis registry, BSTOP, and a cohort of 1461 participants from Novartis clinical trials of secukinumab for psoriasis.
> 
> RESULTS: In the population-based datasets, 9738 of 44,904 individuals with psoriasis (21.7%) were classified as having severe disease. Genetic variants within the major histocompatibility complex (MHC) and the TNIP1 and IL12B psoriasis susceptibility loci were associated with severe disease at genome-wide significance (P < 5.0 × 10). Furthermore, a strong positive correlation was observed between psoriasis susceptibility and severity effect sizes across all psoriasis susceptibility loci. An individual's genetic liability to psoriasis as measured with a polygenic risk score (PRS) strongly associated with disease severity, with a magnitude of effect comparable to established severity risk factors such as obesity and smoking. The top 5% of psoriasis cases by genetic liability to psoriasis were 1.23-to-2.00 times as likely than the average psoriasis case to have severe disease. Psoriasis cases in our external validation datasets (BSTOP registry and Novartis clinical trials) were enriched for a PRS that exceeded the 95th percentile established among UK Biobank psoriasis cases by 3.06-fold and 2.32-fold respectively.
> 
> CONCLUSIONS: The psoriasis susceptibility PRS demonstrates utility and may be more effective than established epidemiological factors, as a stratification tool to identify those individuals that are at greatest risk of severe disease and may benefit most from early intervention.

> **中文摘要：**
> 背景：银屑病是一种常见的炎性皮肤疾病，具有临床表现的异质性。多达30%的患者患有重度疾病，表现为更广的皮肤累及面积、更高的合并症负担以及更显著的生活质量影响。预测银屑病严重程度的生物标志物可改善临床资源分配，并有助于在早期进行干预以防止病情进展；而遗传标志物具备成本效益高、时间稳定且不受治疗或合并症影响的优势。
> 
> 方法：本研究利用来自四个欧洲人群生物样本库（爱沙尼亚生物样本库、HUNT、FinnGen 和英国生物样本库）的数据研究银屑病的严重程度，并根据所接受的临床干预水平进行分级，重度疾病的标准包括因银屑病住院、接受全身免疫调节治疗或光疗。研究在各生物样本库中分别检验常见遗传变异、多基因风险评分（PRS）以及传统流行病学风险因素与重度银屑病的关联，并通过荟萃分析合并结果。同时评估了银屑病多基因风险分布在两个外部队列中的表现：一个为英国重度银屑病登记系统（BSTOP，4151名参与者），另一个为诺华司库奇尤单抗银屑病临床试验（1461名参与者）。
> 
> 结果：在人群数据集中，44,904名银屑病患者中有9,738名（21.7%）被归类为重度。主要组织相容性复合体（MHC）区域，以及 TNIP1 和 IL12B 银屑病易感位点的遗传变异与重度疾病在全基因组水平上达到了显著相关（P < 5.0 × 10）。此外，在所有银屑病易感位点中，银屑病易感性效应值与疾病严重程度效应值之间存在显著正相关。以多基因风险评分（PRS）衡量的个体银屑病遗传易感性与疾病严重程度高度相关，其效应强度可与肥胖和吸烟等已知严重程度风险因素相当。处于银屑病遗传易感性前5%的病例，其患重度银屑病的可能性为平均银屑病患者的1.23至2.00倍。在外部验证数据集中，BSTOP 登记系统和诺华临床试验的银屑病病例中，PRS 超过英国生物样本库银屑病患者第95百分位数的分别富集了3.06倍和2.32倍。
> 
> 结论：银屑病易感性多基因风险评分（PRS）表现出良好的实用价值，可能比传统流行病学指标更有效，作为一种分层工具可识别重度疾病高风险个体，从而获益于早期干预。

### 第二部分 AI 大师评价

该研究旨在验证遗传易感性在银屑病严重程度预测中的作用，通过整合四个大型欧洲生物样本库及两个独立验证队列的数据，揭示银屑病多基因风险评分与疾病严重程度显著相关。研究结果表明，PRS可作为一种稳健且成本效益高的分层工具，用于识别重度银屑病高风险患者。该研究的创新性在于将遗传信息引入疾病严重性预测模型中，显示出与传统流行病学风险因素相当甚至更优的预测能力。但局限性可能包括种群特异性偏倚及临床实现中需进一步验证预测模型的通用性。

---

## 10. 复发/难治性急性髓系白血病成人患者CLL1 CAR-T细胞治疗的最新数据

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408327)
**期刊：** Journal of hematology & oncology
**PMID：** 41408327
**DOI：** 10.1186/s13045-025-01764-5

### 第一部分 原文与翻译

**英文原标题：** Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

> **英文摘要：**
> CLL1-targeted chimeric antigen receptor T (CAR-T) cell therapy has shown clinically meaningful activity in relapsed/refractory acute myeloid leukemia (R/R AML). This updated phase I study enrolled 38 adults with R/R AML to evaluate the safety and efficacy of this treatment according to the prespecified protocol. Treatment-related adverse events included grade 3/4 cytokine release syndrome (CRS) in 17 patients (44.74%) and grade 4 immune effector cell-associated neurotoxicity syndrome (ICANS) in 1 patient (2.63%). Persistent cytopenia (all grades) was observed in all patients, with a median time to neutrophil recovery of 45 days. At a median follow-up of 24.87 months, the objective response rate (ORR) was 73.68% (28/38), and the minimal residual disease-negative complete response rate (MRDCR) was 42.11%. Median progression-free survival (PFS) and overall survival (OS) were 9 months (95%CI 3.03-14.47) and 12.17 months (95%CI 3.03-24.87), respectively. The two-year PFS and OS rates were 47.94% (95%CI: 32.00%-63.83%) and 51.43% (95%CI 35.51%-67.32%), respectively. These results indicate a clinically relevant antitumor efficacy and a manageable safety profile of CLL1-targeted CAR-T cell therapy in adults with R/R AML.Registry:  www.chictr.org.cn , TRN: ChiCTR2000041054, Registration date: 17 December 2020.

> **中文摘要：**
> 以CLL1为靶点的嵌合抗原受体T（CAR-T）细胞疗法已在复发/难治性急性髓系白血病（R/R AML）中表现出具有临床意义的活性。本项更新的I期研究共纳入38例R/R AML成年患者，根据预先设定的方案评估该治疗的安全性与有效性。治疗相关的不良事件包括17例（44.74%）出现3/4级细胞因子释放综合征（CRS），以及1例（2.63%）出现4级免疫效应细胞相关神经毒性综合征（ICANS）。所有患者均出现不同程度的持续性细胞减少症，中性粒细胞恢复的中位时间为45天。中位随访24.87个月时，客观缓解率（ORR）为73.68%（28/38），而微小残留病阴性完全缓解率（MRDCR）为42.11%。中位无进展生存期（PFS）和总生存期（OS）分别为9个月（95%CI 3.03-14.47）和12.17个月（95%CI 3.03-24.87）。两年PFS和OS率分别为47.94%（95%CI：32.00%-63.83%）和51.43%（95%CI 35.51%-67.32%）。这些结果表明，CLL1靶向CAR-T细胞治疗在R/R AML成年患者中具有临床上显著的抗肿瘤疗效，并呈现可控的安全性特征。注册信息：www.chictr.org.cn，注册号ChiCTR2000041054，注册日期为2020年12月17日。

### 第二部分 AI 大师评价

该研究旨在更新和验证CLL1靶向CAR-T细胞疗法在复发/难治性急性髓系白血病成年患者中的疗效与安全性。结果显示，该疗法具有较高的客观缓解率和较长的生存获益，但仍伴随显著的细胞因子释放综合征及持久性骨髓抑制。研究的创新在于提供了长期随访数据，进一步印证了CLL1作为AML免疫治疗靶点的潜力。主要局限在于样本量较小及I期研究设计，仍需在大规模随机试验中验证其长期安全与疗效。

---

## 11. HDAC2作为膀胱癌治疗靶点：关于异常表观遗传调控与赖氨酸乳酰化的机制解析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408324)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41408324
**DOI：** 10.1186/s13046-025-03610-5

### 第一部分 原文与翻译

**英文原标题：** HDAC2 as a therapeutic target in bladder cancer: insights into the altered epigenetic regulation and lysine lactylation.

> **英文摘要：**
> BACKGROUND: The pathogenesis of bladder cancer (BCa) is driven in part by aberrant epigenetic regulation, most notably the dysregulated expression of histone deacetylases (HDACs). As a class I HDAC, HDAC2 is often overexpressed in cancers and promotes malignancy through diverse mechanisms. Given its broad oncogenic role, an in-depth investigation of its specific functions in epigenetic and post-translational regulation within BCa holds significant promise for developing novel precision therapies.
> 
> METHODS: In vitro functional assays, including CCK-8, colony formation, transwell and apoptotic assays, as well as in vivo assays in a nude mouse subcutaneous tumor model, were performed to assess the oncogenic and drug-resistant effects of HDAC2. RNA-seq and ATAC-seq were employed to analyze the epigenetic regulatory mechanisms of HDAC2. Combined proteome, lactylome and acetylome analysis of control and HDAC2-overexpressing BCa cells were conducted to map the global profiling of protein lysine acetylation (Kac) and lactylation (Kla).
> 
> RESULTS: In vitro and in vivo experiments confirmed that HDAC2 overexpression significantly promoted proliferation, metastasis and chemoresistance of BCa. Integrated RNA-seq and ATAC-seq analysis revealed that HDAC2 overexpression led to significant epigenetic alternations, and knockdown of its downstream GRIK2 significantly reversed the oncogenic effects of HDAC2. We screened class I HDACs for their impact on Kac and Kla in BCa cells and found that HDAC2 most significantly reduced global Kla levels. Subsequent proteomic analysis of HDAC2-overexpressing cells identified 528 differentially regulated Kla proteins (encompassing 683 sites) and 1,129 differentially regulated Kac proteins (encompassing 1,458 sites). Notably, DHX15 in the splicesome pathway emerged as the most prominent HDAC2-regulated lactylated protein in the absence of concurrent Kac alterations. Moreover, HDAC2 promoted BCa malignancy through the downregulation of DHX15 Kla and the subsequent modulation of RPL9 splicing.
> 
> CONCLUSION: Collectively, these findings suggest the pivotal role of HDAC2 in epigenetic modulation and lysine lactylation, and underscore HDAC2 as a promising therapeutic target in BCa.

> **中文摘要：**
> 背景：膀胱癌（BCa）的发病机制部分由异常的表观遗传调控驱动，尤其表现为组蛋白去乙酰化酶（HDACs）表达失衡。作为I类HDAC，HDAC2在多种肿瘤中过度表达，并通过多种机制促进恶性进展。鉴于其广泛的致癌作用，深入探讨它在BCa中表观遗传及翻译后调控方面的特异功能，对于开发新型精准治疗具有重要潜力。
> 
> 方法：通过体外功能实验（CCK-8、克隆形成、Transwell迁移和凋亡实验）以及裸鼠皮下移植瘤的体内实验，评估HDAC2的促瘤及耐药作用。采用RNA-seq与ATAC-seq分析HDAC2的表观遗传调控机制。进一步结合蛋白质组、乳酰化组及乙酰化组学，对照组与HDAC2过表达的BCa细胞进行全局赖氨酸乙酰化（Kac）与乳酰化（Kla）谱系分析。
> 
> 结果：体外与体内实验均证实HDAC2过表达显著促进BCa的增殖、转移与化疗耐药。整合RNA-seq与ATAC-seq分析显示，HDAC2过表达导致显著的表观遗传改变，而其下游基因GRIK2的敲低可明显逆转HDAC2的致癌效应。我们筛查了I类HDAC对BCa细胞中Kac与Kla的影响，发现HDAC2最显著降低了全局Kla水平。进一步的蛋白质组学分析鉴定出HDAC2过表达细胞中528个乳酰化调控蛋白（涉及683个位点）及1129个乙酰化调控蛋白（涉及1458个位点）。值得注意的是，在剪接体通路中，DHX15作为最突出的HDAC2调控的乳酰化蛋白被发现，而其未同时表现出Kac变化。此外，HDAC2通过下调DHX15乳酰化水平并进一步调节RPL9剪接，促进了BCa恶性进展。
> 
> 结论：综合结果表明，HDAC2在表观遗传调控及赖氨酸乳酰化中起关键作用，并凸显其作为膀胱癌潜在治疗靶点的价值。

### 第二部分 AI 大师评价

本研究系统揭示了HDAC2在膀胱癌中通过调控表观遗传及赖氨酸乳酰化促进肿瘤进展的分子机制。研究团队综合运用多组学手段（RNA-seq、ATAC-seq、蛋白质组学、乳酰化组、乙酰化组），细致描绘了HDAC2介导的全局修饰图谱及其下游效应分子DHX15的作用。这一发现首次将HDAC2与乳酰化的调控联系起来，为膀胱癌靶向治疗提供了新的生物学依据。研究的创新性突出，但仍需进一步验证其在临床应用中的可行性与安全性。

---

## 12. 使用塞来昔布阻断COX-2/PGE轴通过激活自然杀伤细胞增强射频消融后残余肝细胞癌的抗PD-1疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408296)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41408296
**DOI：** 10.1186/s13046-025-03582-6

### 第一部分 原文与翻译

**英文原标题：** COX-2/PGE axis blockade with celecoxib enhances anti-PD-1 efficacy by activating natural killer cells for residual hepatocellular carcinoma after radiofrequency ablation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究围绕肝细胞癌射频消融后残余病灶的免疫治疗策略展开，提出通过塞来昔布抑制COX-2/PGE通路可激活自然杀伤细胞，从而增强抗PD-1疗效。该思路揭示了肿瘤微环境中炎症通路与免疫检查点抑制剂协同调控的潜力。尽管缺乏摘要细节，但研究概念具有较强的临床转化意义，为术后免疫重塑提供了新的干预方向。

---

## 13. 激动剂信号驱动的中性粒细胞亚群促进或抑制结直肠癌肝转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408063)
**期刊：** Nature communications
**PMID：** 41408063
**DOI：** 10.1038/s41467-025-67579-7

### 第一部分 原文与翻译

**英文原标题：** Agonist signaling drives neutrophil subpopulations to promote/inhibit colorectal cancer liver metastasis.

> **英文摘要：**
> Liver metastasis is a primary cause of death in colorectal cancer, yet the role of immune cells called neutrophils in this process remains complex. In this study, we identify three distinct neutrophil subtypes: anti-tumor high-density neutrophils, pro-tumor mature low-density neutrophils, and immature low-density neutrophils. Here we show that tumor-derived GM-CSF converts anti-tumor neutrophils into a pro-tumor state via the AKT-NF-κB-NFAT5 signaling axis. These activated neutrophils, when further stimulated by CXCR2 ligands, release web-like structures known as neutrophil extracellular traps which promote cancer spread by enhancing cancer cell growth, suppressing immune responses, and preparing the liver for metastasis. Importantly, we demonstrate that using antibodies depleting neutrophils or drugs inhibiting their pro-tumor activity effectively reduces liver metastasis in mice. Our work defines specific neutrophil subsets as key drivers of cancer progression and highlights their therapeutic potential in preventing metastatic spread.

> **中文摘要：**
> 肝转移是结直肠癌致死的主要原因之一，但名为中性粒细胞的免疫细胞在这一过程中的作用依然复杂。在本研究中，我们鉴定出三种不同的中性粒细胞亚型：抗肿瘤的高密度中性粒细胞、促肿瘤的成熟低密度中性粒细胞以及未成熟低密度中性粒细胞。研究显示，肿瘤来源的GM-CSF通过AKT–NF-κB–NFAT5信号轴将抗肿瘤中性粒细胞转化为促肿瘤状态。这些被激活的中性粒细胞在受到CXCR2配体进一步刺激后，会释放称为中性粒细胞胞外捕获网的网状结构，从而通过促进癌细胞生长、抑制免疫反应并为肝脏转移做准备来推动癌症扩散。重要的是，我们证明了使用清除中性粒细胞的抗体或抑制其中促肿瘤活性的药物能够显著减少小鼠的肝转移。我们的研究定义了特定的中性粒细胞亚型作为癌症进展的关键驱动因素，并强调了它们在防止转移扩散方面的治疗潜力。

### 第二部分 AI 大师评价

本研究旨在阐明中性粒细胞在结直肠癌肝转移过程中的双重作用。作者通过单细胞分析和功能实验鉴定出具有抗肿瘤与促肿瘤特性的不同中性粒细胞亚型，并揭示肿瘤分泌的GM-CSF可通过AKT–NF-κB–NFAT5信号通路驱动其表型转变。研究进一步指出CXCR2介导刺激促使这些细胞形成胞外捕获网，促进转移环境形成。通过抗体清除与药物干预实验验证了调控中性粒细胞的治疗潜力。该工作在揭示免疫细胞塑性及其与肿瘤微环境互作机制方面具有重要创新性，但其临床转化仍需在人体模型中验证。

---

## 14. CAT1介导的阳离子氨基酸转运及病毒受体结合的结构学机制解析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408058)
**期刊：** Nature communications
**PMID：** 41408058
**DOI：** 10.1038/s41467-025-67704-6

### 第一部分 原文与翻译

**英文原标题：** Structural insights into cationic amino acid transport and viral receptor engagement by CAT1.

> **英文摘要：**
> Cationic amino acid transporter 1 (CAT1) transports cationic amino acids and plays pivotal roles in cancer proliferation, immune modulation, and nitric oxide metabolism. It also serves as the specific cellular receptor for certain murine leukemia viruses. Here, we report the cryo-electron microscopy (cryo-EM) structure of mammalian CAT1 in complex with its substrate ornithine and the receptor-binding domain (RBD) of Friend murine leukemia virus (FrMLV). CAT1 specifically recognizes the side-chain amino group of ornithine via residue S347 on transmembrane helix 8 (TM8), capturing the transporter in an inward-facing occluded conformation. Notably, the FrMLV RBD (frRBD) primarily engages the third extracellular loop (ECL3) of CAT1-a region marked by substantial species-specific variation that likely governs cross-species viral tropism. Together, our structural and biochemical results elucidate the molecular mechanism of substrate recognition and transport by mCAT1, and unveil the molecular basis for FrMLV receptor specificity. These findings provide a valuable framework for structure-based drug design targeting CAT1 in cancer and infectious diseases.

> **中文摘要：**
> 阳离子氨基酸转运体1（CAT1）负责传输阳离子氨基酸，并在癌症增殖、免疫调节及一氧化氮代谢中发挥关键作用。它还作为某些鼠白血病病毒的特异性细胞受体。在本研究中，我们报道了哺乳动物CAT1与其底物鸟氨酸及友好鼠白血病病毒（FrMLV）受体结合结构域（RBD）复合物的冷冻电镜（cryo-EM）结构。CAT1通过跨膜螺旋8（TM8）上的S347残基特异性识别鸟氨酸的侧链氨基，将转运体捕获于朝内封闭构象中。值得注意的是，FrMLV的RBD（frRBD）主要与CAT1的第三细胞外环（ECL3）相互作用，该区域具有显著的物种特异性差异，可能决定了病毒的跨物种嗜性。综合结构学和生化分析结果，我们阐明了mCAT1识别与转运底物的分子机制，并揭示了FrMLV受体特异性的分子基础。这些发现为基于结构的CAT1靶向药物设计在癌症和传染病领域的应用提供了重要理论框架。

### 第二部分 AI 大师评价

本研究通过冷冻电镜解析了哺乳动物CAT1与鸟氨酸及FrMLV受体结合结构域的复合物结构，揭示了CAT1在底物识别和转运中的关键分子机制。研究明确了S347残基和ECL3区域在底物特异性及病毒受体识别中的核心作用，阐明了病毒跨物种传播的结构基础。该工作在理解CAT家族转运机制及病毒受体相互作用方面具有重要创新性，同时为癌症与感染性疾病中的结构导向靶向药物设计提供了新策略。其局限性在于尚需进一步验证不同物种及动态状态下的结构功能关系。

---

## 15. 稳定药物修饰KRAS新抗原的工程化抗体实现选择性且强效的跨HLA免疫治疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408054)
**期刊：** Nature communications
**PMID：** 41408054
**DOI：** 10.1038/s41467-025-66132-w

### 第一部分 原文与翻译

**英文原标题：** Engineered antibodies that stabilize drug-modified KRAS neoantigens enable selective and potent cross-HLA immunotherapy.

> **英文摘要：**
> Covalent inhibitors of oncoprotein KRAS have initial efficacy, but responses lack durability. Covalently modified oncoproteins are presented as MHC-restricted hapten-peptides (p*MHC) on the cancer cell surface, enabling combination of targeted therapy with immunotherapy to overcome drug resistance. Building on indirect evidence of KRAS-derived p*MHCs, we use immunopeptidomics to identify and directly quantify these synthetic neoantigens. To address challenges by their low copy number, we develop AETX-R114, a T cell engaging bispecific antibody with picomolar affinity for MHC-restricted sotorasib-modified KRAS peptides presented by three HLA-A3 supertype alleles. AETX-R114 dramatically increases the half-life and thereby the number of presented p*MHCs, enabling selective and potent killing of resistant cancer cells both in vitro and in vivo. To broaden the therapeutic potential of creating and targeting synthetic neoantigens, we further develop AETX-R302, which recognizes divarasib-modified KRAS peptides presented on alleles from the HLA-A2 and A3 supertypes. Cryo-EM structure determination reveals the molecular basis for breaking HLA supertype restriction. Collectively, our study illustrates how engineered antibodies can transform synthetic neoantigens into actionable cancer immunotherapy targets.

> **中文摘要：**
> 癌蛋白KRAS的共价抑制剂具有初步疗效，但治疗反应缺乏持久性。共价修饰后的癌蛋白会以MHC限制的半抗原肽（p*MHC）的形式呈现在癌细胞表面，从而使靶向治疗与免疫治疗结合成为可能，以克服药物耐受性。在KRAS来源的p*MHC间接证据基础上，我们运用免疫肽组学直接鉴定并定量这些合成新抗原。为解决其拷贝数低带来的挑战，我们开发了AETX-R114，这是一种T细胞结合型双特异性抗体，对由三种HLA-A3超型等位基因呈递的、经索托拉西布修饰的KRAS肽具有皮摩尔级亲和力。AETX-R114显著延长了p*MHC的半衰期并增加其呈递数目，从而实现在体外和体内对耐药癌细胞的选择性且强效杀伤。为拓展创造与靶向合成新抗原的治疗潜力，我们进一步开发了AETX-R302，它可识别由HLA-A2与A3超型等位基因呈递的、经二瓦拉西布修饰的KRAS肽。冷冻电镜结构解析揭示了突破HLA超型限制的分子机制。总体而言，本研究展示了工程化抗体如何将合成新抗原转化为可操作的癌症免疫治疗靶点。

### 第二部分 AI 大师评价

本研究通过工程化抗体策略，创新性地强化药物修饰KRAS新抗原的稳定性与呈递能力，成功实现跨HLA超型的免疫治疗应用。研究者利用免疫肽组学直接证实合成KRAS新抗原的存在，并开发高亲和力双特异性抗体以增强其免疫效应。结果表明，该策略可有效杀伤耐药癌细胞，揭示了合成新抗原在癌症免疫治疗中的新思路。其主要创新在于通过抗体设计延长p*MHC半衰期并打破HLA限制，虽需进一步验证临床可行性，但为精准免疫联合疗法提供了重要理论与技术突破。

---

## 16. ALK4的缺失通过调控TGF-β受体N-糖基化促进癌症进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408046)
**期刊：** Nature communications
**PMID：** 41408046
**DOI：** 10.1038/s41467-025-67563-1

### 第一部分 原文与翻译

**英文原标题：** Loss of ALK4 promotes cancer progression through regulating TGF-β receptor N-glycosylation.

> **英文摘要：**
> The transforming growth factor-β (TGF-β) pathway typically inhibits tumorigenesis but can promote metastasis during cancer progression. Activin receptor-like kinase 4 (ALK4), a type I TGF-β family receptor, is frequently downregulated or mutated in cancers, and reduced ALK4 expression correlates with poorer outcomes. However, its role and mechanism of action in cancer progression remains unclear. We demonstrate that ALK4 loss enhances anchorage-independent growth, migration, invasion, and epithelial-mesenchymal transition in vitro, as well as cancer progression in breast and pancreatic cancer models in vivo. Importantly, ALK4 loss promotes canonical TGF-β signaling by increasing TGF-β receptor N-linked glycosylation and stabilizing these receptors at the cell surface. Mechanistically, ALK4 loss upregulates β1,6 N-acetylglucosaminyltransferase V (MGAT5) and galectin-3, which binds MGAT5-modified glycoproteins to stabilize surface receptors. Consistent with prior observations that galectin-3 preferentially binds to MGAT5-modified glycoproteins to stabilize cell surface receptors like TGF-β receptors, we demonstrate that ALK4 loss enhances MGAT5-mediated glycosylation of TGF-β receptors, promoting their stabilization and signal transduction. Depleting MGAT5 or inhibiting N-glycosylation effectively suppresses ALK4-loss-induced TGF-β signaling and cancer progression.

> **中文摘要：**
> 转化生长因子β（TGF-β）信号通路通常抑制肿瘤发生，但在癌症进展过程中可促进转移。作为TGF-β家族的I型受体，激活素受体样激酶4（ALK4）在多种癌症中常出现下调或突变，且其表达降低与较差的预后相关。然而，ALK4在癌症进展中的作用及其机制尚不明确。我们的研究表明，ALK4的缺失可在体外增强癌细胞的无依附生长、迁移、侵袭及上皮-间质转化，同时在乳腺癌和胰腺癌体内模型中促进癌症进展。重要的是，ALK4缺失通过增加TGF-β受体的N-连接糖基化并稳定其在细胞表面的存在，从而促进经典TGF-β信号通路的活化。在机制上，ALK4缺失上调β1,6 N-乙酰氨基葡萄糖转移酶V（MGAT5）和半乳糖凝集素-3（galectin-3），后者可结合MGAT5修饰的糖蛋白以稳定膜表面受体。与以往研究发现galectin-3倾向结合MGAT5修饰糖蛋白以稳定包括TGF-β受体在内的细胞表面受体的结果一致，我们证明ALK4缺失增强了MGAT5介导的TGF-β受体糖基化，从而促进受体的稳定及信号传导。耗减MGAT5或抑制N-糖基化可有效抑制因ALK4缺失所致的TGF-β信号活化及癌症进展。

### 第二部分 AI 大师评价

本研究揭示了ALK4缺失在肿瘤进展中的关键作用及其通过调控TGF-β受体N-糖基化的分子机制。作者综合运用体内外模型，证明ALK4缺失可增强TGF-β信号并促进癌细胞侵袭性。其发现MGAT5和galectin-3在受体稳定化过程中的协同作用，为TGF-β信号调控提供了新视角。该研究创新性地将糖基化修饰与受体信号活性联系起来，但仍需更多临床证据验证其在不同癌种中的普适性。

---

## 17. 心代谢疾病与癌症疾病轨迹的多组学洞察

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408044)
**期刊：** Nature communications
**PMID：** 41408044
**DOI：** 10.1038/s41467-025-67510-0

### 第一部分 原文与翻译

**英文原标题：** Multiomics insight into disease trajectories of cardiometabolic diseases and cancer.

> **英文摘要：**
> Multimorbidity of cardiometabolic disease (CMD) and cancer is a growing but understudied global challenge in an aging world. Here, we perform multistate analysis in 429,555 UK Biobank participants to investigate transition patterns, identify multiomics signatures, and construct prediction models from baseline to single and multiple morbidities. During a median follow-up of 15 years, 105,903 participants develop single morbidity and 15,088 develop multimorbidity of CMD and cancer. Participants with multimorbidity have a 13%-33% higher mortality probability than those healthy or with single morbidity. In individuals living with multimorbidity, the development of CMD before cancer presents a higher mortality risk than the reverse order. Distinct and shared multiomics signatures are identified, with proteomics scores outperforming other omics in predicting disease trajectories (ΔC-statistic vs. base model: 0.03-0.14). This study reveals distinct transition patterns in CMD-cancer multimorbidity cluster and develops potentially useful prediction tools for supporting risk management if externally validated.

> **中文摘要：**
> 心代谢疾病（CMD）与癌症的多重共病在老龄化社会中是一个日益严重但尚未得到充分研究的全球性挑战。本文在英国生物样本库的429,555名参与者中进行了多状态分析，以探究疾病转变模式、鉴定多组学标志物，并从基线状态到单一及多重共病构建预测模型。在中位随访15年期间，105,903名参与者发展为单一疾病，15,088名参与者发展为CMD与癌症的多重共病。多重共病者的死亡概率比健康人群或单一疾病者高出13%–33%。在多重共病个体中，若CMD先于癌症发生，其死亡风险高于相反顺序的情况。研究识别出了不同及共享的多组学特征，其中蛋白质组学评分在预测疾病轨迹方面优于其他组学（ΔC统计相对于基线模型：0.03–0.14）。该研究揭示了CMD-癌症多重共病群的独特转变模式，并提出了在外部验证后可用于风险管理的潜在预测工具。

### 第二部分 AI 大师评价

该研究利用英国生物样本库的大规模人群数据，结合多状态统计模型与多组学分析，系统解析了心代谢疾病与癌症之间的共病轨迹及风险模式。结果显示，不同发病顺序的共病个体存在显著的死亡风险差异，蛋白质组学对疾病进展的预测能力最为突出。此研究为多重慢性病的动态风险评估提供了新的生物学标志和建模框架，但其外部可推广性仍需进一步验证。整体而言，该工作在多组学预测共病轨迹领域具有重要的创新价值。

---

## 18. NAT10介导的PIK3R2 mRNA N4-乙酰胞苷（ac4C）修饰促进胶质母细胞瘤的恶性进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41408025)
**期刊：** Cell death & disease
**PMID：** 41408025
**DOI：** 10.1038/s41419-025-08328-y

### 第一部分 原文与翻译

**英文原标题：** NAT10-mediated N4-acetylcytidine (ac4C) modification of PIK3R2 mRNA promotes malignant progression of glioblastoma.

> **英文摘要：**
> Glioma is the most common primary tumor in the central nervous system, with glioblastoma (GBM) representing one of the most malignant forms, accounting for 46.1% of cases. GBM is characterized by rapid progression, high malignancy, and poor prognosis, with median survival remaining less than 15 months despite combined surgery, radiotherapy, and chemotherapy. NAT10, the only known acetyltransferase mediating N4-acetylcytidine (ac4C) modification in eukaryotes, has been implicated in promoting tumorigenesis and progression in colon cancer, bladder cancer, pancreatic ductal cancer, among others. In this study, we found that NAT10 is highly expressed in GBM and is positively correlated with malignant pathological features and poor prognosis in patients. In vitro experiments demonstrated that NAT10 promotes tumor proliferation, migration, and invasion. In vivo experiments further confirmed that NAT10 facilitates malignant progression of tumors. Mechanistically, we revealed that NAT10 regulates PIK3R2 stabilization through ac4C modification, thereby participating malignant characterization of GBM. Additionally, our data demonstrated a positive correlation between NAT10 and PIK3R2 in glioma patients. Taken together, our findings strongly suggest that NAT10 is a potential therapeutic target for GBM.

> **中文摘要：**
> 胶质瘤是中枢神经系统中最常见的原发性肿瘤，而胶质母细胞瘤（GBM）是其最具恶性特征的类型之一，占病例的46.1%。GBM具有进展迅速、恶性程度高和预后差等特点，即使经过手术、放疗和化疗的联合治疗，中位生存期仍不足15个月。NAT10是目前已知的唯一能在真核生物中介导N4-乙酰胞苷（ac4C）修饰的乙酰转移酶，已被证实在结肠癌、膀胱癌、胰管癌等多种肿瘤的发生和进展中起促进作用。本研究发现，NAT10在GBM中高表达，并与恶性病理特征及患者的不良预后呈正相关。体外实验表明，NAT10可促进肿瘤增殖、迁移和侵袭；体内实验进一步证实NAT10促进肿瘤的恶性进展。从机制上看，我们揭示了NAT10通过ac4C修饰调控PIK3R2的稳定性，从而参与GBM的恶性表型形成。此外，我们的数据还显示，在胶质瘤患者中NAT10与PIK3R2表达呈正相关。综上所述，我们的研究结果强烈表明NAT10可能是GBM的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究系统探讨了NAT10在胶质母细胞瘤发生和进展中的作用，结合体内外实验及分子机制分析，发现其通过ac4C修饰稳定PIK3R2 mRNA，从而促进恶性表型形成。研究不仅揭示了GBM中NAT10的致瘤功能，也指出其与PIK3R2在临床样本中的正相关关系。该工作创新性地将RNA乙酰化修饰与GBM进展联系起来，为靶向NAT10的治疗策略提供了理论依据。但仍需进一步阐明其在不同分子亚型中的特异性作用及临床应用可行性。

---

## 19. 成人胰腺母细胞瘤：胰腺神经内分泌肿瘤鉴别诊断中的挑战

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407939)
**期刊：** Endocrine pathology
**PMID：** 41407939
**DOI：** 10.1007/s12022-025-09897-6

### 第一部分 原文与翻译

**英文原标题：** Adult Pancreatoblastoma: A Challenge in the Differential Diagnosis of Pancreatic Neuroendocrine Neoplasms.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文聚焦于成人胰腺母细胞瘤，这是一种极为罕见的胰腺肿瘤类型，其临床及病理特征常与胰腺神经内分泌肿瘤相似，给诊断带来显著挑战。尽管缺乏摘要，标题表明研究可能探讨了两者在组织学及免疫组化层面的鉴别要点。该研究对于提高病理诊断准确性和指导临床治疗具有潜在价值，但其创新性和临床推广性或受限于病例数量稀少及研究样本代表性。

---

## 20. 远离病灶的星形胶质细胞调控由小胶质细胞介导的白质修复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407858)
**期刊：** Nature
**PMID：** 41407858
**DOI：** 10.1038/s41586-025-09887-y

### 第一部分 原文与翻译

**英文原标题：** Lesion-remote astrocytes govern microglia-mediated white matter repair.

> **英文摘要：**
> Spared regions of the damaged central nervous system undergo dynamic remodelling and exhibit a remarkable potential for therapeutic exploitation. Lesion-remote astrocytes (LRAs), which interact with viable neurons and glia, undergo reactive transformations whose molecular and functional properties are poorly understood. Here, using multiple transcriptional profiling methods, we investigated LRAs from spared regions of mouse spinal cord following traumatic spinal cord injury. We show that LRAs acquire a spectrum of molecularly distinct, neuroanatomically restricted reactivity states that evolve after spinal cord injury. We identify transcriptionally unique reactive LRAs in degenerating white matter that direct the specification and function of local microglia that clear lipid-rich myelin debris to promote tissue repair. Fuelling this LRA functional adaptation is the secreted matricellular protein CCN1. Loss of astrocyte-derived CCN1 results in excessive, aberrant activation of local microglia, characterized by abnormal molecular specification, impaired debris processing reflected by the intracellular accumulation of myelin and axon debris, and dysregulated lipid metabolism with distinctive attenuation in lipid droplet accumulation. Mechanistically, we find that CCN1 binds microglial SDC4 to augment lipid storage, linking this signalling axis to a vital repair-associated lipid buffering response in debris-clearing microglia. Accordingly, microglial deficits resulting from astrocyte CCN1 depletion culminate in blunted clearance of white matter debris and impaired neurological recovery from spinal cord injury. Ccn1-expressing white matter astrocytes are induced by local myelin damage and are generated in diverse demyelinating disorders in mice and humans, pointing to their fundamental, evolutionarily conserved role in white matter repair. Our findings show that context-specific cues shape regionally distinct LRA reactivity states with functional adaptations that orchestrate multicellular processes underlying neural repair and influence disease outcome.

> **中文摘要：**
> 受损中枢神经系统中得以保留的区域经历动态重塑，并表现出显著的治疗潜力。远离病灶的星形胶质细胞（lesion-remote astrocytes，LRAs）与存活的神经元和胶质细胞相互作用，经历反应性转变，其分子和功能特征尚不清楚。在本研究中，我们利用多种转录谱分析方法，研究了小鼠脊髓损伤后保留区域中的LRA。我们发现，LRA在脊髓损伤后会获得一系列在分子上具有差异、在神经解剖上受限的反应性状态。我们鉴定出一种在退变白质中具有独特转录特征的反应性LRA，它们能够调控局部小胶质细胞的特化和功能，从而清除富含脂类的髓鞘碎片，促进组织修复。支撑这种LRA功能适应的是分泌性的基质细胞外蛋白CCN1。丧失星形胶质细胞来源的CCN1会导致局部小胶质细胞的过度和异常激活，其表现为分子特化异常、碎屑处理受损（反映为胞内髓鞘和轴突碎片的积累）以及脂质代谢紊乱（伴随脂滴积累显著减少）。在机制上，我们发现CCN1可与小胶质细胞的SDC4结合以增强脂质储存，将此信号轴与清除碎片小胶质细胞中与修复相关的重要脂质缓冲反应联系起来。因此，由于星形胶质细胞CCN1耗竭所致的小胶质细胞缺陷，会导致白质碎片清除减弱，并削弱脊髓损伤后的神经功能恢复。表达Ccn1的白质星形胶质细胞可由局部髓鞘损伤诱导，并在小鼠与人类的多种脱髓鞘性疾病中生成，提示其在白质修复中具有基本且进化上保守的作用。我们的研究结果表明，特定微环境线索塑造了区域性差异的LRA反应性状态及其功能适应，这些特化状态协调多细胞修复过程并影响疾病结局。

### 第二部分 AI 大师评价

本研究聚焦于脊髓损伤后远离病灶区域的星形胶质细胞，通过多维转录谱分析揭示其反应性状态的异质性及在白质修复中的关键作用。研究发现，特异性分泌蛋白CCN1通过与小胶质细胞受体SDC4结合，调控其清除碎片及脂质代谢过程，从而促进组织修复。该工作创新性地揭示了星形胶质细胞与小胶质细胞之间的分子互作及其在髓鞘再生中的协同机制。尽管研究主要基于动物模型，仍为脱髓鞘疾病与神经修复研究提供了潜在的治疗靶点与机制框架。

---

## 21. 人类组装类器官在体外重现门周肝组织结构。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407857)
**期刊：** Nature
**PMID：** 41407857
**DOI：** 10.1038/s41586-025-09884-1

### 第一部分 原文与翻译

**英文原标题：** Human assembloids recapitulate periportal liver tissue in vitro.

> **英文摘要：**
> The development of complex multicellular human in vitro systems holds great promise for modelling disease and advancing drug discovery and tissue engineering. In the liver, despite the identification of key signalling pathways involved in hepatic regeneration, in vitro expansion of human hepatocytes directly from fresh patient tissue has not yet been achieved, limiting the possibility of modelling liver composite structures in vitro. Here we first developed human hepatocyte organoids (h-HepOrgs) from 28 different patients. Patient-derived hepatocyte organoids sustained long-term expansion of hepatocytes in vitro and maintained patient-specific gene expression and bile canaliculus features and function of the in vivo tissue. After transplantation, expanded h-HepOrgs rescued the phenotype of a mouse model of liver disease. By combining h-HepOrgs with portal mesenchyme and our previously published cholangiocyte organoids, we generated patient-specific periportal liver assembloids that retain the histological arrangement, gene expression and cell interactions of periportal liver tissue, with cholangiocytes and mesenchyme embedded in the hepatocyte parenchyma. We leveraged this platform to model aspects of biliary fibrosis. Our human periportal liver assembloid system represents a novel in vitro platform to investigate human liver pathophysiology, accelerate drug development, enable early diagnosis and advance personalized medicine.

> **中文摘要：**
> 复杂多细胞人类体外系统的发展在疾病建模、药物研发和组织工程领域具有巨大潜力。在肝脏研究中，尽管已识别出参与肝脏再生的关键信号通路，但从新鲜患者组织中直接体外扩增人肝细胞尚未实现，这限制了在体外模拟肝脏复合结构的可能性。本研究首先从28例不同患者中建立了人源性肝细胞类器官（h-HepOrgs）。患者来源的肝细胞类器官能够在体外实现肝细胞的长期扩增，并维持患者特异性的基因表达、胆小管特征及其与在体组织相符的功能。移植后，扩增的h-HepOrgs能够恢复肝病小鼠模型的表型。通过将h-HepOrgs与门区间质细胞及先前构建的胆管上皮类器官结合，我们生成了患者特异性的门周肝组装类器官，其保留了门周肝组织的组织学结构、基因表达和细胞相互作用特点，其中胆管细胞和间质细胞嵌入肝细胞实质中。我们利用该平台模拟了胆道纤维化的部分特征。该人源性门周肝组装类器官体系为研究人类肝脏病理生理学、加速药物开发、实现早期诊断及推动个体化医疗提供了一种全新的体外平台。

### 第二部分 AI 大师评价

本研究通过整合肝细胞、胆管细胞及门区间质细胞，成功构建出能够重现门周肝微环境的人类组装类器官，突破了体外长期维持肝细胞功能的挑战。其在模拟胆道纤维化及疾病模型验证方面展现出显著潜力，提供了临床转化与精准医疗的重要工具。该平台的创新在于实现患者特异性肝组织的体外重构，但仍需评估其在更复杂肝组织及长期功能维持中的适用性。

---

## 22. 人类四维核基因组结构与功能的综合视角

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407856)
**期刊：** Nature
**PMID：** 41407856
**DOI：** 10.1038/s41586-025-09890-3

### 第一部分 原文与翻译

**英文原标题：** An integrated view of the structure and function of the human 4D nucleome.

> **英文摘要：**
> The dynamic three-dimensional (3D) organization of the human genome (the 4D nucleome) is linked to genome function. Here we describe efforts by the 4D Nucleome Project to map and analyse the 4D nucleome in widely used H1 human embryonic stem cells and immortalized fibroblasts (HFFc6). We produced and integrated diverse genomic datasets of the 4D nucleome, each contributing unique observations, which enabled us to assemble extensive catalogues of more than 140,000 looping interactions per cell type, to generate detailed classifications and annotations of chromosomal domain types and their subnuclear positions, and to obtain single-cell 3D models of the nuclear environment of all genes including their long-range interactions with distal elements. Through extensive benchmarking, we describe the unique strengths of different genomic assays for studying the 4D nucleome, providing guidelines for future studies. Three-dimensional models of population-based and individual cell-to-cell variation in genome structure showed connections between chromosome folding, nuclear organization, chromatin looping, gene transcription and DNA replication. Finally, we demonstrate the use of computational methods to predict genome folding from DNA sequence, which will facilitate the discovery of potential effects of genetic variants, including variants associated with disease, on genome structure and function.

> **中文摘要：**
> 人类基因组的动态三维（3D）组织结构（即四维核基因组，4D nucleome）与基因组功能密切相关。在本研究中，我们描述了“四维核基因组计划”在广泛使用的人类胚胎干细胞系 H1 和永生化成纤维细胞系 HFFc6 中绘制与分析四维核基因组的努力。我们构建并整合了多种类型的四维核基因组数据集，每种数据集均提供了独特的观察结果，这使我们能够为每种细胞类型组建包含超过14万条环状相互作用的广泛目录，生成染色体结构域类型及其亚核定位的详细分类与注释，并获得所有基因的单细胞三维核环境模型，包括其与远端元件的长程相互作用。通过大规模的基准测试，我们描述了不同基因组检测技术在四维核基因组研究中的独特优势，并为未来的相关研究提供了指导。基于种群水平与单细胞差异的三维结构模型揭示了染色体折叠、核体组织、染色质环、基因转录与DNA复制之间的联系。最后，我们展示了利用计算方法根据DNA序列预测基因组折叠的可行性，这将有助于发现遗传变异（包括与疾病相关的变异）对基因组结构和功能的潜在影响。

### 第二部分 AI 大师评价

本研究以系统性的数据整合与建模手段，全面描绘了人类四维核基因组的结构与功能联系。通过对H1胚胎干细胞及成纤维细胞的多组学分析，研究团队建立了高分辨率的染色体相互作用图谱及核内定位注释。其创新性体现在大规模整合数据驱动的单细胞三维模型构建及DNA序列到空间结构的预测框架，为阐释遗传变异对基因组结构功能影响提供了新思路。然而，该研究仍主要基于特定细胞系统，未来需扩展至更广谱细胞类型与动态状态以完善模型的普适性。

---

## 23. 肝脏营养因子的瞬时重建可增强老年免疫功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407851)
**期刊：** Nature
**PMID：** 41407851
**DOI：** 10.1038/s41586-025-09873-4

### 第一部分 原文与翻译

**英文原标题：** Transient hepatic reconstitution of trophic factors enhances aged immunity.

> **英文摘要：**
> Ageing erodes human immunity, in part by reshaping the T cell repertoire, leading to increased vulnerability to infection, malignancy and vaccine failure. Attempts to rejuvenate immune function have yielded only modest results and are limited by toxicity or lack of clinical feasibility. Here we show that the liver can be transiently repurposed to restore age-diminished immune cues and improve T cell function in aged mice. These immune cues were found by performing multi-omic mapping across central and peripheral niches in young and aged animals, leading to the identification of Notch and Fms-like tyrosine kinase 3 ligand (FLT3L) pathways, together with interleukin-7 (IL-7) signalling, as declining with age. Delivery of mRNAs encoding Delta-like ligand 1 (DLL1), FLT3L and IL-7 to hepatocytes expanded common lymphoid progenitors, boosted de novo thymopoiesis without affecting haematopoietic stem cell (HSC) composition, and replenished T cells while enhancing dendritic cell abundance and function. Treatment with these mRNAs improved peptide vaccine responses and restored antitumour immunity in aged mice by increasing tumour-specific CD8 infiltration and clonal diversity and synergizing with immune checkpoint blockade. These effects were reversible after dosing ceased and did not breach self-tolerance, in contrast to the inflammatory and autoimmune liabilities of recombinant cytokine treatments. These findings underscore the promise of mRNA-based strategies for systemic immune modulation and highlight the potential of interventions aimed at preserving immune resilience in ageing populations.

> **中文摘要：**
> 衰老会削弱人体免疫力，部分原因在于重塑了T细胞库，从而导致感染、恶性肿瘤和疫苗失效的风险增加。试图恢复免疫功能的努力仅取得了有限成效，并受到毒性或临床可行性不足的限制。本研究表明，肝脏可被瞬时重编程，以恢复因衰老而减弱的免疫信号，并改善老年小鼠的T细胞功能。通过在年轻与老年动物的中枢和外周免疫生态位执行多组学图谱分析，研究发现Notch及类Fms酪氨酸激酶3配体（FLT3L）通路与白细胞介素-7（IL-7）信号均随年龄下降。将编码Δ样配体1（DLL1）、FLT3L和IL-7的mRNA递送至肝细胞，可扩增共同淋巴祖细胞，促进新的胸腺生成，而不影响造血干细胞（HSC）组成，并在补充T细胞的同时增强树突状细胞的数量与功能。该mRNA治疗提高了老年小鼠对肽疫苗的应答并恢复了抗肿瘤免疫，通过增加肿瘤特异性CD8浸润与克隆多样性，并与免疫检查点阻断产生协同作用。这些效应在停止给药后可逆，且未破坏自身耐受性，与重组细胞因子治疗导致的炎症和自身免疫风险形成对比。这些发现强调了基于mRNA的系统性免疫调控策略的潜力，并突出了旨在维持老年人群免疫韧性的干预手段的前景。

### 第二部分 AI 大师评价

该研究旨在探索通过肝脏瞬时重新编程恢复衰老免疫信号的新策略。作者结合多组学映射发现关键免疫通路如Notch、FLT3L和IL-7随年龄下调，并通过mRNA递送方式在小鼠中重新激活这些信号，显著改善T细胞生成和抗肿瘤免疫反应。结果展示了mRNA技术在安全、可控的全身免疫重塑中的潜力，突破了以往细胞因子疗法的毒性和自免风险限制。其创新性在于利用肝脏作为暂时性免疫调控平台，但其在人类中的可持续性和可转化性仍需深入验证。

---

## 24. 源自 TP53 突变性克隆性造血的治疗相关性髓系肿瘤的发病机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407825)
**期刊：** Leukemia
**PMID：** 41407825
**DOI：** 10.1038/s41375-025-02839-5

### 第一部分 原文与翻译

**英文原标题：** The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.

> **英文摘要：**
> Therapy-related acute myeloid leukemia and myelodysplastic neoplasms (t-AML/MDS) are devastating complications of chemo- or radiation therapy in patients treated for an unrelated primary malignancy. Cancer patients with TP53-mutant hematopoietic stem and progenitor cells (HSPCs) - a condition termed clonal hematopoiesis (CH) - are at a particularly high risk for t-AML/MDS. However, the pathogenesis of TP53-mutant t-AML/MDS, especially the role of the TP53 allelic state (i.e., mono- vs. biallelic), and its prognostic impact in AML/MDS have remained only poorly understood. We developed novel in vitro and in vivo mouse models to investigate how mono- or biallelic Trp53 mutations influence clonal expansion and leukemic progression from CH to t-AML/MDS. While HSPCs with monoallelic Trp53 mutations gain clonal fitness but retain their genomic integrity under chemo- or radiation therapy, biallelic Trp53 mutations result in genomic instability and are essential for leukemic transformation. Moreover, we provide proof of concept that non-mutational p53 inactivation, such as MDM2 overexpression, can replicate the effects of biallelic TP53 mutations, providing a possible explanation for cases of TP53-mutant AML/MDS that retain one wild-type TP53 allele. Our findings elucidate the pathogenesis of TP53-mutant t-AML/MDS and support the classification of biallelic TP53-mutant AML/MDS as distinct clinical entities.

> **中文摘要：**
> 治疗相关性急性髓系白血病和骨髓发育异常性肿瘤（t-AML/MDS）是发生在接受针对其他原发恶性肿瘤化疗或放疗患者中的毁灭性并发症。具有 TP53 突变性造血干/祖细胞（HSPCs）的癌症患者——即所谓克隆性造血（CH）状态——特别容易发生 t-AML/MDS。然而，TP53 突变型 t-AML/MDS 的发病机制，特别是 TP53 等位基因状态（即单等位基因与双等位基因）的作用及其在 AML/MDS 中的预后意义，仍然知之甚少。我们建立了新型的体内外小鼠模型，用以研究单等位或双等位 Trp53 突变如何影响从 CH 到 t-AML/MDS 的克隆扩增与白血病进展。结果显示，带有单等位 Trp53 突变的 HSPCs 在化疗或放疗下获得克隆适应性优势，但仍能保持基因组完整性；而双等位 Trp53 突变会导致基因组不稳定性，是白血病转化的关键。进一步地，我们提供了非突变性 p53 失活（如 MDM2 过表达）能够模拟双等位 TP53 突变效应的概念性证据，这为保留一个野生型 TP53 等位基因的 TP53 突变型 AML/MDS 病例提供了可能的解释。我们的研究结果阐明了 TP53 突变型 t-AML/MDS 的发病机制，并支持将双等位 TP53 突变型 AML/MDS 作为独立临床实体进行分类。

### 第二部分 AI 大师评价

本研究旨在揭示源自 TP53 突变性克隆性造血的治疗相关性髓系肿瘤的分子发病机制。作者通过创新的体内外小鼠模型，对单等位与双等位 TP53 突变在克隆扩增及白血病转化中的差异进行了系统分析。研究发现，双等位 TP53 突变导致基因组不稳定并驱动白血病转化，而单等位突变仅提升克隆适应性。更重要的是，非突变性 p53 失活（如 MDM2 过表达）可模拟双等位突变效应。该研究为 t-AML/MDS 的分子分类提供了重要依据，但仍需进一步临床验证其预后与治疗意义。

---

## 25. 对映选择性蛋白亲和筛选质谱技术（E‑ASMS）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407727)
**期刊：** Nature communications
**PMID：** 41407727
**DOI：** 10.1038/s41467-025-67403-2

### 第一部分 原文与翻译

**英文原标题：** Enantioselective protein affinity selection mass spectrometry (E-ASMS).

> **英文摘要：**
> We report an enantioselective protein affinity selection mass spectrometry screening approach (E-ASMS) that enables the detection of weak binders, informs on selectivity, and generates orthogonal confirmation of binding. After method development with control proteins, we screen 31 human proteins against a designed library of 8,217 chiral compounds. We identify 16 binders to 12 targets, including many proteins predicted to be "challenging to ligand", and confirm their interactions through orthogonal biophysical assays. Seven binders to six targets display enantioselective binding, with K values ranging from 3 to 20 µM. Binders for four targets (DDB1, WDR91, WDR55, and HAT1) are selected for in-depth characterization using X-ray crystallography. In all four cases, the mechanisms underlying enantioselectivity are readily explained. These results demonstrate that E-ASMS enables the identification and characterization of selective and weakly binding ligands for novel protein targets with unprecedented throughput and sensitivity.

> **中文摘要：**
> 我们报道了一种对映选择性蛋白亲和筛选质谱技术（E‑ASMS），该方法能够检测弱结合物，提供选择性信息，并生成结合的正交验证。在使用对照蛋白进行方法开发之后，我们将31种人源蛋白与一个包含8,217个手性化合物的设计库进行筛选。我们鉴定出16个配体与12个靶标结合，其中包括许多被预测为“难以结合配体”的蛋白，并通过正交的生物物理分析验证了这些相互作用。其中，7个配体与6个靶标表现出对映选择性结合，结合常数（K）范围为3至20 µM。我们选择了4个靶标（DDB1、WDR91、WDR55和HAT1）的配体，利用X射线晶体学进行了深入表征。在这四种情况下，对映选择性背后的机制均得到明确解释。这些结果表明，E‑ASMS能够以前所未有的通量和灵敏度识别并表征针对新型蛋白靶标的选择性及弱亲和力配体。

### 第二部分 AI 大师评价

该研究提出了一种创新的E‑ASMS筛选策略，用于在复杂蛋白体系中高通量识别弱结合的手性配体。作者在方法建立后对31种人源蛋白进行了系统性筛查，成功发现多个具有对映选择性的蛋白‑配体相互作用，并通过正交生物物理方法和晶体学验证其结合机制。研究显著拓展了质谱筛选在手性药物发现中的应用范围。其创新性在于结合选择性检测与结构确认的整合流程，但局限性可能在于对膜蛋白或超弱结合物的适用性仍需进一步验证。

---

## 26. AAV递送的工程化抑制型tRNA在遗传性视网膜疾病小鼠中恢复视觉功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407712)
**期刊：** Nature communications
**PMID：** 41407712
**DOI：** 10.1038/s41467-025-66176-y

### 第一部分 原文与翻译

**英文原标题：** AAV-delivered engineered suppressor tRNA rescues visual function in mice with an inherited retinal disease.

> **英文摘要：**
> Nonsense mutations change a sense codon into a premature termination codon (PTC) in mRNA and account for approximately 18.5% of human inherited retinal diseases (IRDs)-related mutation. Nonsense suppression therapies by small molecular drugs or suppressor tRNAs (sup-tRNAs) can introduce an amino acid at PTC, thereby promoting the production of full-length proteins. While sup-tRNA-based therapies have shown promising results in cell culture models, challenges remain for in vivo delivery, particularly regarding efficacy, stability, and safety. In this study, we engineer the body sequence of sup-tRNA to enhance readthrough efficiency at clinically relevant PTCs in the RPE65 and ABCA4 genes. By using the self-complementary adeno-associated virus (scAAV), we achieve restoration of RPE65 protein expression in up to 50.2% retinal pigment epithelium (RPE) cells in a mouse model carrying the RPE65-R44X nonsense mutation. Notably, the engineered sup-tRNA significantly restores retinal function in mice, with effects lasting for at least 36 weeks. Furthermore, scAAV8.sup-tRNA exhibits minimal retinal toxicity and had negligible effects on global readthrough at native termination codons as revealed by ribosome profiling. Our findings demonstrate scAAV-delivered sup-tRNA is a potential therapeutic intervention for IRDs caused by nonsense mutations in RPE65 gene.

> **中文摘要：**
> 无义突变会将mRNA中的有义密码子变为提前终止密码子（PTC），约占人类遗传性视网膜疾病（IRD）相关突变的18.5%。通过小分子药物或抑制型tRNA（sup-tRNA）进行的无义突变抑制疗法，可以在PTC处引入一个氨基酸，从而促进全长蛋白的产生。尽管基于sup-tRNA的疗法在细胞培养模型中已显示出良好前景，但在体内递送方面仍面临挑战，尤其是在疗效、稳定性和安全性方面。在本研究中，我们对sup-tRNA的主体序列进行了工程化改造，以增强其在RPE65和ABCA4基因中临床相关PTC处的读通效率。通过使用自互补腺相关病毒（scAAV），在携带RPE65-R44X无义突变的小鼠模型中，我们实现了视网膜色素上皮（RPE）细胞中最高达50.2%的RPE65蛋白表达恢复。值得注意的是，工程化的sup-tRNA显著恢复了小鼠的视网膜功能，其疗效至少可持续36周。此外，scAAV8.sup-tRNA表现出极低的视网膜毒性，并且核糖体分析表明其对内源性终止密码子的全局读通影响可忽略不计。我们的研究结果表明，scAAV递送的sup-tRNA是治疗由RPE65基因无义突变引起的IRD的潜在疗法。

### 第二部分 AI 大师评价

这项研究旨在开发一种针对RPE65无义突变导致的遗传性视网膜疾病的新型基因疗法。作者通过工程化抑制型tRNA并利用自互补腺相关病毒实现高效递送，显著提高了在小鼠模型中的读通效率和蛋白表达水平。研究结果证实该疗法能够长期恢复视觉功能，且安全性良好，显示出对无义突变相关疾病的治疗潜力。其创新性在于将工程化tRNA与AAV递送系统结合，实现了在体内稳定、有效的读通修复。然而，疗效转化至人体仍需进一步验证。

---

## 27. 针对ER阳性/HER2阴性晚期或转移性乳腺癌的内质网受体降解：一期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407710)
**期刊：** Nature communications
**PMID：** 41407710
**DOI：** 10.1038/s41467-025-67485-y

### 第一部分 原文与翻译

**英文原标题：** ER degradation for ER/HER2- advanced or metastatic breast cancer: a phase 1 trial.

> **英文摘要：**
> AC699 is a novel, orally bioavailable chimeric estrogen receptor-α (ERα) degrader that induces proteasome-dependent ERα degradation via cereblon E3 ligase recruitment. Here we report findings from a first-in-human, phase 1, dose-escalation study of once-daily AC699 (100-600 mg) in patients with heavily-pretreated, locally-advanced/metastatic ER-positive/HER2-negative breast cancer (ClinicalTrials.gov Identifier: NCT05654532). Primary objectives are to assess dose-limiting toxicities and treatment-emergent adverse events (TEAEs). Secondary objectives are to evaluate pharmacokinetics, objective response rate (ORR), clinical benefit rate (CBR, including stable disease ≥24 weeks), duration of response (DOR), and progression-free survival (PFS). Among 37 treated patients, TEAEs occurred in 78% of patients, most commonly nausea (19%), fatigue (16%), and neutropenia (16%). All treatment-related adverse events were Grade 1/2, with no dose reductions/discontinuations; the maximum tolerated dose was not reached. Of 26 efficacy-evaluable patients, 4 (15%) achieved partial responses and CBR was 23%. In exploratory analysis of patients with ESR1 mutations, ORR and CBR were 40% and 45%, respectively. Median DOR and PFS were 6.5 and 3.6 months overall, and 6.5 and 7.4 months in ESR1-mutant patients. AC699 steady-state exposure increased approximately dose-proportionally between 100-400 mg, plateauing at 600 mg. AC699 demonstrated favorable safety, predictable PK, and encouraging antitumor activity, particularly in ESR1-mutant disease.

> **中文摘要：**
> AC699是一种新型、可口服的嵌合雌激素受体α（ERα）降解剂，通过募集cereblon E3连接酶诱导依赖蛋白酶体的ERα降解。本研究报告了一项首次人体、剂量递增的一期临床试验结果，评估每日一次AC699（100–600 mg）在经大量预处理的局部晚期或转移性ER阳性/HER2阴性乳腺癌患者中的应用（ClinicalTrials.gov编号：NCT05654532）。主要研究目标为评估剂量限制性毒性和治疗相关不良事件（TEAE）。次要目标包括评估药代动力学、客观缓解率（ORR）、临床获益率（CBR，包括疾病稳定≥24周）、缓解持续时间（DOR）以及无进展生存期（PFS）。在37例接受治疗的患者中，78%出现TEAE，最常见的是恶心（19%）、乏力（16%）和中性粒细胞减少（16%）。所有治疗相关不良事件均为1/2级，无剂量降低或治疗中止；未达到最大耐受剂量。在26例可评估疗效的患者中，4例（15%）获得部分缓解，CBR为23%。在携带ESR1突变的患者探索性分析中，ORR和CBR分别为40%和45%。总体中位DOR和PFS分别为6.5个月和3.6个月，而ESR1突变患者中分别为6.5个月和7.4个月。AC699在100–400 mg之间的稳态暴露近似呈剂量比例增加，在600 mg时趋于平台。AC699显示出良好的安全性、可预测的药代特征以及令人鼓舞的抗肿瘤活性，尤其在ESR1突变疾病中表现突出。

### 第二部分 AI 大师评价

本研究首次在人群中评估了新型ERα降解剂AC699在ER阳性/HER2阴性晚期乳腺癌患者中的安全性与初步疗效。结果表明AC699具有良好的耐受性，未发现剂量限制性毒性，并展现出剂量可预测的药代动力学特征以及一定的抗肿瘤活性。尤其在ESR1突变患者中，客观缓解率和临床获益率显著提高，提示其在耐药性人群中的潜在优势。尽管样本量有限且随访时间较短，但该研究为后续更大规模临床验证奠定了重要基础。

---

## 28. 构建定点氧化紫杉烷的氧化酶工具箱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407708)
**期刊：** Nature communications
**PMID：** 41407708
**DOI：** 10.1038/s41467-025-67544-4

### 第一部分 原文与翻译

**英文原标题：** Designing an oxidase toolbox for site-directed oxidation of taxanes.

> **英文摘要：**
> Paclitaxel is one of the most prominent drugs for cancer therapy, and its synthesis has long been pursued by scientific community. Although the biosynthetic pathway has been gradually unraveled, its synthetic efficiency remains severely constrained by the low activity and low product selectivity of the hydrolases involved. In this study, an artificial toolbox of oxidases derived from mutants of TteUPO (unspecific peroxygenase from Thielavia terrestris) is developed for site-directed oxidation of taxanes at the C-4, C-6, C-10, C-11, C-12, and C-13 positions. Furthermore, de novo biosynthesis of oxidized taxadiene products is achieved in an engineered E. coli chassis. These findings offer an unconventional strategy for developing an efficient route toward paclitaxel and constructing paclitaxel analogs with different structures for medicinal evaluation.

> **中文摘要：**
> 紫杉醇是最具代表性的抗癌药物之一，其合成长期以来一直是科研界追求的目标。尽管其生物合成途径已逐步被揭示，但由于相关水解酶的活性低、产物选择性差，其合成效率仍受到严重限制。在本研究中，研究人员基于来源于地衣霉 Thielavia terrestris 的非特异性过氧化物酶（TteUPO）突变体，构建了一套人工氧化酶工具箱，用于紫杉烷分子在 C-4、C-6、C-10、C-11、C-12 及 C-13 位点的定点氧化。此外，在经过工程改造的大肠杆菌底盘中成功实现了氧化紫杉二烯产物的从头生物合成。这些研究结果提供了一种非常规策略，有助于开发高效的紫杉醇合成路线，并为构建具有多样结构的紫杉醇类似物进行药理评估奠定基础。

### 第二部分 AI 大师评价

该研究以提高紫杉醇生物合成效率为目标，采用突变体来源的氧化酶构建了一套用于紫杉烷分子定点氧化的人工工具箱。通过实现特定位点的选择性氧化并在工程化大肠杆菌中实现氧化产物的从头合成，工作展示了合成生物学与酶工程的融合创新。该成果为紫杉醇及其衍生物的高效生产提供了新策略，也为多样结构药物先导物的开发打开了途径。其创新性在于氧化酶定点改造和底盘菌整合设计，但仍需进一步验证产率稳定性与工业化可行性。

---

## 29. HLA-A2限制性免疫优势型SARS-CoV-2特异性CD8 T细胞受体库对抗原漂移的抗逃逸潜能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407706)
**期刊：** Nature communications
**PMID：** 41407706
**DOI：** 10.1038/s41467-025-67336-w

### 第一部分 原文与翻译

**英文原标题：** Resistance potential of the HLA-A2-restricted immunodominant SARS-CoV-2-specific CD8 T cell receptor repertoire to antigenic drift.

> **英文摘要：**
> A major concern of COVID-19 is immune escape. While T cells are implicated in protection against severe disease, direct evaluation of their capacity to specifically target SARS-CoV-2 variants remains limited. We aim to narrow this gap by profiling the ability of CD8 T cells to recognize SARS-CoV-2 mutations after vaccination and observe a high degree of phenotype and repertoire diversity. To better understand the breadth of antigen repertoire coverage, we interrogate the ability of SARS-CoV-2 specific TCRs to bind all point mutations of the immunodominant HLA-A2:S epitope. While mutation space coverage is surprisingly vast, specific substitutions are not recognized by the vaccine-elicited repertoire. Structural analyses reveal a TCR sequence-based antigen recognition limitation intrinsic to vaccination. Further investigation reveals that this repertoire 'hole' is not present in the naive repertoire, suggesting future immune escape through these potential escape mutations could be relieved by modifications to vaccines.

> **中文摘要：**
> COVID-19的主要关注点之一是免疫逃逸。尽管T细胞与防止重症相关，但针对其特异性识别SARS-CoV-2变异株能力的直接评估仍然有限。本研究旨在缩小这一差距，通过分析接种疫苗后CD8 T细胞识别SARS-CoV-2突变的能力，观察到表型和受体库的高度多样性。为更好理解抗原受体库覆盖范围，我们检测了SARS-CoV-2特异性TCR与免疫优势性HLA-A2:S表位所有点突变的结合能力。虽然突变空间的覆盖范围出乎意料地广，但疫苗诱导的受体库无法识别特定的氨基酸替换。结构分析显示，这种局限源于TCR序列层面的抗原识别约束，是疫苗接种固有的限制。进一步研究发现，这种受体库的“空洞”在未暴露（初始）受体库中并不存在，这提示通过疫苗改良有望缓解未来可能由这些潜在逃逸突变引起的免疫逃逸问题。

### 第二部分 AI 大师评价

该研究聚焦于疫苗诱导的HLA-A2限制性SARS-CoV-2特异性CD8 T细胞受体库的抗原漂移抗性，结合功能分析与结构解析揭示TCR识别的序列性约束。研究发现尽管总体突变覆盖广泛，但存在识别空缺，可能成为未来免疫逃逸风险点。这一工作在T细胞免疫演化与疫苗优化方向上具有重要启示，体现出高水平的实验设计与结构生物学整合。但其局限在于主要基于体外体系，尚需验证临床保护效应的相关性。

---

## 30. 拟南芥SLAH家族协同调控的结构性机制解析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407702)
**期刊：** Nature communications
**PMID：** 41407702
**DOI：** 10.1038/s41467-025-67283-6

### 第一部分 原文与翻译

**英文原标题：** Structural insights into the coordinated regulation of the SLAH family in Arabidopsis thaliana.

> **英文摘要：**
> S-type anion channel homologs (SLAH) are widely expressed in various plant tissues and play a key role in anion transport, which is crucial for plant adaptation to both biotic and abiotic stresses. In this study, we employ cryo-electron microscopy (cryo-EM) to analyze four SLAH channel complexes from Arabidopsis thaliana: the homotrimeric SLAH3 channel, the 2SLAH1 + SLAH3+tRNA complex, the 1SLAH1 + 2SLAH3 complex, and the 3SLAH1+tRNA complex. Critically, our studies reveal that tRNA directly binds to and occupies the intracellular entrance of the SLAH1 homotrimer and the 2SLAH1 + SLAH3 heterocomplex. Electrophysiological experiments confirm tRNA's role as a potent inhibitory regulatory subunit: RNase-mediated tRNA degradation robustly activates SLAH1 currents, while targeted mutagenesis of SLAH1 tRNA-interacting residues phenocopy this activation and enhanced ABA-induced stomatal closure. Combining with structural biology, electrophysiology, and biochemistry, we comprehensively examine the key residues in SLAH1 and SLAH3 that are responsible for the anion permeation. This mechanistic advancement provides a deeper understanding of the molecular basis for plant stress tolerance and identifies specific molecular targets for future engineering crops.

> **中文摘要：**
> S型阴离子通道同源蛋白（SLAH）在植物的多种组织中广泛表达，在阴离子转运中发挥关键作用，这一过程对植物适应生物和非生物胁迫至关重要。本研究采用冷冻电子显微镜（cryo-EM）分析了来自拟南芥的四种SLAH通道复合物：SLAH3同源三聚体通道、2SLAH1 + SLAH3 +tRNA复合物、1SLAH1 + 2SLAH3复合物以及3SLAH1 +tRNA复合物。研究发现，tRNA可直接结合并占据SLAH1同源三聚体及2SLAH1 + SLAH3异源复合物的胞内入口部位。电生理实验进一步证实tRNA作为一种强效抑制性调控亚基的作用：通过RNase介导的tRNA降解可显著激活SLAH1电流，而靶向突变SLAH1中与tRNA相互作用的残基亦可模拟此激活效应，并增强ABA诱导的气孔关闭。结合结构生物学、电生理学和生物化学实验，研究全面解析了SLAH1与SLAH3中决定阴离子通透性的关键残基。本研究的机制性进展为理解植物耐逆机制的分子基础提供了更深层次的认识，并为未来作物改良提供了潜在的分子靶点。

### 第二部分 AI 大师评价

该研究旨在阐明拟南芥SLAH阴离子通道家族的协同调控机制。作者通过冷冻电镜结构解析、电生理实验和生化分析相结合的方法，揭示了tRNA可直接作为抑制性调控因子结合SLAH1并影响通道活性。研究首次发现tRNA参与离子通道调控的结构基础，扩展了植物信号转导与离子运输的分子图谱。此工作具有显著的创新性，同时其结构-功能关联仍需在生理条件下进一步验证。

---

## 31. AAK1激活介导的铁转运驱动铁死亡细胞凋亡

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407700)
**期刊：** Nature communications
**PMID：** 41407700
**DOI：** 10.1038/s41467-025-67523-9

### 第一部分 原文与翻译

**英文原标题：** AAK1 activation-mediated iron trafficking drives ferroptotic cell death.

> **英文摘要：**
> Ferrous iron is necessary for the occurrence of ferroptosis. The molecular mechanisms that maintain iron homeostasis within cells play a crucial role in the regulation of ferroptosis. However, how cells regulate iron uptake during ferroptosis remains unclear. Here, PKCβII is identified as a key kinase mediating transferrin receptor 1 (TFR1) endocytosis through phosphorylation and activation of AP2-associated protein kinase 1 (AAK1) during the ferroptotic process. Mechanistically, activated AAK1 phosphorylates AP2M1, which facilitates the recruitment of clathrin to mediate the endocytosis of TFR1, increasing the levels of both cellular total iron and ferrous iron and thereby promoting ferroptosis. The non-phosphorylatable mutation of AAK1 inhibits ferroptosis and consequently promotes breast tumor growth in vivo. In conclusion, we identify that the PKCβII-AAK1-AP2M1 pathway is a crucial mechanism for the regulation of cellular iron uptake during ferroptosis, which is correlated with the prognosis of breast cancer patients and presents a potential target for cancer therapy.

> **中文摘要：**
> 亚铁离子是铁死亡发生所必需的。维持细胞内铁稳态的分子机制在铁死亡的调控中起着关键作用。然而，细胞在铁死亡过程中如何调节铁的摄取仍不清楚。本研究鉴定出PKCβII是在铁死亡过程中通过磷酸化并激活AP2相关蛋白激酶1（AAK1）来介导转铁蛋白受体1（TFR1）内吞的关键激酶。在机制层面上，活化的AAK1磷酸化AP2M1，从而促进网格蛋白的募集以介导TFR1的内吞，增加细胞总铁和亚铁的水平，从而促进铁死亡。AAK1的不可磷酸化突变可抑制铁死亡，进而在体内促进乳腺肿瘤的生长。综上所述，我们发现PKCβII–AAK1–AP2M1通路是调控铁死亡过程中细胞铁摄取的重要机制，与乳腺癌患者的预后相关，并为癌症治疗提供了潜在靶点。

### 第二部分 AI 大师评价

该研究揭示了PKCβII–AAK1–AP2M1信号通路在铁死亡调控中的关键作用，明确了AAK1通过促进转铁蛋白受体内吞而调节细胞铁摄取的分子机制。研究采用分子生物学、细胞实验及体内肿瘤模型相结合的方法，严谨地验证了各关键蛋白的功能关联。其发现不仅加深了人们对铁死亡调控网络的理解，也提示AAK1可能作为乳腺癌治疗的新型靶点。研究的创新性在于首次连接了铁摄取内吞途径与铁死亡机制，但其临床转化仍需进一步验证。

---

## 32. 循环肿瘤DNA突变检测方法的综合基准评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407694)
**期刊：** Nature communications
**PMID：** 41407694
**DOI：** 10.1038/s41467-025-67842-x

### 第一部分 原文与翻译

**英文原标题：** Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA.

> **英文摘要：**
> Detection of somatic mutations in cell-free DNA (cfDNA) is challenging due to low variant allele frequencies and extensive DNA degradation. Here we develop a benchmarking strategy using longitudinal patient-matched cfDNA samples from individuals with colorectal and breast cancer. Samples with high and ultra-low levels of tumor-derived DNA are combined into controlled dilution series that preserve the properties of authentic cell-free DNA, including each patient's germline and blood-cell mutation backgrounds. Using deep whole-genome (150x) and exome (2,000x) sequencing, we define a reference set of ~37,000 single nucleotide variants and ~58,000 indels to benchmark nine somatic variant callers across varying ctDNA levels and sequencing depths. We also explore machine learning-based tuning of individual callers and identify features that improve accuracy in cfDNA. This benchmarking resource clarifies the detection limits of current approaches and provides practical guidance for selecting somatic variant calling methods in liquid biopsy applications.

> **中文摘要：**
> 由于变异等位基因频率低且DNA降解严重，在无细胞DNA（cfDNA）中检测体细胞突变具有挑战性。本研究开发了一种基准测试策略，利用来自结直肠癌和乳腺癌患者的纵向、匹配的cfDNA样本。将具有高含量与超低含量肿瘤来源DNA的样本组合为受控稀释系列，从而保留真实cfDNA的特性，包括每位患者的生殖系和血细胞突变背景。通过深度全基因组（150x）和外显子组（2000x）测序，我们定义了约37,000个单核苷酸变异和约58,000个插入/缺失变异的参考集，以在不同ctDNA水平和测序深度下对九种体细胞变异检测工具进行基准评估。同时，我们探索了基于机器学习的单个检测器参数优化，并确定了可提高cfDNA检测准确性的特征。该基准资源阐明了当前方法的检测极限，并为液体活检应用中体细胞变异检测方法的选择提供了实用指导。

### 第二部分 AI 大师评价

本研究旨在系统评估循环肿瘤DNA突变检测算法的性能，通过构建患者匹配的稀释序列样本及高深度测序，形成了大规模参考变异集。作者比较了九种体细胞变异检测工具，并尝试运用机器学习优化算法表现。此工作不仅揭示了cfDNA突变检测的技术边界，还提供了可复用的基准资源，为液体活检领域的方法选择与算法改进奠定了坚实基础。但其评估仍受限于选定癌种与实验条件的代表性。

---

## 33. PARP1介导的ADP-核糖化全局重塑抑制甲型流感病毒感染

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407686)
**期刊：** Nature communications
**PMID：** 41407686
**DOI：** 10.1038/s41467-025-66136-6

### 第一部分 原文与翻译

**英文原标题：** Global remodeling of ADP-ribosylation by PARP1 suppresses influenza A virus infection.

> **英文摘要：**
> ADP-ribosylation is a highly dynamic and fully reversible post-translational modification performed by PARP enzymes that modulates protein function, abundance, localization, and turnover. Here we show that PARPs mount an antiviral response to influenza A virus infection causing a rapid and dramatic upregulation of global ADP-ribosylation that inhibits viral replication. Mass spectrometry analyzes define the global ADP-ribosylome during infection, creating an infection-specific profile with almost 4000 modification sites on ~1000 host proteins, as well as over 100 modification sites on viral proteins. Our data suggest that the global increase reflects a change in the form of ADP-ribosylation rather than modification of new targets. Functional assays demonstrate that modification of the viral replication machinery antagonizes its activity. We further show that the influenza A virus protein NS1 counteracts the anti-viral activity of PARPs and ADP-ribosylation, assigning a new activity to the primary viral antagonist of innate immunity. We identify PARP1 as the enzyme producing the majority of poly(ADP-ribose) present during infection. Influenza A virus replicates faster in cells lacking PARP1, linking PARP1 and ADP-ribosylation to the anti-viral phenotype. Together, these data establish ADP-ribosylation as an anti-viral innate immune-like response to viral infection antagonized by a previously unknown activity of NS1.

> **中文摘要：**
> ADP-核糖化是一种由PARP酶介导的高度动态且完全可逆的翻译后修饰，可调控蛋白的功能、丰度、定位和周转。我们在此发现，PARPs在应对甲型流感病毒感染时会触发抗病毒反应，导致全局ADP-核糖化水平迅速且显著上升，从而抑制病毒复制。基于质谱分析，我们描绘了感染过程中的全局ADP-核糖化组特征，建立了感染特异性的修饰谱，其中包含约4000个修饰位点，分布于约1000种宿主蛋白上，并在病毒蛋白上识别出100多个修饰位点。我们的数据表明，这种全局增加反映的是ADP-核糖化形式的变化，而非新靶点的修饰。功能实验显示，对病毒复制机器的修饰会拮抗其活性。进一步研究表明，甲型流感病毒蛋白NS1能够抵消PARPs和ADP-核糖化的抗病毒效应，为先天免疫主要拮抗因子NS1赋予了一项新的功能。我们鉴定出PARP1是感染过程中产生大部分多(ADP-核糖)的主要酶。缺乏PARP1的细胞中，甲型流感病毒复制速度更快，表明PARP1及其介导的ADP-核糖化与抗病毒表型密切相关。总体而言，这些结果确立了ADP-核糖化作为类似先天免疫的抗病毒反应，并指出NS1具有此前未知的拮抗活性。

### 第二部分 AI 大师评价

该研究揭示了PARP1在调控ADP-核糖化全局重塑过程中发挥的抗甲型流感病毒作用。通过质谱组学与功能实验，作者系统界定了感染相关的ADP-核糖化组特征，并发现其主要通过改变修饰形式抑制病毒复制。研究首次明确NS1可拮抗PARP1的抗病毒功能，为理解病毒-宿主免疫博弈提供了新视角。该工作在机制阐释和蛋白修饰组分析方面具有显著创新性，但仍需在体内模型中验证其生理相关性。

---

## 34. 核受体Nur77破坏血红素稳态，通过颗粒酶B依赖的GSDMC切割诱导细胞焦亡。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407678)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41407678
**DOI：** 10.1038/s41392-025-02528-w

### 第一部分 原文与翻译

**英文原标题：** Disruption of heme homeostasis by nuclear receptor Nur77 induces pyroptosis through granzyme B-dependent GSDMC cleavage.

> **英文摘要：**
> Pyroptosis plays a crucial role in physiological and pathological processes. As melanoma cells are resistant to apoptosis but express gasdermin proteins, it is appealing to counter melanoma with the induction of gasdermin-executed pyroptosis. GSDMC, initially cloned from metastatic melanoma cells, has been demonstrated as a potential executioner of pyroptosis. However, no lead compounds that trigger GSDMC-mediated pyroptosis have been reported, which limits the in-depth investigation of GSDMC functions. Here, we discovered a chemical compound, dodecyl 1H-benzo[d]imidazole-5-carboxylate (DdBIC), that targeted the nuclear receptor Nur77 to induce pyroptosis through cleaving GSDMC by granzyme B in melanoma cells. Upon DdBIC binding, Nur77 was translocated to the mitochondria to activate the hemoprotein SDHA to overconsume succinyl-CoA, subsequently disrupting the homeostasis of heme in the SDH complex and resulting in electron leakage to induce mito-ROS production. This mito-ROS signal was sensed by the mitochondrial protease OMA1 via oxidation, which led to downstream OPA1 cleavage and subsequent released into the cytoplasm. Cytosolic OPA1 activated PERK to induce the integrated stress response (ISR), which further activated granzyme B to cleave GSDMC, culminating in the induction of pyroptosis. Together, this study elucidates a signal cascade from Nur77-impaired homeostasis of heme metabolism to PERK-mediated ISR activation, and reveals a novel paradigm, by which granzyme B, rather than caspases, cleaves GSDMC for pyroptotic induction and provides a new strategy for the therapeutic treatment of melanoma by lead compound DdBIC.

> **中文摘要：**
> 细胞焦亡在生理和病理过程中发挥着关键作用。由于黑色素瘤细胞对凋亡具有抗性但表达gasdermin蛋白，诱导gasdermin介导的细胞焦亡以对抗黑色素瘤成为一个有吸引力的策略。最早从转移性黑色素瘤细胞中克隆得到的GSDMC，已被证实是细胞焦亡的潜在执行蛋白。然而，目前尚无可诱导GSDMC介导细胞焦亡的先导化合物的报道，这限制了对GSDMC功能的深入研究。在本研究中，我们发现一种化学化合物——十二烷基苯并咪唑-5-羧酸酯（DdBIC），该化合物靶向核受体Nur77，在黑色素瘤细胞中通过颗粒酶B切割GSDMC诱导细胞焦亡。当DdBIC与Nur77结合后，Nur77转位至线粒体并激活血红素蛋白SDHA，过度消耗琥珀酰辅酶A，进而破坏SDH复合物中的血红素稳态，导致电子泄漏并诱导线粒体活性氧（mito-ROS）产生。线粒体蛋白酶OMA1通过氧化感受到该mito-ROS信号，从而引发下游OPA1的切割并使其释放到胞质中。胞质中的OPA1激活PERK，从而诱导整合应激反应（ISR），进一步激活颗粒酶B以切割GSDMC，最终导致细胞焦亡的发生。总的来说，本研究阐明了一条由Nur77破坏血红素代谢稳态到PERK介导ISR激活的信号级联途径，并揭示了一种新的模式，即由颗粒酶B而非半胱天冬酶切割GSDMC以诱导细胞焦亡，同时为应用先导化合物DdBIC治疗黑色素瘤提供了新的策略。

### 第二部分 AI 大师评价

该研究以黑色素瘤为模型，发现核受体Nur77通过破坏血红素稳态并激活颗粒酶B介导的GSDMC切割，从而诱导细胞焦亡。研究团队鉴定出小分子化合物DdBIC作为Nur77的靶向激动剂，揭示了从线粒体代谢紊乱到整合应激反应的信号通路。其创新之处在于发现颗粒酶B而非传统半胱天冬酶可剪切GSDMC触发焦亡，拓展了焦亡调控机制的新认知。该研究为开发以焦亡为靶点的抗黑色素瘤疗法提供了新的分子基础和候选化合物。

---

## 35. AMP活化蛋白激酶驱动的脂滴动态调控黑色素瘤对多不饱和脂肪酸及铁诱导铁死亡的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407674)
**期刊：** Nature communications
**PMID：** 41407674
**DOI：** 10.1038/s41467-025-66113-z

### 第一部分 原文与翻译

**英文原标题：** AMP-activated protein kinase-driven lipid droplet dynamics govern melanoma sensitivity to polyunsaturated fatty acid and iron-induced ferroptosis.

> **英文摘要：**
> Ferroptosis, a regulated form of cell death driven by lipid peroxidation, holds promise for targeting treatment-resistant cancer cells. Using a panel of melanoma cell lines, we uncover variability in the timing of ferroptosis onset upon exposure to iron and polyunsaturated fatty acids (PUFAs). This heterogeneity is linked to differences in PUFA sequestration into lipid droplets (LDs) and their subcellular distribution, particularly near lipid-metabolizing organelles such as mitochondria. In late-onset models, ferroptosis is delayed by peripheral LD retention and triggered by nutrient deprivation and AMP-activated protein kinase (AMPK) activation, which promotes LD trafficking toward mitochondria. Early responders bypass this mechanism. Our findings identify nutrient status and LD dynamics as key modulators of PUFA- and iron-induced ferroptosis, offering insights for therapeutic exploitation in cancer.

> **中文摘要：**
> 铁死亡是一种由脂质过氧化驱动的受调控的细胞死亡形式，被认为有望用于靶向治疗耐药性癌细胞。通过使用一组黑色素瘤细胞系，我们发现当暴露于铁和多不饱和脂肪酸（PUFAs）时，铁死亡发生的时间存在差异。这种异质性与PUFA在脂滴（LDs）中的封存及其在细胞内分布的差异有关，尤其是在靠近线粒体等脂质代谢细胞器的区域。在迟发型模型中，铁死亡因外周LDs的滞留而被延迟，并由营养剥夺和AMP活化蛋白激酶（AMPK）的激活所触发，后者促进LDs向线粒体的转运。早期反应型细胞则绕过这一机制。我们的研究发现，营养状态和LDs动态是PUFA和铁诱导铁死亡的关键调节因子，为癌症治疗的潜在应用提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在阐明脂滴动力学和代谢信号如何调控黑色素瘤细胞对铁死亡的敏感性。研究者通过多株细胞系比较，揭示了铁与多不饱和脂肪酸诱导铁死亡时的异质性来源。结果显示，AMPK活化通过促进脂滴向线粒体转运，加速脂质过氧化，从而影响铁死亡进程。该研究创新性地将细胞代谢状态与铁死亡易感性联系起来，为开发代谢依赖型抗癌策略提供了新思路，但仍需在体内验证其普适性与治疗潜力。

---

## 36. 关于：肿瘤转录组范围表达分类器可预测晚期前列腺癌的治疗敏感性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407563)
**期刊：** European urology
**PMID：** 41407563
**DOI：** 10.1016/j.eururo.2025.12.012

### 第一部分 原文与翻译

**英文原标题：** Re: Tumor Transcriptome-wide Expression Classifiers Predict Treatment Sensitivity in Advanced Prostate Cancers.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文发表于《European Urology》，标题显示其为一篇针对先前研究的学术评论或回应，主题聚焦于通过肿瘤转录组表达特征预测晚期前列腺癌对治疗的敏感性。虽然原文未提供摘要，但可以推测该文章可能探讨了利用全转录组数据构建分类模型的有效性与临床适用性。此研究方向具有重要的精准医疗价值，尤其在个体化治疗决策中潜力巨大。然而，作为一篇“Re:”类型文章，其内容可能更偏向学术讨论或方法学评述，而非原始实验性研究。

---

## 37. 回复：欧洲前列腺癌筛查研究——23年随访

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407562)
**期刊：** European urology
**PMID：** 41407562
**DOI：** 10.1016/j.eururo.2025.12.009

### 第一部分 原文与翻译

**英文原标题：** Re: European Study of Prostate Cancer Screening - 23-Year Follow-up.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为对欧洲前列腺癌筛查研究长期随访结果的回复或评论性文章，聚焦于23年的随访数据与其临床意义。虽然缺乏摘要内容，但标题显示作者旨在对前列腺癌筛查策略的长期效果进行反思或补充讨论。此类研究有助于评估筛查的长期获益与潜在过度诊断风险，为群体性癌症预防策略提供重要参考。

---

## 38. 关于Niraparib联合乙酸阿比特龙加泼尼松用于HRR缺陷型转移性去势敏感性前列腺癌的随机Ⅲ期试验的回复。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407561)
**期刊：** European urology
**PMID：** 41407561
**DOI：** 10.1016/j.eururo.2025.12.008

### 第一部分 原文与翻译

**英文原标题：** Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该文是对一项探讨Niraparib联合阿比特龙及泼尼松治疗HRR缺陷型转移性去势敏感性前列腺癌的Ⅲ期随机试验的评论或回复。由于正文摘要缺失，无法直接评估研究结果，但标题表明研究聚焦于合并PARP抑制剂与雄激素合成抑制剂的联合策略。该主题具有较强的转化医学潜力，为精准治疗前列腺癌提供了新的研究方向。

---

## 39. 色氨酸代谢物吲哚-3-乙酸：伊立替康诱导肠上皮损伤的新罪魁祸首

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407526)
**期刊：** Gut
**PMID：** 41407526
**DOI：** 10.1136/gutjnl-2025-336758

### 第一部分 原文与翻译

**英文原标题：** Tryptophan metabolite indole-3-acetate: a new culprit in irinotecan-induced gut epithelial injury.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究聚焦于色氨酸代谢产物吲哚-3-乙酸与伊立替康化疗相关肠上皮损伤之间的潜在致病联系。标题暗示作者可能通过代谢组学或动物模型揭示吲哚-3-乙酸在药物相关肠道毒性中的新作用机制。此研究有助于深化我们对药物—微生物代谢相互作用导致肠黏膜损伤的理解，为减轻化疗不良反应提供新的干预靶点。其创新性在于强调代谢物层面对化疗毒性的贡献，但具体机制和临床可验证性尚待进一步探索。

---

## 40. PCK1缺乏通过12-HETE介导的CD8 T细胞功能障碍促进MASH-HCC进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407525)
**期刊：** Gut
**PMID：** 41407525
**DOI：** 10.1136/gutjnl-2024-334562

### 第一部分 原文与翻译

**英文原标题：** PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8 T cell dysfunction.

> **英文摘要：**
> BACKGROUND: Metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma (MASH-HCC) has been reported to be less responsive to immune checkpoint inhibitors, which may be associated with metabolic reprogramming of tumour cells and abnormal tumour microenvironment.
> 
> OBJECTIVE: Here, we aim to investigate the role of gluconeogenic enzyme phosphoenolpyruvate carboxykinase 1 (PCK1) in MASH-HCC and its interplay with the tumour microenvironment.
> 
> DESIGN: Hepatocyte-specific phosphatase and tensin homologue () and  biallelic knockout mice were established to induce MASH-HCC. Single-cell RNA sequencing and multiparametrical flow cytometry were performed to analyse the immune landscape alterations. Untargeted metabolomics was conducted to elucidate the hepatic metabolism dysregulation.
> 
> RESULTS: PCK1 is downregulated in tumour tissues compared with adjacent non-cancerous tissues from patients with MASH-HCC. Hepatocyte-specific  knockout mice exhibited markedly increased tumorigenesis in dietary models and genetic models of spontaneous MASH-HCC, together with inhibited effector function of tumour-infiltrating CD8 T cells. Mechanistically, PCK1 deficiency induces the accumulation of endogenous metabolite 12-hydroxyeicosatetraenoic acid (12-HETE), which can be taken up by CD8 T cells and activate the p38 mitogen-activated protein kinase pathway by directly interacting with the BTB and CNC homology 1 transcription factor, ultimately leading to CD8 T cells dysfunction. Notably, PCK1 restoration or 12-HETE inhibition combined with anti-PD-1 treatment increases the antitumour capability of CD8 T cells and suppresses MASH-HCC development.
> 
> CONCLUSION: This study reveals the pivotal role of the hepatic cell-intrinsic enzyme PCK1 in mediating CD8 T cell dysfunction via 12-HETE-p38 signalling in MASH-HCC. PCK1 could be a metabolic checkpoint to enhance the efficacy of anti-PD-1 immunotherapy in MASH-HCC.

> **中文摘要：**
> 背景：代谢功能障碍相关脂肪性肝炎相关肝细胞癌（MASH-HCC）已被报道对免疫检查点抑制剂反应较差，这可能与肿瘤细胞的代谢重编程及异常的肿瘤微环境有关。
> 
> 目的：本研究旨在探讨糖异生酶——磷酸烯醇式丙酮酸羧激酶1（PCK1）在MASH-HCC中的作用及其与肿瘤微环境的相互关系。
> 
> 设计：构建肝细胞特异性磷酸酶及张力蛋白同源物（）与双等位基因敲除小鼠，以诱导MASH-HCC的发生。采用单细胞RNA测序及多参数流式细胞术分析免疫图谱变化。进行非靶向代谢组学以阐明肝脏代谢失调机制。
> 
> 结果：与邻近的非癌组织相比，患者MASH-HCC肿瘤组织中PCK1表达下调。肝细胞特异性敲除小鼠在饮食模型与自发性遗传模型中肿瘤发生显著增加，同时肿瘤浸润性CD8 T细胞的效应功能受抑制。在机制上，PCK1缺乏导致内源性代谢物12-羟基二十碳四烯酸（12-HETE）积累，后者可被CD8 T细胞摄取并通过直接与BTB及CNC同源1转录因子相互作用激活p38丝裂原活化蛋白激酶通路，最终引发CD8 T细胞功能障碍。值得注意的是，恢复PCK1表达或抑制12-HETE联合抗PD-1治疗可增强CD8 T细胞的抗肿瘤能力并抑制MASH-HCC的发展。
> 
> 结论：本研究揭示了肝细胞内源性酶PCK1通过12-HETE–p38信号通路介导MASH-HCC中CD8 T细胞功能障碍的关键作用。PCK1可能成为提高抗PD-1免疫治疗效能的代谢检查点。

### 第二部分 AI 大师评价

本研究聚焦于代谢酶PCK1在MASH相关肝癌免疫逃逸中的作用，创新性地揭示了PCK1缺乏通过12-HETE介导的信号通路导致CD8 T细胞功能障碍的机制。研究采用动物模型、单细胞转录组及代谢组学等多维手段，系统描绘了代谢重编程与免疫抑制间的关联。结果指出，纠正PCK1缺陷或阻断12-HETE信号可显著增强抗PD-1治疗效果，为MASH-HCC免疫治疗提供了新的代谢靶点。其创新性在于提出“代谢检查点”这一免疫调控概念，但仍需进一步验证其在人群层面的临床可行性。

---

## 41. CD300e 通过重编程巨噬细胞驱动免疫抑制性肿瘤微环境和结直肠癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407401)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41407401
**DOI：** 10.1136/jitc-2025-013249

### 第一部分 原文与翻译

**英文原标题：** CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming.

> **英文摘要：**
> BACKGROUND: Colorectal cancer (CRC) progression is shaped by the tumor microenvironment, particularly tumor-associated macrophages (TAMs), which often adopt immunosuppressive functions. CD300e, a myeloid receptor involved in immune regulation, has an uncharacterized role in CRC.
> 
> METHODS: Functional studies were conducted in azoxymethane/dextran sodium sulfate and MC38 murine CRC models using CD300e systemic and myeloid-specific CD300e knockout mice, and adoptive transfer experiments assessed macrophage-intrinsic effects. Human studies included analysis of CD300e expression in matched tumor and normal tissue from patients with CRC and in vitro co-culture of patient-derived colon tumor organoids with monocytes to study CD300e induction and TAM polarization.
> 
> RESULTS: In vivo, CD300e deficiency led to reduced tumor burden, enhanced major histocompatibility complex expression on TAMs, and improved T-cell responses. CD300e-deficient macrophages exhibited increased phagocytic activity, antigen presentation, and support for T-cell proliferation and cytotoxicity. Adoptive transfer confirmed that macrophage-intrinsic CD300e expression is sufficient to suppress T-cell function and promote tumor growth. In patients with CRC, CD300e is selectively upregulated in tumor-infiltrating monocytes and macrophages, driving a suppressive phenotype marked by impaired antigen presentation. Tumor-derived signals in vitro induce CD300e expression and promote a protumorigenic macrophage profile.
> 
> CONCLUSIONS: Our findings identify CD300e as a critical regulator of macrophage-mediated immune suppression in CRC and a potential target for reprogramming TAMs to enhance immunotherapy.

> **中文摘要：**
> 背景：结直肠癌（CRC）的进展受肿瘤微环境塑造，尤其是肿瘤相关巨噬细胞（TAMs），它们常常表现出免疫抑制功能。CD300e 是一种参与免疫调控的髓系受体，其在 CRC 中的作用尚未明了。
> 
> 方法：本研究在偶氮甲烷/葡聚糖硫酸钠（AOM/DSS）及 MC38 小鼠结直肠癌模型中，分别采用全身性及髓系特异性 CD300e 基因敲除小鼠进行功能研究，并通过过继转移实验评估巨噬细胞内在效应。人类研究部分包括分析 CRC 患者配对的肿瘤与正常组织中 CD300e 的表达情况，以及利用患者来源的结肠肿瘤类器官与单核细胞体外共培养，研究 CD300e 的诱导机制及 TAM 极化特征。
> 
> 结果：体内实验显示，CD300e 缺失导致肿瘤负荷降低，TAM 上主要组织相容性复合体（MHC）表达增强，且 T 细胞反应得到改善。CD300e 缺失的巨噬细胞表现出更高的吞噬活性、抗原呈递能力以及对 T 细胞增殖和细胞毒性的支持作用。过继转移实验证实，巨噬细胞内在的 CD300e 表达足以抑制 T 细胞功能并促进肿瘤生长。在 CRC 患者中，CD300e 在肿瘤浸润的单核细胞和巨噬细胞中选择性上调，驱动一种以抗原呈递受损为特征的抑制性表型。体外实验显示，肿瘤来源信号可诱导 CD300e 表达并促进促肿瘤性巨噬细胞表型形成。
> 
> 结论：本研究发现 CD300e 是调控 CRC 中巨噬细胞介导免疫抑制的关键分子，并可作为重编程 TAM 以增强免疫治疗效果的潜在靶点。

### 第二部分 AI 大师评价

本研究系统揭示了 CD300e 在结直肠癌免疫抑制性微环境形成中的核心作用，证明其通过重塑巨噬细胞功能促进肿瘤进展。研究设计涵盖小鼠模型、人类组织样本及类器官共培养，实验体系较为完整。结果明确表明 CD300e 缺失能增强抗肿瘤免疫反应，为免疫治疗策略提供新的分子靶点。该研究的创新性在于首次界定了 CD300e 的免疫调控作用，但后续还需进一步阐明其上下游信号通路及临床可行性。

---

## 42. 利用新抗原刺激选择性扩增具有增强干样表型的T细胞受体工程化T细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407400)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41407400
**DOI：** 10.1136/jitc-2025-013373

### 第一部分 原文与翻译

**英文原标题：** Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation.

> **英文摘要：**
> BACKGROUND: Adoptive transfer of T-cell receptor-engineered T cells (TCR-T cells) has shown promising efficacy in solid tumor treatment, but achieving clinical benefit typically requires infusion of tens of billions of cells. The commonly used rapid expansion protocol (REP), based on the CD3-agonistic OKT3 antibody and irradiated allogeneic feeder cells, exponentially expands tumor-infiltrating lymphocytes (TILs). However, the effect of REP on TCR-T cell frequency and phenotype remains unclear. This study aimed to evaluate the impact of REP on TCR-T cells and to assess the potential of a neoantigen-specific stimulation platform, NeoExpand, as a strategy to selectively expand TCR-T cells with favorable phenotypes.
> 
> METHODS: We compared the effects of REP and NeoExpand on the frequency, yield, and phenotype of TCR-T cells engineered against shared neoantigens. Various autologous antigen-presenting cell (APC) types, including dendritic cells and bulk peripheral blood mononuclear cells (PBMCs), were tested as stimulators in NeoExpand. Additionally, we combined NeoExpand with CD3 activation, with or without allogeneic feeders, to improve scalability. The role of exogenous interleukin (IL)-21 in shaping TCR-T cell phenotypes was also investigated.
> 
> RESULTS: REP impaired the frequency and phenotype of TCR-T cells, particularly CD4 and CD8 subsets matched to their engineered TCRs. In contrast, NeoExpand selectively increased TCR-T cell frequency and improved their phenotypes but did not consistently achieve higher total yields compared with REP. Among the tested autologous APCs, PBMCs effectively supported selective expansion. Further optimization using PBMCs as APCs revealed that combining NeoExpand with CD3 activation enabled exponential expansion without compromising selectivity. Inclusion of IL-21 during NeoExpand promoted a naïve/stem-like phenotype in CD8 TCR-T cells, with minimal effect on CD4 TCR-T cells.
> 
> CONCLUSIONS: These findings demonstrate that NeoExpand enables selective expansion of TCR-T cells while preserving favorable phenotypes and scalability. The approach supports further clinical evaluation of NeoExpand as a strategy to generate high-quality TCR-T cell products for adoptive cell therapy.

> **中文摘要：**
> 背景：过继转移经T细胞受体（TCR）工程化的T细胞（TCR‑T细胞）在实体瘤治疗中显示出有前景的疗效，但要获得临床获益通常需输注数百亿个细胞。基于CD3激动性OKT3抗体和照射的异基因饲养细胞的常用快速扩增方案（REP）可使肿瘤浸润淋巴细胞（TILs）呈指数扩增。然而，REP对TCR‑T细胞的频率和表型的影响仍不清楚。本研究旨在评估REP对TCR‑T细胞的影响，并探讨一种新抗原特异性刺激平台NeoExpand作为选择性扩增具有良好表型的TCR‑T细胞的策略的潜力。
> 
> 方法：我们比较了REP和NeoExpand在针对共享新抗原的TCR‑T细胞的频率、产量及表型方面的影响。在NeoExpand体系中测试了多种自体抗原呈递细胞（APC）类型，包括树突状细胞和外周血单个核细胞（PBMCs），作为刺激源。此外，我们将NeoExpand与CD3激活结合，分别在有无异基因饲养细胞的条件下进行，以提高可扩展性。同时还研究了外源性白介素（IL）‑21在塑造TCR‑T细胞表型中的作用。
> 
> 结果：REP降低了TCR‑T细胞的频率并改变其表型，尤其是与工程化TCR配对的CD4与CD8亚群。相反，NeoExpand能选择性提高TCR‑T细胞的频率并改善其表型，但与REP相比，其总产量未见持续性提高。在测试的自体APCs中，PBMCs能有效支持选择性扩增。以PBMCs为APCs进一步优化后显示，NeoExpand与CD3激活联合可实现指数级扩增而不削弱选择性。在NeoExpand过程中加入IL‑21可促进CD8 TCR‑T细胞向初始/干样表型分化，而对CD4 TCR‑T细胞影响甚微。
> 
> 结论：本研究结果表明，NeoExpand能够在保持良好表型和可扩展性的同时实现TCR‑T细胞的选择性扩增。该方法为进一步临床评估NeoExpand用于制备高质量的TCR‑T细胞产品以开展过继细胞治疗提供了依据。

### 第二部分 AI 大师评价

该研究聚焦于优化TCR‑T细胞的体外扩增策略，对比传统的快速扩增方案（REP）与新抗原特异性刺激平台NeoExpand的效果。研究表明，NeoExpand能在保持甚至改善TCR‑T细胞干样与初始表型的同时实现选择性扩增，且在加入IL‑21后对CD8 T细胞的表型优化尤为明显。虽然NeoExpand在总体细胞产量上不一定超过REP，但其质量优势突显了潜在的临床价值。该研究创新地提出了一种兼顾扩增效率与表型质量的TCR‑T制备策略，为未来个体化免疫治疗提供了可行路径。

---

## 43. 自体特征分析揭示由细胞外基质-BTN3A轴驱动的Vδ2γδTIL对胶质母细胞瘤反应中的患者间异质性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407399)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41407399
**DOI：** 10.1136/jitc-2025-013018

### 第一部分 原文与翻译

**英文原标题：** Autologous profiling reveals inter-patient heterogeneity in Vδ2γδTIL responses to glioblastoma driven by extracellular matrix-BTN3A axis.

> **英文摘要：**
> BACKGROUND: The effectiveness of immunotherapies against glioblastoma (GB) remains limited. A major obstacle in advancing new strategies is the reliance on non-autologous systems, which do not accurately mimic the true extent of inter-patient heterogeneity in both immune responses and tumor susceptibility. This often leads to misleading conclusions about therapeutic efficacy and targetability.
> 
> METHODS: In this study, we addressed this critical gap by employing a fully autologous model. We phenotypically characterized primary αβ and γδT cells from the peripheral blood and tumors of 40 brain tumor patients, including 36 with confirmed GB, and expanded and functionally assessed the autologous anti-GB reactivity in a subset of patients.
> 
> RESULTS: Notably, only Vδ2 and Vδ2 γδT cells, but not αβT cells, recognized autologous tumors. While Vδ2 γδT cells showed activity in a subset of patients, Vδ2 γδTILs from all patients responded to autologous GB cells in the presence of pamidronate. In patients, a higher percentage of Vδ2 γδTILs was associated with longer overall survival. However, the potency of Vδ2 γδTILs varied markedly between individuals, highlighting substantial inter-patient heterogeneity in γδT cell-mediated tumor recognition. This variability was driven by differences in both immune cell-intrinsic features and tumor-intrinsic factors, including expression of BTN2A1 and especially BTN3A, the ligands of the Vδ2 γδTCR. Functional assays revealed that anti-GB reactivity was further modulated by stimulatory and inhibitory co-receptors such as NKG2D, CD94, and TIGIT. Transcriptomic analysis linked Vδ2 γδT cell reactivity to extracellular matrix (ECM) pathways and disrupting ECM components such as LAMA5 and TGFB1 enhanced T cell responses. Knockout of ITGA3, a LAMA5 receptor, increased BTN2A1 and BTN3A expression on GB cells, improving immune recognition.
> 
> CONCLUSIONS: This study demonstrates that inter-patient heterogeneity in Vδ2 γδTIL responses to GB is driven by the extracellular matrix-BTN3A axis. Autologous systems effectively capture this heterogeneity, offering a reliable platform to identify determinants of both immune function and tumor vulnerability, insights that are essential for the rational design of γδTIL-based immunotherapies.

> **中文摘要：**
> 背景：针对胶质母细胞瘤（GB）的免疫治疗效果仍然有限。推进新策略的主要障碍在于依赖非自体系统，这些系统无法准确模拟患者间在免疫反应和肿瘤易感性方面的真实异质性程度。这常常导致对治疗效能和靶向性的误导性结论。
> 
> 方法：在本研究中，我们通过采用完全自体模型弥补了这一关键空白。我们对包括36例确诊为GB在内的40例脑肿瘤患者外周血和肿瘤中的原代αβ和γδT细胞进行了表型特征分析，并在部分患者中扩增并功能性评估了自体抗GB反应。
> 
> 结果：值得注意的是，只有Vδ2和Vδ2 γδT细胞，而非αβT细胞，能够识别自体肿瘤。虽然Vδ2 γδT细胞在部分患者中表现出活性，但在帕米膦酸存在的情况下，所有患者的Vδ2 γδTILs均对自体GB细胞产生反应。在患者中，更高比例的Vδ2 γδTILs与更长的总生存期相关。然而，Vδ2 γδTILs的效能在个体间差异显著，突显出γδT细胞介导的肿瘤识别存在显著的患者间异质性。这种变异受到免疫细胞内在特征和肿瘤内在因素的共同影响，包括Vδ2 γδTCR配体BTN2A1和尤其是BTN3A的表达。功能实验显示，抗GB反应进一步受NKG2D、CD94和TIGIT等刺激性和抑制性共受体的调控。转录组分析将Vδ2 γδT细胞反应与细胞外基质（ECM）通路相关联，并且破坏LAMA5和TGFB1等ECM成分可增强T细胞反应。敲除LAMA5受体ITGA3可增加GB细胞中BTN2A1和BTN3A的表达，从而改善免疫识别。
> 
> 结论：本研究表明，Vδ2 γδTIL对GB的患者间反应异质性由细胞外基质-BTN3A轴驱动。自体系统能够有效捕获这种异质性，为识别免疫功能和肿瘤脆弱性决定因素提供了可靠平台，这一洞见对于理性设计γδTIL为基础的免疫治疗具有重要意义。

### 第二部分 AI 大师评价

本研究旨在通过全自体体系揭示胶质母细胞瘤患者γδT细胞反应的异质性。通过对40例患者外周血与肿瘤来源T细胞的系统表型与功能分析，作者发现Vδ2 γδTILs在抗GB反应中起核心作用，其效能受细胞外基质-BTN3A轴以及共受体信号调节所影响。研究创新性地建立了可反映患者个体免疫差异的模型，强调了ECM在调控免疫识别中的关键作用。该工作为γδTIL靶向免疫治疗的个体化开发提供了机制基础，但仍需进一步临床验证以评估其可转化潜力。

---

## 44. ANICCA-Class II 研究的最终结果：一项单臂、开放标签的 II 期临床试验，评估尼沃利单抗用于组织特异性 II 类分子表达的转移性微卫星稳定型结直肠癌，并平行评估免疫评分–免疫检查点作为单药抗 PD-1 疗法预测性生物标志物的作用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41407398)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41407398
**DOI：** 10.1136/jitc-2025-012749

### 第一部分 原文与翻译

**英文原标题：** Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.

> **英文摘要：**
> BACKGROUND: Neutralization of interferon (IFN)-γ abrogates the efficacy of anti-programmed death-ligand 1 (PD-(L)1) checkpoint inhibitors. Most epithelial cells do not constitutively express major histocompatibility complex (MHC) class II but can be induced to do so by IFN-γ. Inducible tumor-specific MHC class II (tsMHC-II) underlies responsiveness to anti-PD-(L)1. Retrospective studies show that tsMHC-II positivity associates with improved outcomes in patients treated with anti-PD-(L)1. The ANICCA-Class II single-arm Bayesian phase II trial prospectively explored whether positive tsMHC-II status could be a useful selection marker for anti-programmed cell death protein-1 (PD-1) in proficient mismatch repair colorectal cancer (pMMR CRC). In parallel, we retrospectively evaluated the potential predictive power of immunoscore-immune checkpoint (IS-IC) for outcome with single-agent immune checkpoint blockade.
> 
> METHODS: Patients with histologically confirmed locally advanced/metastatic pMMR CRC with >1% MHC class II expression, Eastern Cooperative Oncology Group performance status 0-2, aged ≥18 years were eligible. Participants received 480 mg nivolumab every 28 days for up to 24 cycles. The primary outcome was durable clinical benefit (DCB) defined as participants remaining progression-free at their third trial-specific scan since treatment start (ie, at approximately 27 weeks). Secondary outcomes included progression-free survival time (PFS) and overall survival time (OS).
> 
> RESULTS: 35 participants were treated: 65.7% of participants' cancers were tsMHC-II ≥5%. 3/35 patients achieved DCB (8.6%), estimating the true DCB rate (R) of 11% (95% credible interval 3% to 22%) with 0.002 probability that the true DCBR was >30%, below the required 0.5 to warrant further research. The higher tsMHC-II cut-point ≥5% was not more useful in predicting duration of disease stabilization. All three participants who achieved DCB had no evidence of liver metastases (LM); DCBR 23.1% in those without versus 0% in those with LM. PFS and OS were significantly greater in those without LM. There was no evidence that IS-IC high predicted for prolonged time on treatment or improved tumor growth inhibition.
> 
> CONCLUSIONS: In pMMR CRC, tsMHC-II positivity fails to identify a subset of patients with metastatic pMMR CRC obtaining potentially meaningful benefit from single-agent anti-PD-1. Although numbers are limited, there is no clear evidence that IS-IC is predictive of outcome with single-agent anti-PD-1. The poor outcome in those with LM underscores the need for therapies that overcome the systemic immunosuppression driven by LM.

> **中文摘要：**
> 背景：干扰素（IFN）-γ 的中和会削弱抗程序性死亡配体 1（PD-(L)1）检查点抑制剂的疗效。大多数上皮细胞并不持续表达主要组织相容性复合体（MHC）II 类分子，但可通过 IFN-γ 诱导表达。可诱导的肿瘤特异性 MHC II 类分子（tsMHC-II）是肿瘤对抗 PD-(L)1 治疗产生应答的基础。回顾性研究表明，tsMHC-II 阳性与接受抗 PD-(L)1 治疗患者的更好结局相关。ANICCA-Class II 单臂贝叶斯 II 期试验前瞻性探讨了 tsMHC-II 阳性状态是否可作为熟练错配修复结直肠癌（pMMR CRC）患者选择抗 PD-1 治疗的有用标志物。同时，我们回顾性评估了免疫评分–免疫检查点（IS-IC）在单药免疫检查点抑制治疗中预测疗效的潜力。
> 
> 方法：纳入经组织学确诊的局部晚期或转移性 pMMR CRC 且 MHC II 类表达 >1%、ECOG 体能状态评分 0–2、年龄 ≥18 岁的患者。受试者每 28 天接受 480 mg 尼沃利单抗，最长 24 个周期。主要终点为持久临床获益（DCB），定义为治疗开始后至第三次特定试验影像评估（约第 27 周）时仍无进展。次要终点包括无进展生存期（PFS）和总生存期（OS）。
> 
> 结果：共纳入 35 名受试者，其中 65.7% 的肿瘤 tsMHC-II 表达 ≥5%。共有 3/35 名患者获得 DCB（8.6%），估计真实 DCB 比例为 11%（95% 可信区间 3%–22%），真实 DCB 比例 >30% 的概率仅为 0.002，低于继续研究所需的 0.5。较高的 tsMHC-II 阈值（≥5%）未能更好预测疾病稳定持续时间。获得 DCB 的三名患者均无肝转移（LM）；无肝转移者 DCB 比例为 23.1%，有肝转移者为 0%。无肝转移患者的 PFS 与 OS 均显著更长。未见 IS-IC 高值可预测更长治疗时间或更好的肿瘤生长抑制。
> 
> 结论：在 pMMR CRC 中，tsMHC-II 阳性未能识别出可从单药抗 PD-1 治疗中获得显著临床获益的患者亚群。尽管样本数量有限，但目前无明确证据显示 IS-IC 具有预测单药抗 PD-1 疗效的作用。肝转移患者的不良结局提示亟需开发能够克服肝转移相关全身性免疫抑制的治疗策略。

### 第二部分 AI 大师评价

该研究通过一项单臂、开放 II 期试验，前瞻性评估了 tsMHC-II 阳性是否能作为微卫星稳定型（pMMR）转移性结直肠癌患者接受单药抗 PD-1 治疗的筛选标志物，同时回顾性分析 IS-IC 的预测价值。结果显示，无论 tsMHC-II 阳性或 IS-IC 水平均未能识别对免疫治疗有显著获益的患者亚群。肝转移状态在治疗反应中表现为关键影响因素。该研究的创新在于首次前瞻性验证 tsMHC-II 的预测潜力，但受样本量较小和单臂设计限制，结果仍需进一步验证。

---

## 45. 靶向TFAP2β凝聚可抑制食管鳞状细胞癌的发生发展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406964)
**期刊：** Cell
**PMID：** 41406964
**DOI：** 10.1016/j.cell.2025.11.019

### 第一部分 原文与翻译

**英文原标题：** Targeting TFAP2β condensation suppresses the development of esophageal squamous cell carcinoma.

> **英文摘要：**
> Exploring targeted therapies for esophageal squamous cell carcinoma (ESCC) remains challenging. Although investigating the roles and therapeutic applications of liquid-liquid phase separation (LLPS) is increasingly of interest, its relationship with ESCC remains unclear. After improving the assay for transposase-accessible chromatin using sequencing (ATAC-seq) protocol for limited-amount clinical samples, we unravel transcription factor AP-2 beta (TFAP2β) as a key downregulated transcription factor (TF) through combined chromatin accessibility and gene expression analyses with cancerous and paracancerous tissues from early-stage ESCC patients. TFAP2β undergoes condensation in the nucleus to bind the zinc finger protein 131 (ZNF131) promoter, thereby inhibiting ZNF131 expression and ESCC progression. The other two crucial downregulated TFs uncovered are incorporated into TFAP2β condensates to bind their corresponding target, suggesting that LLPS may be a hallmark of ESCC transcription. In addition, we obtained compound A6 that mediates intrinsically disordered region conformational changes to enhance TFAP2β condensation and specific ESCC suppression in cells, mice, and patient-derived organoids. Thus, we indicate an LLPS-mediated transcriptional mechanism and a potential therapeutic approach for ESCC.

> **中文摘要：**
> 探索食管鳞状细胞癌（ESCC）的靶向治疗仍然具有挑战性。尽管液-液相分离（LLPS）的功能及其治疗应用越来越受到关注，但其与ESCC的关系尚不明确。在改进用于有限量临床样本的ATAC-seq（转座酶可及染色质测序）实验方案后，我们通过结合早期ESCC患者的癌组织与癌旁组织的染色质可及性和基因表达分析，发现转录因子AP-2β（TFAP2β）是一个关键的下调转录因子。TFAP2β在细胞核内形成凝聚体并结合锌指蛋白131（ZNF131）的启动子，从而抑制ZNF131的表达并阻止ESCC的进展。另有两个重要的下调转录因子被发现可并入TFAP2β凝聚体并结合各自靶基因，提示LLPS可能是ESCC转录活动的一个标志。此外，我们获得化合物A6，该化合物可介导固有无序区构象变化，从而增强TFAP2β凝聚并在细胞、小鼠和患者来源的类器官中实现对ESCC的特异性抑制。由此，我们揭示了一种由LLPS介导的转录调控机制及一种潜在的ESCC治疗策略。

### 第二部分 AI 大师评价

本研究针对食管鳞状细胞癌靶向治疗的难题，从液-液相分离（LLPS）机制入手，揭示转录因子TFAP2β在肿瘤转录调控中的关键作用。作者通过优化ATAC-seq方法及整合多组学分析，发现TFAP2β凝聚体可抑制ZNF131等基因表达，从而阻止肿瘤进展。进一步开发的化合物A6能增强TFAP2β凝聚并特异性抑制ESCC，展示出潜在的治疗价值。该研究创新性地将LLPS机制与癌症转录调控及药物干预联系起来，为ESCC治疗开辟了新方向，但仍需临床验证其安全性与有效性。

---

## 46. mRNA 疫苗的不同组分协同作用以诱导高效的生发中心反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406961)
**期刊：** Cell
**PMID：** 41406961
**DOI：** 10.1016/j.cell.2025.11.023

### 第一部分 原文与翻译

**英文原标题：** Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses.

> **英文摘要：**
> Nucleoside-modified messenger RNA (mRNA) vaccines elicit protective antibodies through their ability to promote T follicular helper (Tfh) cell differentiation. The lipid nanoparticles (LNPs) of mRNA vaccines possess inherent adjuvant activity. However, the extent to which the nucleoside-modified mRNA is sensed and contributes to Tfh cell responses remains undefined. Herein, we deconvolute the signals induced by LNPs and mRNA that instruct dendritic cells (DCs) to promote Tfh cell differentiation. We demonstrate that the mRNA drives the production of type I interferons, which act on DCs to enhance their maturation and Tfh cell differentiation, and favors plasma cells and memory B cell responses. In parallel, LNPs, which allow for mRNA uptake by DCs within the draining lymph node, also modulate Tfh cell responses by shaping the localization of CD25 DCs. Our work unravels distinct adjuvant features of mRNA and LNPs necessary for the induction of Tfh cells, with implications for rational vaccine design.

> **中文摘要：**
> 核苷修饰的信使 RNA（mRNA）疫苗通过促进滤泡辅助性 T（Tfh）细胞分化而诱导保护性抗体的产生。mRNA 疫苗的脂质纳米颗粒（LNPs）具有固有的佐剂活性。然而，核苷修饰的 mRNA 在何种程度上被识别并对 Tfh 细胞反应作出贡献尚不清楚。在本研究中，我们解析了由 LNPs 和 mRNA 诱导的信号，它们指导树突状细胞（DCs）促进 Tfh 细胞分化。我们证明，mRNA 驱动 I 型干扰素的产生，这种干扰素作用于 DC 以增强其成熟和 Tfh 细胞分化，同时有利于浆细胞和记忆 B 细胞反应。与此同时，LNPs 通过支持引流淋巴结内 DC 对 mRNA 的摄取，并通过调控 CD25+ DC 的定位来调节 Tfh 细胞反应。我们的研究揭示了 mRNA 与 LNPs 在诱导 Tfh 细胞时所需的不同佐剂特征，对理性疫苗设计具有重要启示意义。

### 第二部分 AI 大师评价

本研究旨在区分 mRNA 疫苗中 mRNA 与脂质纳米颗粒各自对免疫诱导的贡献，阐明其在 Tfh 细胞分化中的协同作用。研究采用信号解构的方法，揭示 mRNA 通过促进 I 型干扰素生成增强树突状细胞成熟，而 LNPs 则通过改变特定 DC 亚群定位调节免疫反应。该成果在机制层面上揭示了 mRNA 疫苗佐剂效应的双重性，为优化疫苗设计提供了新思路。研究的创新性突出，但仍需在不同抗原模型中进一步验证其普适性。

---

## 47. ctDNA指导的膀胱癌治疗——准备好了吗？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406450)
**期刊：** The New England journal of medicine
**PMID：** 41406450
**DOI：** 10.1056/NEJMe2514185

### 第一部分 原文与翻译

**英文原标题：** ctDNA-Guided Therapy in Bladder Cancer - Ready?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文发表于《新英格兰医学杂志》，标题提示其探讨利用循环肿瘤DNA（ctDNA）指导膀胱癌治疗的现实准备度。文章很可能综述了当前ctDNA在膀胱癌监测与个体化治疗中的研究进展及应用前景，分析其在精准医疗中的潜在价值与技术挑战。创新点可能在于评估分子残留病检测在治疗决策中的可行性，而局限性可能包括样本标准化和真实世界转化的障碍。整体上，该评论为ctDNA在泌尿系肿瘤管理中的临床转化提供了关键思考。

---

## 48. 默克尔细胞癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406446)
**期刊：** The New England journal of medicine
**PMID：** 41406446
**DOI：** 10.1056/NEJMicm2513302

### 第一部分 原文与翻译

**英文原标题：** Merkel-Cell Carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要不可用。

### 第二部分 AI 大师评价

该文发表于《新英格兰医学杂志》，主题聚焦于默克尔细胞癌，这是一种罕见且具有高度侵袭性的皮肤神经内分泌癌。尽管全文摘要未提供，但推测该文旨在综述此疾病的病理特征、诊断要点及治疗进展。默克尔细胞癌在免疫治疗领域的发展尤为瞩目，PD-L1 抑制剂带来了新的治疗前景。文章的创新性可能体现在临床实践案例解析或新疗法验证，但由于缺乏摘要，其研究深度与局限尚需阅读全文评估。

---

## 49. 回复：REZILIENT-1研究中的盲点——铂类治疗后使用Zipalertinib是否满足EGFR ex20ins+非小细胞肺癌的治疗需求？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406409)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41406409
**DOI：** 10.1200/JCO-25-02185

### 第一部分 原文与翻译

**英文原标题：** Reply to: Blind Spots in REZILIENT-1: Does Post-platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文为对先前关于REZILIENT-1研究的评论性回复，重点探讨Zipalertinib在既往接受铂类化疗后EGFR ex20ins突变非小细胞肺癌患者中的临床应用价值。虽然文章未提供完整摘要，但可以推测其核心在于回应研究设计或解释的潜在偏差，并进一步澄清药物疗效与适应症的问题。此类学术交流有助于推动新型EGFR变异靶向药物疗法的更精准定位，但受限于篇幅，具体数据和方法细节仍需参考原始研究。

---

## 50. REZILIENT-1 研究的盲点：铂类治疗后的 Zipalertinib 是否满足表皮生长因子受体 ex20ins+ 非小细胞肺癌的治疗需求？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406405)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41406405
**DOI：** 10.1200/JCO-25-01501

### 第一部分 原文与翻译

**英文原标题：** Blind Spots in REZILIENT-1: Does Post-Platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文探讨了 REZILIENT-1 研究中可能存在的不足，聚焦于铂类治疗后使用 Zipalertinib 对 EGFR ex20ins+ 非小细胞肺癌患者的潜在疗效和临床意义。尽管缺少摘要，但从标题可推测其核心在于评估罕见基因突变亚型的治疗策略。研究可能关注未被充分覆盖的患者需求与新一代靶向药物的应用前景。整体看，该研究具有一定临床创新价值，但结果和数据仍需正式公布后方可全面评估。

---

## 51. 曾接受腹盆部放射治疗的儿童癌症幸存者中结直肠癌筛查的获益、危害与负担

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406404)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41406404
**DOI：** 10.1200/JCO-25-00661

### 第一部分 原文与翻译

**英文原标题：** Benefits, Harms, and Burden of Colorectal Cancer Screening Among Childhood Cancer Survivors Previously Treated With Abdominopelvic Radiation.

> **英文摘要：**
> PURPOSE: Childhood cancer survivors treated with abdominopelvic radiation (RT) are at increased risk of colorectal cancer (CRC), yet adherence to Children's Oncology Group screening guidelines remains low. Estimating the benefits, burdens, and costs of all guideline-recommended screening modalities, including those not previously evaluated, may help identify strategies that align with survivors' preferences and access, potentially improving adherence.
> 
> METHODS: Using data from the Childhood Cancer Survivor Study and published studies, we adapted a CRC simulation model to evaluate CRC screening among 5-year survivors. Strategies included colonoscopy, multitarget stool DNA (mtsDNA), and fecal immunochemical testing (FIT) at various intervals, starting at age 25-45 years. Outcomes included CRC cases and deaths, additional colonoscopies per additional life-year gained (burden-to-benefit ratio [BBR]), and cost per quality-adjusted life-year gained (QALYG; incremental cost-effectiveness ratios [ICERs]).
> 
> RESULTS: At age 45 years, survivors had a 0.6% cumulative CRC risk (relative risk, 3.3  average-risk individuals). Without screening, an estimated 75 per 1,000 survivors would be diagnosed with CRC in their lifetime and 30 would die from CRC. Screening averted 47-73 cases and 23-29 CRC deaths per 1,000. Based on average-risk BBR benchmarks, the optimal strategies by modality were colonoscopy every 10 years starting at age 30 years, mtsDNA every 3 years starting at age 30 years, and FIT every 3 years starting at age 25 years (then annually as of age 45 years, as recommended for average-risk individuals). ICERs were $146,000 in US dollars (USD)/QALYG, $166,000 (USD)/QALYG, and $123,000 (USD)/QALYG, respectively.
> 
> CONCLUSION: Early initiation of screening with colonoscopy or stool-based tests may substantially reduce CRC incidence and early mortality among survivors treated with abdominopelvic RT, with reasonable burden-to-benefit trade-offs, and be considered cost-effective. These findings can facilitate clinician-survivor discussions on CRC screening and inform guideline refinements.

> **中文摘要：**
> 目的：接受腹盆部放射治疗（RT）的儿童癌症幸存者患结直肠癌（CRC）的风险增加，但对儿童肿瘤学组筛查指南的遵循率仍然较低。评估所有指南推荐筛查方式（包括先前未评估的方式）的获益、负担和成本，可能有助于识别与幸存者偏好及可及性相符的策略，从而潜在提高依从性。
> 
> 方法：利用儿童癌症幸存者研究及已发表研究的数据，我们调整了CRC模拟模型以评估五年期幸存者的CRC筛查。筛查策略包括结肠镜检查、多靶点粪便DNA检测（mtsDNA）及粪便免疫化学检测（FIT），并在25至45岁不同年龄起始、不同比例间隔下进行。结局指标包括CRC发生与死亡病例数、每增加一个生命年所需的额外结肠镜检查次数（负担—获益比，BBR）以及每获得一个质量调整生命年（QALYG）的成本（增量成本效果比，ICER）。
> 
> 结果：在45岁时，幸存者的CRC累积风险为0.6%（相对风险为平均风险人群的3.3倍）。若不进行筛查，估计每1000名幸存者中有75人一生中将被诊断为CRC，30人死于CRC。筛查可避免每1000人中47至73例CRC病例及23至29例CRC死亡。根据平均风险人群的BBR基准，各筛查方式的最优策略为：30岁起每10年一次结肠镜检查；30岁起每3年一次mtsDNA检测；25岁起每3年一次FIT检测（至45岁后改为每年一次，符合平均风险人群建议）。其ICER分别为每获益一个QALYG146,000美元、166,000美元和123,000美元。
> 
> 结论：通过结肠镜或基于粪便的检测早期启动筛查，可显著降低接受腹盆部RT治疗幸存者的CRC发病率和早期死亡率，在负担与获益之间具有合理平衡，并可视为具成本效益。这些发现有助于促进临床医生与幸存者之间关于CRC筛查的讨论，并为指南优化提供依据。

### 第二部分 AI 大师评价

本研究针对曾接受腹盆部放疗的儿童癌症幸存者，系统评估了结直肠癌不同筛查策略的获益、负担与成本效益，具有较高的临床应用价值。研究通过仿真模型比较了结肠镜、mtsDNA及FIT三种方式的长期预后，提出了与平均风险人群不同的最优筛查起始年龄及间隔。结果显示提前筛查可显著降低发病与死亡风险，且在合理成本范围内具成本效益。其创新在于首次全面量化此高风险人群的负担—获益平衡，但模型假设及数据外推仍是潜在局限。

---

## 52. 造血干细胞移植及急性白血病患者中宽松饮食与中性粒细胞减少饮食的随机非劣效性试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406403)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41406403
**DOI：** 10.1200/JCO-25-00889

### 第一部分 原文与翻译

**英文原标题：** Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.

> **英文摘要：**
> PURPOSE: Patients undergoing hematopoietic stem-cell transplantation (HSCT) or induction chemotherapy for acute leukemia (AL) generally receive a low-bacterial neutropenic diet (ND) to minimize infection from ingested microbes. Recent studies suggest that a more liberalized diet (LD) might be safe. However, those studies lacked robust designs to demonstrate noninferiority and did not address whether an LD improves caloric intake or nutritional status. This trial aimed to determine whether the rate of major infections in LD patients was noninferior to that in ND patients and whether an LD improved caloric intake and nutritional status.
> 
> METHODS: In this phase III noninferiority trial, patients were randomly assigned to either an ND or LD, containing fresh fruits and vegetables. The primary end point was the development of any major infection during neutropenia. The noninferiority margin was set at a difference of ≤10% in the major infection rate.
> 
> RESULTS: The trial was halted at the second interim analysis after enrolling 214 evaluable patients, because of the LD arm's major infection rate surpassing the predefined stopping boundary. In the LD arm, major infections occurred in 31.4% of patients compared with 20.2% of patients in the ND arm, a difference of 11.2% ([95% CI, -0.4 to 22.9];  = .58). Furthermore, the caloric intake in the LD arm was not improved and nearly two thirds of patients on both diets reported critical nutritional problems. There was no advantage in symptoms, quality of life, or survival for the LD arm.
> 
> CONCLUSION: These findings suggest that LD is not a safe alternative to ND in HSCT patients and patients with AL because of increased infection risk without nutritional or other benefit. Further dietary strategies are needed to improve nutrition without compromising safety.

> **中文摘要：**
> 目的：接受造血干细胞移植（HSCT）或急性白血病（AL）诱导化疗的患者通常采用低细菌的中性粒细胞减少饮食（ND），以最大限度减少摄入微生物引起的感染。近期研究提示，更宽松的饮食（LD）可能是安全的。然而，这些研究的设计尚不够严谨，未能充分证明非劣效性，也未探讨LD能否改善热量摄入或营养状况。本试验旨在确定LD患者的主要感染发生率是否不劣于ND患者，并评估LD是否能改善热量摄入和营养状况。
> 
> 方法：在本III期非劣效性随机试验中，患者被随机分配至ND组或LD组，后者饮食中包含新鲜水果和蔬菜。主要终点为中性粒细胞减少期内是否发生任何主要感染。非劣效性界值设定为主要感染率差异≤10%。
> 
> 结果：本试验在入组214名可评估患者后，于第二次中期分析时因LD组主要感染率超过预设停止界限而提前终止。在LD组中，主要感染发生率为31.4%，而ND组为20.2%，两组差异为11.2%（95%置信区间：-0.4至22.9；P＝0.58）。此外，LD组的热量摄入无明显改善，两组中近三分之二的患者报告严重的营养问题。LD组在症状、生活质量或生存方面均无优势。
> 
> 结论：研究结果提示，对于HSCT和AL患者，LD因感染风险增加且无营养或其他获益，不能作为ND的安全替代方案。未来应探索能在不影响安全性的前提下改善营养的饮食策略。

### 第二部分 AI 大师评价

本研究是一项随机III期非劣效性试验，比较宽松饮食与中性粒细胞减少饮食在造血干细胞移植及急性白血病患者中的感染风险与营养效果。研究显示宽松饮食组主要感染率显著高于中性粒细胞减少饮食组，且未改善热量摄入或营养状况。结果提示宽松饮食并非安全替代方案，强调在保证安全的前提下开发新的营养干预策略。研究设计严谨但因早期终止样本有限，结果仍需进一步验证。

---

## 53. 嵌合抗原受体协调肿瘤抗原摄取与树突状细胞活化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406244)
**期刊：** Science translational medicine
**PMID：** 41406244
**DOI：** 10.1126/scitranslmed.adq4060

### 第一部分 原文与翻译

**英文原标题：** Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors.

> **英文摘要：**
> Effective antitumor immunity requires dendritic cells (DCs) to internalize, process, and present tumor antigens to T cells. Adoptive transfer of DCs that were loaded ex vivo with tumor antigens has been shown to stimulate antitumor immunity in patients with cancer, but clinical responses have been mixed. To address the limitations of traditional DC-based therapies, we constructed and functionally screened a panel of chimeric antigen receptors (CARs) optimized for expression and activity in DCs. Through this screening, we identified key functional components that guided the development of an inducible platform centered on an instructive chimeric antigen receptor (iCAR). This iCAR enabled DCs to (i) recognize a surface molecule present on cancer cells or their extracellular vesicles (EVs), such as disialoganglioside GD2 (expressed in melanoma and other tumors of neuroectodermal origin) or HER2 (expressed in some epithelial cancers), thereby promoting the acquisition of tumor-derived material containing putative tumor antigens; (ii) undergo immunostimulatory activation to prime antigen-specific T cells via both cross-dressing and cross-presentation; and (iii) transactivate the expression of the therapeutic cytokine interleukin-12 (IL-12) in response to antigen uptake. The iCAR converted melanoma-derived EVs from immune-suppressive to stimulatory cues for DCs in cell culture assays. Moreover, systemic administration of iCAR-DCs enhanced antigen-specific T cells, expanded low-frequency T cell clonotypes, and delayed tumor growth in immunotherapy-resistant melanoma models without the need for ex vivo antigen loading or cell maturation. iCAR-DCs may therefore provide a platform for antigen-agnostic cancer immunotherapy that integrates antigen uptake with programmable DC activation.

> **中文摘要：**
> 有效的抗肿瘤免疫需要树突状细胞（DCs）内化、加工并将肿瘤抗原呈递给T细胞。体外负载肿瘤抗原的DCs采用性输注已被证明能刺激癌症患者的抗肿瘤免疫，但临床反应并不一致。为克服传统DC为基础疗法的局限性，我们构建并功能筛选了一系列针对DCs表达与活性优化的嵌合抗原受体（CARs）。通过此筛选，我们鉴定出关键功能组分，从而开发出一种以指导性嵌合抗原受体（iCAR）为核心的可诱导平台。该iCAR使DCs能够：(i) 识别存在于癌细胞或其细胞外囊泡（EVs）表面的分子，如二唾液酸神经节苷脂GD2（在黑色素瘤及其他神经外胚层来源肿瘤中表达）或HER2（在部分上皮性癌中表达），从而促进摄取含有潜在肿瘤抗原的肿瘤来源物质；(ii) 经过免疫刺激性激活，通过交叉装饰和交叉呈递两种机制启动抗原特异性T细胞；以及(iii) 在抗原摄取后转激活治疗性细胞因子白细胞介素-12（IL-12）的表达。在细胞培养实验中，iCAR将源自黑色素瘤的EVs从免疫抑制信号转变为DCs的免疫刺激信号。此外，系统给药的iCAR-DCs在无需体外抗原负载或细胞成熟的情况下，增强了抗原特异性T细胞反应，扩增了低频T细胞克隆型，并在免疫治疗耐受的黑色素瘤模型中延缓了肿瘤生长。因此，iCAR-DCs可能提供一种“抗原无关”的癌症免疫治疗平台，将抗原摄取与可编程的DC激活相结合。

### 第二部分 AI 大师评价

本研究旨在解决传统树突状细胞疗法中抗原加载效率及免疫激活受限的问题。作者设计并筛选了针对DCs功能优化的嵌合抗原受体，开发出一种具诱导性和指导性的iCAR平台。该平台通过识别肿瘤相关分子实现DCs抗原摄取、自主激活及IL-12表达，从而增强抗原特异性T细胞反应并显著延缓肿瘤生长。研究在机制上创新性地将嵌合抗原受体技术拓展至DCs，提出了无须预加载抗原的新型免疫疗法思路，但其在不同肿瘤类型和人类临床转化中的安全性仍需验证。

---

## 54. 酪氨酸激酶抑制剂心脏毒性的多尺度谱系分析揭示机械敏感性离子通道PIEZO1具有心脏保护作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406242)
**期刊：** Science translational medicine
**PMID：** 41406242
**DOI：** 10.1126/scitranslmed.adv9403

### 第一部分 原文与翻译

**英文原标题：** Multiscale profiling of tyrosine kinase inhibitor cardiotoxicity reveals mechanosensitive ion channel PIEZO1 as cardioprotective.

> **英文摘要：**
> Tyrosine kinase inhibitors (TKIs) have improved cancer outcomes but are limited by cardiovascular toxicity, most notably hypertension and heart failure. The underlying mechanisms remain poorly understood, hindering the development of protective strategies. Here, we investigated the role of endothelial mechanotransduction in mediating vascular and cardiac injury caused by the vascular endothelial growth factor receptor-targeting TKI sunitinib. Using patient-specific induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and a mouse model of TKI-induced hypertension, we identified down-regulation of  (), a mechanically activated ion channel, as a driver of endothelial dysfunction. Restoring  expression, either pharmacologically with Yoda1, a selective agonist, or through inducible overexpression in iPSC-ECs, reversed sunitinib-induced endothelial dysfunction and mitigated its hypertensive effects, providing both mechanistic and genetic validation of PIEZO1's protective role against vascular toxicity. In mice, cotreatment with sunitinib and Yoda1 prevented the long-term cardiac dysfunction observed after sunitinib exposure and normalized elevations in circulating cardiac stress biomarkers. Single-nucleus multiomic profiling of mouse hearts revealed that sunitinib exposure activated chromatin remodeling and fibrogenic programs, which were reversed with PIEZO1 activation. Human engineered cardiac organoids further demonstrated that sunitinib impaired cardiomyocyte function only in the presence of endothelial cells, confirming a role for disrupted endothelial-cardiomyocyte cross-talk in TKI cardiotoxicity. Together, these findings identify endothelial PIEZO1 as a mediator of TKI-induced hypertension and cardiac dysfunction and highlight PIEZO1 activation as a potential therapeutic strategy for protecting cardiovascular health during cancer therapy.

> **中文摘要：**
> 酪氨酸激酶抑制剂（TKIs）改善了癌症治疗结局，但其应用受到心血管毒性的限制，尤其是高血压和心力衰竭。其潜在机制尚不清楚，阻碍了保护性策略的开发。本研究探讨了内皮细胞机械转导在靶向血管内皮生长因子受体的TKI舒尼替尼所致血管和心脏损伤中的作用。利用患者特异性的诱导多能干细胞来源的内皮细胞（iPSC-ECs）以及TKI诱导的高血压小鼠模型，我们发现机械激活离子通道PIEZO1的下调是导致内皮功能障碍的驱动因素。通过药理学方法（使用选择性激动剂Yoda1）或在iPSC-ECs中诱导过表达恢复PIEZO1的表达，可逆转舒尼替尼引起的内皮功能障碍并减轻其升压效应，从机制和遗传层面验证了PIEZO1在防止血管毒性中的保护作用。在小鼠中，舒尼替尼与Yoda1的联合治疗可预防舒尼替尼暴露后出现的长期心功能障碍，并使循环心脏应激生物标志物的升高恢复正常。对小鼠心脏进行单核多组学分析显示，舒尼替尼暴露激活了染色质重塑和成纤维化程序，而PIEZO1的激活可以逆转这些变化。人源化工程心脏类器官进一步表明，舒尼替尼仅在存在内皮细胞的情况下损害心肌细胞功能，证实了内皮-心肌细胞间信号互作破坏在TKI心脏毒性中的作用。综合来看，这些发现确定了内皮PIEZO1是介导TKI诱导的高血压和心功能障碍的关键因子，并强调PIEZO1激活可能成为癌症治疗过程中保护心血管健康的潜在治疗策略。

### 第二部分 AI 大师评价

该研究以舒尼替尼为模型，从多尺度角度揭示了TKI相关心血管毒性的分子机制。作者通过iPSC来源内皮细胞、小鼠模型和多组学分析系统阐明了PIEZO1在抵御血管及心脏损伤中的保护作用。研究不仅明确了内皮机械转导在TKI毒性中的核心地位，还验证了PIEZO1激活剂Yoda1的干预效果。其创新之处在于将机械敏感离子通道与抗癌药物心血管安全性相联系，为精准心血管保护策略提供了新方向。局限性在于其临床转化仍需进一步验证。

---

## 55. 在突变型乳腺癌中，克服对CDK4/6抑制剂和内分泌治疗耐药性需要双重PI3K/mTOR抑制。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406241)
**期刊：** Science translational medicine
**PMID：** 41406241
**DOI：** 10.1126/scitranslmed.adp5088

### 第一部分 原文与翻译

**英文原标题：** Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in -mutant breast cancer.

> **英文摘要：**
> Combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) improves outcomes in advanced estrogen receptor-positive (ER) breast cancer, but emergence of resistance to this combination underscores the pressing need for alternative therapeutic strategies. A promising approach involves adding an inhibitor of the PI3K/AKT/mTOR pathway to the standard combined CDK4/6i and ET, but selecting the most effective inhibitors and their optimal combinations has proven to be challenging. Here, we compared the efficacy of various triple combinations using single- or dual-point PI3K/AKT/mTOR pathway inhibitors in breast cancer cell lines, cell line xenografts, patient-derived xenografts, and organoids resistant to CDK4/6i and ET and exhibiting , , or  mutations. -mutant, -wild type, CDK4/6i-resistant, and ET-resistant models required the addition of the dual PI3K/mTOR inhibitor gedatolisib to effectively impede tumor growth by blocking the HIF-1α pathway through both mTORC1 inhibition and PI3K/AKT-mediated modulation of GSK3α/β activity. Conversely, -wild type, -null cells benefited from triple combinations incorporating either the AKT inhibitor capivasertib or the dual mTORC1/2 inhibitor sapanisertib to block tumor growth. In addition, gedatolisib reduced viability of - or -mutant and -wild type CDK4/6i-resistant patient-derived organoids compared with the α-specific PI3K inhibitor alpelisib. Our data support the higher efficacy of gedatolisib over alpelisib in ER breast tumors harboring alterations of the PI3K/AKT/mTOR pathway including  or  mutations.

> **中文摘要：**
> 联合使用CDK4/6抑制剂（CDK4/6i）和内分泌治疗（ET）能够改善晚期雌激素受体阳性（ER）乳腺癌的疗效，但该联合方案出现耐药性凸显出寻找替代治疗策略的迫切需求。一种有前景的方法是在标准CDK4/6i与ET方案中加入PI3K/AKT/mTOR通路抑制剂，但筛选出最有效的抑制剂及其最佳组合仍具挑战性。本研究在多种乳腺癌模型中比较了使用单一或双靶点PI3K/AKT/mTOR通路抑制剂的三药组合的疗效，这些模型包括乳腺癌细胞系、细胞系异种移植瘤、患者来源异种移植瘤以及对CDK4/6i与ET均耐药并携带特定突变的类器官。在突变型、野生型、对CDK4/6i耐药及对ET耐药模型中，需要加入双重PI3K/mTOR抑制剂gedatolisib来有效抑制肿瘤生长，其机制通过抑制mTORC1及通过PI3K/AKT介导调控GSK3α/β活性共同阻断HIF-1α通路。相反，在野生型或空缺型细胞中，将AKT抑制剂capivasertib或双重mTORC1/2抑制剂sapanisertib纳入三联组合可实现肿瘤抑制。此外，与α特异性PI3K抑制剂alpelisib相比，gedatolisib可更显著降低突变型或野生型CDK4/6i耐药患者来源类器官的活性。我们的数据支持，在携带PI3K/AKT/mTOR通路改变（包括特定突变）的ER乳腺癌中，gedatolisib较alpelisib具有更高的抗肿瘤效力。

### 第二部分 AI 大师评价

本研究旨在探讨如何克服雌激素受体阳性乳腺癌对CDK4/6抑制剂及内分泌治疗的耐药性。作者系统地评估了多种PI3K/AKT/mTOR通路抑制剂的组合策略，发现双靶点PI3K/mTOR抑制剂gedatolisib能通过阻断HIF-1α通路有效抑制肿瘤生长。研究揭示了不同突变背景下适配的最佳三联治疗方案，强调了双通路抑制的关键作用。该研究的创新性在于以多层次模型系统验证组合策略，但仍需临床试验验证其转化潜力。

---

## 56. 靶表位中的单个氨基酸变异可赋予抗体疗法耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406240)
**期刊：** Science translational medicine
**PMID：** 41406240
**DOI：** 10.1126/scitranslmed.ady4877

### 第一部分 原文与翻译

**英文原标题：** Single-amino acid variants in target epitopes can confer resistance to antibody-based therapies.

> **英文摘要：**
> Monoclonal antibodies have transformed the therapeutic landscape across oncology, immunology, and infectious diseases by enabling high-affinity, antigen-specific targeting to neutralize soluble molecules, block cellular interactions, or deplete cells. Although high specificity is critical for safety, it may confer an inherent susceptibility to even minor variations in the target epitope. Here, we investigated the impact of natural single-nucleotide variants on antigen recognition by therapeutic monoclonal antibodies, both approved and in clinical development. For almost every antibody analyzed, we identified protein variants in or near the antibody-antigen interface, a subset of which were predicted to disrupt antigen recognition. Experimental studies corroborated the impact of select variants for four different antigens, revealing complete loss of antibody binding in some cases. For example, a human breast cancer cell line overexpressing human epidermal growth factor receptor 2 (HER-2), but engineered to carry the HER-2 variant, was completely resistant to killing even by highly potent clinical antibody-drug conjugates. These findings suggest that natural variants can confer primary resistance to antibody-based therapies, with critical implications for treatment outcomes, patient management, and safety, particularly in the context of potent modalities such as antibody-drug conjugates. Individual resistance-associated variants, although globally rare, are enriched in specific populations, underscoring the importance of accounting for genetic diversity in both drug development and clinical decision-making.

> **中文摘要：**
> 单克隆抗体通过实现高亲和力、抗原特异性的靶向作用，能够中和可溶性分子、阻断细胞相互作用或清除细胞，从而彻底改变了肿瘤学、免疫学及感染性疾病的治疗格局。尽管高特异性对于安全性至关重要，但这也可能使其对靶表位中哪怕极其微小的变异具有内在的易感性。在本研究中，我们探讨了天然单核苷酸变异对治疗性单克隆抗体（包括已获批准及处于临床开发阶段的抗体）抗原识别能力的影响。几乎在每一种被分析的抗体中，我们都发现靶抗原-抗体结合界面处或其邻近区域存在蛋白质变异，其中部分变异被预测会破坏抗原识别。实验研究验证了针对四种不同抗原的部分变异的影响，在某些情况下显示抗体结合能力完全丧失。例如，一株过表达人表皮生长因子受体2（HER-2）的乳腺癌细胞系若被工程化以携带HER-2变异，即便面对高效的临床抗体药物偶联物，其杀伤作用也完全失效。这些发现提示，天然变异可导致针对抗体疗法的原发性耐药性，对治疗结果、患者管理及安全性产生深远影响，尤其是在抗体药物偶联物等高效治疗形式中。尽管与耐药相关的个体变异在全球总体上较为罕见，但在特定人群中可能富集，这强调了在药物研发及临床决策中考虑遗传多样性的重要性。

### 第二部分 AI 大师评价

该研究旨在探讨天然单核苷酸变异如何影响治疗性单克隆抗体的抗原识别能力，揭示微小氨基酸差异即可导致药物结合丧失甚至完全耐药。作者结合预测分析及实验验证，证实多种抗原变异均可削弱或消除抗体结合。此发现突出了个体遗传差异在抗体疗法疗效与安全性评估中的关键作用，具有重要临床与药物开发意义。研究创新性在于系统性揭示自然变异与抗体耐药性的直接关系，但其普遍性与临床验证仍需更大样本及真实世界数据支持。

---

## 57. RIPK1 抑制可减轻原发性硬化性胆管炎中的胆道损伤和纤维化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406236)
**期刊：** Science advances
**PMID：** 41406236
**DOI：** 10.1126/sciadv.adz7907

### 第一部分 原文与翻译

**英文原标题：** RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis.

> **英文摘要：**
> Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with no effective curative therapies. Necroptosis, a regulated necrotic cell death pathway controlled by receptor-interacting protein kinase 1 (RIPK1), has emerged as a potential driver of inflammation and fibrosis in chronic liver disorders. We investigated the role of necroptosis in PSC and whether RIPK1 inhibition could modify disease course and progression. Spatial profiling of human PSC biopsies revealed that necroptosis primarily affects cholangiocytes, while apoptosis was more frequent in hepatocytes and nonbiliary cells. In vitro, necroptosis inhibition protected cholangiocytes, and  deletion conferred resistance to TNF-mediated cytotoxicity. In a murine model of PSC, pharmacological RIPK1 inhibition reduced cholestatic injury, hepatic inflammation, and biliary fibrosis. Multiomic analyses comprehensively demonstrated reprogramming toward wild-type-like profiles following treatment. These findings identify necroptosis as a critical effector in PSC and highlight RIPK1 inhibition as a promising disease-modifying approach, opening the door to targeted necroptosis-based therapies for this otherwise untreatable disease.

> **中文摘要：**
> 原发性硬化性胆管炎（PSC）是一种慢性胆汁淤积性肝病，目前尚无有效的治愈性治疗方法。受体相互作用蛋白激酶1（RIPK1）调控的程序性坏死是一种受调控的坏死性细胞死亡途径，已被认为可能驱动慢性肝病中的炎症和纤维化。我们研究了程序性坏死在PSC中的作用，以及抑制RIPK1是否能改变疾病进程及发展。对人类PSC活检样本的空间分析显示，程序性坏死主要影响胆管上皮细胞，而凋亡在肝细胞和非胆道细胞中更为常见。在体外实验中，抑制程序性坏死可保护胆管上皮细胞，且RIPK1的缺失可赋予其对TNF介导的细胞毒性作用的抗性。在小鼠PSC模型中，药理性RIPK1抑制可减轻胆汁淤积性损伤、肝脏炎症和胆道纤维化。多组学分析全面表明，治疗后细胞程序被重新编程，趋向于野生型样特征。这些发现表明，程序性坏死是PSC中的关键效应机制，且RIPK1抑制是一种具有潜力的疾病修饰性治疗策略，为这一迄今仍无法治愈的疾病开辟了基于程序性坏死靶向治疗的新途径。

### 第二部分 AI 大师评价

该研究旨在阐明RIPK1介导的程序性坏死在原发性硬化性胆管炎发病中的作用，并评估其抑制的治疗潜力。作者通过人类组织空间转录组、细胞实验及小鼠模型系统性证实了抑制RIPK1能显著改善胆道损伤、炎症及纤维化。多组学分析进一步揭示了治疗后向健康表型的转录重编程。这项工作创新性地提出了靶向程序性坏死通路的疾病修饰性干预策略，但其在临床的长期安全性与疗效仍需进一步验证。

---

## 58. 长链非编码RNA LINC-PINT 调控淋巴功能及淋巴水肿中的炎症特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406225)
**期刊：** Science advances
**PMID：** 41406225
**DOI：** 10.1126/sciadv.aea2960

### 第一部分 原文与翻译

**英文原标题：** lncRNA LINC-PINT controls lymphatic function and inflammatory profile in lymphedema.

> **英文摘要：**
> Lymphedema is a lymphatic dysfunction leading to an accumulation of fluid and fat in the arm or leg. Here, we performed noncoding RNA profiling of human breast cancer-induced secondary lymphedema. We identified the long intergenic non-protein coding RNA, P53-induced transcript (), as essential for the lymphedema development.  is the most expressed lncRNA in human lymphatic endothelial cells (LECs) under stress condition. Knocking down  in LECs promotes the expression of inflammation-related genes. Mechanistically, ATAC-seq revealed that  induces the transcription of genes involved in lymphangiogenesis and immune cell adhesion by increasing chromatin accessibility. Notably,  deficiency impairs LEC proliferation, migration, and sprouting. Conditional deletion of  in mouse lymphatic endothelium (Lnc-Pint) leads to a reduction in dermal lymphatic network density. Lnc-Pint mice exhibit decreased lymphedema, reduced dermal backflow, fibrosis, and inflammation. Our findings unveil a crucial molecular role of  in lymphatic function and hold substantial clinical implications for lncRNA as biomarker of lymphedema.

> **中文摘要：**
> 淋巴水肿是一种淋巴功能障碍，导致手臂或腿部液体和脂肪的积聚。在此研究中，我们对人类乳腺癌诱导的继发性淋巴水肿进行了非编码RNA谱分析。我们鉴定出一种由P53诱导的长链间隔非蛋白编码RNA（LINC-PINT），其在淋巴水肿的发生中具有关键作用。在应激条件下，LINC-PINT是人类淋巴内皮细胞（LECs）中表达最高的lncRNA。敲低LECs中的LINC-PINT可促进与炎症相关基因的表达。从机制上看，ATAC-seq结果显示，LINC-PINT通过提高染色质可及性来诱导参与淋巴管生成和免疫细胞黏附的基因转录。值得注意的是，缺失LINC-PINT会削弱LECs的增殖、迁移和萌芽能力。在小鼠中对淋巴内皮特异性条件性敲除Lnc-Pint可导致皮肤淋巴网络密度下降。Lnc-Pint缺失小鼠表现出淋巴水肿减轻、皮肤反流、纤维化和炎症减少。我们的研究揭示了LINC-PINT在淋巴功能中的关键分子作用，并为lncRNA作为淋巴水肿生物标志物的潜在临床意义提供了重要依据。

### 第二部分 AI 大师评价

本研究针对乳腺癌相关继发性淋巴水肿，系统分析了非编码RNA的表达谱，并鉴定出LINC-PINT作为调控淋巴功能与炎症反应的关键lncRNA。作者结合转录组与ATAC-seq技术揭示了其通过染色质可及性影响淋巴内皮细胞的功能机制。在小鼠模型中，Lnc-Pint的缺失显著改善了淋巴水肿的结构与炎症表型。该研究为lncRNA在淋巴系统疾病中的功能提供了全新分子证据，具有潜在诊断与治疗启示，但仍需进一步验证其在人类中的转化应用价值。

---

## 59. 持续的糖酵解界定了与聚合物植入物相关的病理性异物炎症。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406214)
**期刊：** Science advances
**PMID：** 41406214
**DOI：** 10.1126/sciadv.adx6368

### 第一部分 原文与翻译

**英文原标题：** Persistent glycolysis defines pathological foreign body-associated inflammation to polymeric implants.

> **英文摘要：**
> The clinical deployment of nondegradable polymeric medical devices is hindered by unresolving inflammation that drives localized fibrosis. This inflammatory niche is distinct; phagocytic macrophages remain persistently activated by biomolecular signals adsorbed to the implant surface, exhibiting profibrotic behavior. Increasingly, alterations to metabolic regulation offers insight into chronically inflamed macrophage function, which remains unexplored in peri-implant inflammation. Here, ex vivo profiling of metabolic dependence and capacity in peri-implant tissues revealed persistent glycolytic reliance by macrophages up to 6 weeks postimplantation. Expression of glucose transporter 1 (GLUT1) increased temporally and with proximity to the implant interface in glycolytically dependent cells, paired with increased capacity for biosynthetic pathways. Glycolytic dependence was notable in multinucleated macrophages, hallmark to the phagocytic behavior of implant pathology. Transcriptomic assessment correlated the up-regulation of pathological wound healing to cells where the capacity for glucose import was highest, highlighting glycolysis as the definitive metabolic system in persistent peri-implant inflammation.

> **中文摘要：**
> 不可降解聚合物医疗器械的临床应用受到无法消退的炎症的阻碍，这种炎症驱动了局部纤维化的形成。该炎症性微环境具有独特性；吞噬性巨噬细胞由于吸附在植入物表面的生物分子信号而持续被激活，并表现出促纤维化行为。越来越多的研究表明，代谢调控的变化为慢性炎症状态下巨噬细胞的功能提供了新见解，而这一机制在植入物周围的炎症中尚未得到充分探讨。在本研究中，对植入物周围组织的代谢依赖性和代谢能力进行离体分析显示，巨噬细胞在植入后长达6周内持续依赖糖酵解代谢。检测发现，葡萄糖转运蛋白1（GLUT1）的表达随时间推移而升高，并且在距离植入表面较近的糖酵解依赖细胞中更为明显，同时伴随生物合成途径能力的增强。多核巨噬细胞表现出显著的糖酵解依赖性，这也是植入物病理特征中吞噬活性的标志。转录组学分析发现，病理性伤口愈合相关基因的上调与高葡萄糖摄取能力的细胞密切相关，突出了糖酵解作为持续性植入周围炎症中主要代谢系统的决定性作用。

### 第二部分 AI 大师评价

本研究从代谢重塑角度揭示了聚合物植入物相关炎症的病理机制，发现巨噬细胞在炎症环境中长期保持糖酵解依赖性。研究采用离体代谢分析与转录组学结合，明确GLUT1介导的葡萄糖摄取与促纤维化反应密切相关。该工作创新性地将代谢表型与异物反应关联，为植入材料的生物相容性改进提供了新方向。其局限在于主要基于离体模型，需进一步验证其在体内干预可行性。

---

## 60. 驻留吞噬细胞促进凋亡细胞的非细胞自主性碎裂

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406211)
**期刊：** Science advances
**PMID：** 41406211
**DOI：** 10.1126/sciadv.adz5264

### 第一部分 原文与翻译

**英文原标题：** Resident phagocytes promote non-cell-autonomous fragmentation of apoptotic cells.

> **英文摘要：**
> Phagocytosis of apoptotic cells maintains tissue homeostasis and regulates inflammation. A proposed facilitator of apoptotic cell clearance is the fragmentation of these cells into apoptotic bodies (ApoBDs) through cell-autonomous processes involving caspases and cytoskeletal rearrangement. Although this fragmentation process is considered a hallmark of apoptosis, its progression in tissue environments remains underexplored. Here, we examine the in vivo apoptotic dynamics of mouse thymocytes and pluripotent cells from zebrafish embryos. We show that the in vivo biogenesis of ApoBDs is independent of known cell-intrinsic regulators. Instead, fragmentation depends on actin-rich protrusions from neighboring resident phagocytes, which mechanically compress apoptotic cells to break them into smaller particles. Four-dimensional in vivo tracking of apoptotic cells reveals that both phagocyte-mediated fragmentation and phagocytosis are size sensitive, indicating that apoptotic size reduction mediated by phagocytes enhances their own clearance abilities. This non-cell-autonomous fragmentation ensures rapid apoptotic cell clearance, crucial for maintaining tissue homeostasis in physiological settings.

> **中文摘要：**
> 吞噬凋亡细胞有助于维持组织稳态并调节炎症反应。已提出的一种促进凋亡细胞清除的机制，是通过涉及半胱天冬酶和细胞骨架重排的细胞自主性过程，将凋亡细胞碎裂为凋亡小体（ApoBDs）。尽管这种碎裂过程被认为是凋亡的标志之一，但其在组织环境中的进程仍未得到充分探究。在此，我们考察了小鼠胸腺细胞和斑马鱼胚胎多能细胞的体内凋亡动态。我们发现，ApoBDs 的体内生成独立于已知的细胞内在调控因子。相反，碎裂依赖于邻近驻留吞噬细胞中富含肌动蛋白的突起，这些突起通过机械性压缩凋亡细胞将其分解成更小的颗粒。四维体内追踪结果显示，吞噬细胞介导的碎裂和吞噬过程均对尺寸敏感，这说明吞噬细胞介导的凋亡细胞尺寸缩小可增强其清除能力。这种非细胞自主性的碎裂确保了凋亡细胞的快速清除，对维持生理条件下的组织稳态至关重要。

### 第二部分 AI 大师评价

该研究以体内模型揭示驻留吞噬细胞在促进凋亡细胞非自主性碎裂中的关键作用，挑战了凋亡碎裂完全由细胞内机制主导的传统观点。作者利用小鼠与斑马鱼的体内成像及四维追踪技术，揭示吞噬细胞通过肌动蛋白突起施加机械性压力以实现凋亡细胞分解。该发现不仅阐明了凋亡清除的组织层面动态机制，也提示细胞间相互作用对稳态维持的重要性。研究创新性地将吞噬功能与机械作用联系起来，但其在其他组织环境和病理状态下的普适性仍待进一步验证。

---

## 61. 组蛋白变体 H2A.X 与 H2A.W 的 N 端尾部直接招募 TONSOKU 并协调 DNA 修复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41406205)
**期刊：** Science advances
**PMID：** 41406205
**DOI：** 10.1126/sciadv.ady2104

### 第一部分 原文与翻译

**英文原标题：** Direct recruitment of TONSOKU by the N-terminal tails of histone variants H2A.X and H2A.W coordinates DNA repair.

> **英文摘要：**
> Histone variants play crucial roles in DNA replication and repair. The plant TONSOKU (TSK) requires histone H3.1 unmethylated at lysine 27 for DNA repair at replication forks, but how TSK is recruited to double-strand break (DSB) sites remains unclear. In this study, we show that the leucine-rich repeat (LRR) domain of TSK recognizes the N-terminal tails of histone variants H2A.X and H2A.W-key for DNA repair in euchromatin and heterochromatin, respectively-but not the H2A.Z variant. A unique motif containing multiple basic and acidic residues (BAR motif) in H2A.Z prevents TSK binding. Moreover, disrupting TSK-H2A.X/W binding impairs TSK-mediated DNA repair. Genetic analyses reveal functional complementation between H2A.X and H2A.W in DNA repair, with the H2A.X N terminus being essential. This study reveals a previously unrecognized, H2A.X/W-dependent mechanism for recruiting the DNA repair protein TSK, highlighting the critical role of their N-terminal tails in plant DNA repair.

> **中文摘要：**
> 组蛋白变体在 DNA 复制和修复中起关键作用。植物中的 TONSOKU (TSK) 蛋白在复制叉处的 DNA 修复中需要赖氨酸 27 无甲基化的组蛋白 H3.1，但 TSK 如何被招募至双链断裂（DSB）位点仍不清楚。在本研究中，我们发现 TSK 的富亮氨酸重复（LRR）结构域可识别组蛋白变体 H2A.X 和 H2A.W 的 N 端尾部——这分别是常染色质和异染色质中 DNA 修复的关键——但不识别组蛋白变体 H2A.Z。H2A.Z 中具有多种碱性与酸性残基的独特基序（BAR 基序）会阻止 TSK 的结合。此外，破坏 TSK 与 H2A.X/W 的结合会削弱 TSK 介导的 DNA 修复。遗传学分析揭示了 H2A.X 与 H2A.W 在 DNA 修复中的功能互补性，其中 H2A.X 的 N 端对其功能至关重要。本研究揭示了一种此前未被认识的依赖 H2A.X/W 的 TSK 招募机制，强调了它们的 N 端尾部在植物 DNA 修复中的关键作用。

### 第二部分 AI 大师评价

本研究旨在阐明植物 DNA 修复蛋白 TONSOKU（TSK）在双链断裂修复中的招募机制。通过结构域识别实验与遗传学分析，作者发现 TSK 的 LRR 结构域可通过识别组蛋白变体 H2A.X 和 H2A.W 的 N 端尾部实现定位，而 H2A.Z 因具有特殊 BAR 基序而阻止结合。该研究不仅揭示了 H2A.X/W 依赖的 TSK 招募新机制，也阐明了组蛋白变体在常染色质与异染色质修复中的互补功能。其创新之处在于系统揭示了组蛋白尾部序列对 DNA 修复蛋白识别的决定性作用，但仍需进一步探明该机制在不同植物物种中的保守性。

---

## 62. Janus激酶1和2的非STAT依赖性功能对乳腺上皮导管出生后发育至关重要

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405992)
**期刊：** Cell reports
**PMID：** 41405992
**DOI：** 10.1016/j.celrep.2025.116703

### 第一部分 原文与翻译

**英文原标题：** STAT-independent functions of Janus kinases 1 and 2 are obligatory for the postnatal development of mammary epithelial ducts.

> **英文摘要：**
> Janus kinases 1 and 2 and STAT transcription factors are critical signaling nodes for numerous growth factors. In the mammary gland, JAK2 and STAT5a/b are essential for alveolar cell differentiation and lactation, but little is known about the cooperative roles of JAKs and STATs before pregnancy. We examined female mice conditionally deficient in JAK1/2 and discovered that both kinases jointly regulate epithelial cell proliferation and ductal morphogenesis. To assess the role of downstream STATs, we generated genetic models co-deficient in STAT3/5a/5b with or without STAT1 or JAK1. Although loss of STAT3/5a/5b leads to a JAK1-dependent upregulation of STAT1, the formation of mammary ducts is unaffected by the lack of expression and activation of all seven STAT proteins. Additionally, STAT deficiency impairs the cytokine-induced autophosphorylation of JAK1/2. These findings suggest that mammary duct development is orchestrated by STAT-independent signaling mechanisms of JAK1 and JAK2, potentially beyond their roles as tyrosine kinases.

> **中文摘要：**
> Janus激酶1和2以及STAT转录因子是多种生长因子信号通路中的关键节点。在乳腺中，JAK2和STAT5a/b对腺泡细胞分化和泌乳至关重要，但关于JAKs与STATs在妊娠前阶段的协同作用知之甚少。我们研究了条件性缺失JAK1/2的雌性小鼠，发现这两种激酶共同调控上皮细胞的增殖与导管形态发生。为评估下游STATs的作用，我们构建了同时缺失STAT3/5a/5b的遗传模型，并结合或不结合STAT1或JAK1的缺失。尽管缺失STAT3/5a/5b会导致一种依赖于JAK1的STAT1上调，但即使缺乏全部七种STAT蛋白的表达和活化，乳腺导管的形成亦不受影响。此外，STAT缺失可削弱细胞因子诱导的JAK1/2自磷酸化。这些结果表明，乳腺导管的发育由JAK1和JAK2的非STAT依赖性信号机制驱动，其功能可能超越其作为酪氨酸激酶的经典角色。

### 第二部分 AI 大师评价

本研究旨在揭示Janus激酶（JAK1和JAK2）在乳腺导管出生后发育中的独立功能，不依赖传统的STAT通路。作者通过多种小鼠遗传模型系统地剖析了JAK-STAT轴的功能分化，发现JAK1/2能够在缺乏所有STAT蛋白的情况下维持导管发育，为非典型信号通路提供了新证据。研究方法严谨，遗传策略复杂，突显了JAK的非传统功能。但研究尚未完全阐明这些非STAT机制的具体分子下游，需进一步细化分子网络。

---

## 63. Liprin-α1 通过激活 mTORC2–AKT1 通路增强 PHLDB3 在结直肠癌中的致癌功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405991)
**期刊：** Cell reports
**PMID：** 41405991
**DOI：** 10.1016/j.celrep.2025.116722

### 第一部分 原文与翻译

**英文原标题：** Liprin-α1 enhances PHLDB3 oncogenic function in colorectal cancer via activation of mTORC2-AKT1 pathway.

> **英文摘要：**
> Colorectal cancer (CRC) progression is driven by aberrant activation of oncogenic pathways, including AKT1, which requires mTORC2-mediated phosphorylation at Ser473. This study identifies PHLDB3 and Liprin-α1 as key regulators of RICTOR-dependent, mTORC2-mediated AKT1 signaling, independently of p53. PHLDB3 interacts with RICTOR to enhance AKT1 phosphorylation and promote tumor progression. In p53-null CRC cells, PHLDB3 knockdown reduces AKT1 activation, whereas PHLDB3 overexpression increases it. Liprin-α1 stabilizes PHLDB3 by limiting its proteasomal degradation, thereby maintaining mTORC2 activity. Liprin-α1 depletion lowers PHLDB3 levels and impairs AKT1 signaling, whereas Liprin-α1 overexpression boosts PHLDB3-mediated AKT1 activation and CRC cell proliferation. Importantly, the Liprin-α1-PHLDB3 axis depends on RICTOR, underscoring a hierarchical regulation essential for AKT1 activation. PHLDB3 is significantly overexpressed in CRC and is associated with poor prognosis. These findings reveal a Liprin-α1-PHLDB3-mTORC2-AKT1 signaling pathway important for CRC growth and present this pathway as a promising therapeutic target in CRC.

> **中文摘要：**
> 结直肠癌（CRC）的进展由多种致癌信号通路异常激活所驱动，其中包括需要 mTORC2 介导在 Ser473 位点磷酸化的 AKT1。 本研究鉴定了 PHLDB3 和 Liprin-α1 是 RICTOR 依赖的、mTORC2 介导的 AKT1 信号的关键调控因子，且其功能独立于 p53。 PHLDB3 与 RICTOR 相互作用以增强 AKT1 的磷酸化并促进肿瘤进展。 在 p53 缺失的结直肠癌细胞中，沉默 PHLDB3 可降低 AKT1 的活化，而过表达 PHLDB3 则可增强其活化。 Liprin-α1 通过限制 PHLDB3 的蛋白酶体降解来稳定其水平，从而维持 mTORC2 的活性。 缺失 Liprin-α1 会降低 PHLDB3 表达并削弱 AKT1 信号，而过表达 Liprin-α1 则促进 PHLDB3 介导的 AKT1 激活和 CRC 细胞增殖。 重要的是，Liprin-α1–PHLDB3 轴依赖于 RICTOR，强调了维持 AKT1 激活所必需的层级性调控。 PHLDB3 在 CRC 中明显高表达，并与预后不良相关。 这些发现揭示了 Liprin-α1–PHLDB3–mTORC2–AKT1 信号通路在结直肠癌生长中的关键作用，并提出该通路可能是潜在的治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于结直肠癌中 AKT1 激活的分子机制，揭示了 Liprin-α1 与 PHLDB3 在 mTORC2 依赖信号调控中的关键作用。 研究通过在不同 p53 状态下的细胞实验，证明 Liprin-α1 稳定 PHLDB3 并增强其促进 AKT1 磷酸化和肿瘤细胞生长的功能。 该工作创新性地定义了 Liprin-α1–PHLDB3–mTORC2–AKT1 的层级信号轴，为理解 CRC 的进展机制及靶向治疗提供了新思路。 然而，其主要基于细胞实验，尚需更多动物模型和临床数据验证。

---

## 64. 一种由20个氨基酸组成的心肌病毒蛋白展现细胞因子仿效活性以调控病毒复制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405988)
**期刊：** Cell reports
**PMID：** 41405988
**DOI：** 10.1016/j.celrep.2025.116740

### 第一部分 原文与翻译

**英文原标题：** A 20-amino-acid Cardiovirus protein exhibits cytokine-mimicry activity to regulate viral replication.

> **英文摘要：**
> Viral protein genome-linked (VPg) is a small protein encoded by several non-enveloped positive-sense RNA viruses, including Cardiovirus. Although VPg is widely recognized as essential for viral RNA synthesis, its additional roles remain largely unexplored. Here, we report an alternative function of Cardiovirus VPg as an interferon-γ receptor agonist. During encephalomyocarditis virus (EMCV) infection, a member of the Cardiovirus genus, we uncovered that VPg from EMCV (VPg) is released extracellularly from host cells. VPg is then sensed by uninfected host cells, activating the interferon-γ signaling cascade and ultimately producing nitric oxide (NO) through inducible NO synthase induction. NO accumulation is crucial for triggering potent cell death in cooperation with tumor necrosis factor α (TNF-α) signaling, with TNF-α also being induced as an antiviral host response during EMCV infection. We demonstrate that VPg, comprising merely 20 amino acids, can exhibit cytokine-mimicry activity, with the synergistic interplay between VPg and TNF-α signaling regulating viral replication and disease pathogenesis.

> **中文摘要：**
> 病毒基因组连接蛋白（VPg）是一种由包括心肌病毒在内的多种无包膜正链RNA病毒编码的小分子蛋白。尽管VPg被广泛认为对病毒RNA合成至关重要，但其其他功能仍 largely 未被探索。在本研究中，我们报道了心肌病毒VPg的另一种功能，即其作为干扰素-γ受体激动剂的作用。在心脑肌炎病毒（EMCV，属心肌病毒属）感染过程中，我们发现来自EMCV的VPg能够从宿主细胞释放至细胞外。随后，该VPg可被未感染宿主细胞感知，从而激活干扰素-γ信号级联反应，并最终通过诱导型一氧化氮合酶的诱导产生一氧化氮（NO）。NO的积累对于与肿瘤坏死因子α（TNF-α）信号通路协同触发强烈细胞死亡至关重要，而TNF-α在EMCV感染期间同样作为抗病毒宿主反应被诱导。我们证明，仅由20个氨基酸组成的VPg即可表现出细胞因子仿效活性，VPg与TNF-α信号的协同互作共同调控病毒复制及疾病发病机制。

### 第二部分 AI 大师评价

本研究揭示心肌病毒VPg在经典的RNA合成功能之外，兼具细胞因子模拟活性这一新的生物学功能。作者基于EMCV感染模型发现，VPg可被宿主释放至胞外并模拟干扰素-γ受体激动剂，从而诱导NO合成与细胞死亡信号。该研究首次将20个氨基酸的小分子病毒蛋白与细胞因子信号联结，为理解病毒与宿主免疫系统的交互提供了新视角。其创新性体现在小分子蛋白的细胞因子仿效机制，但仍需进一步验证其在体内感染模型中的普遍性和生理意义。

---

## 65. 将自然杀伤细胞引入临床：超越癌症的机遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405717)
**期刊：** The Journal of experimental medicine
**PMID：** 41405717
**DOI：** 10.1084/jem.20250612

### 第一部分 原文与翻译

**英文原标题：** Bringing natural killer cells to the clinic: Opportunities beyond cancer.

> **英文摘要：**
> Natural killer (NK) cells are cytotoxic and cytokine-producing innate lymphocytes with established roles in antiviral and antitumor immunity. In recent years, the biology of NK cells has been exploited in innovative cancer immunotherapies, leading to clinical advances including allogeneic NK cell infusions, chimeric antigen receptor NK cells, and NK cell engager technologies. These studies pave the way to explore how advances in NK cell-based immunotherapies could be leveraged outside of oncology to selectively target pathogenic cells and restore tissue homeostasis in viral infections, neurodegenerative disorders, autoimmunity, and transplantation medicine.

> **中文摘要：**
> 自然杀伤（NK）细胞是具有细胞毒性并能产生细胞因子的先天性淋巴细胞，在抗病毒和抗肿瘤免疫中发挥确立的作用。近年来，NK 细胞生物学被应用于创新性的癌症免疫疗法，促成了包括异体 NK 细胞输注、嵌合抗原受体 NK 细胞以及 NK 细胞接合技术等多项临床进展。这些研究为探索如何将基于 NK 细胞的免疫治疗进展拓展至肿瘤学之外奠定了基础，以选择性地靶向致病细胞，并在病毒感染、神经退行性疾病、自身免疫及移植医学中恢复组织稳态。

### 第二部分 AI 大师评价

该研究综述了自然杀伤细胞在从基础生物学到临床转化中的关键进展，强调其在癌症免疫治疗之外的潜在应用价值。作者指出，NK 细胞的靶向功能与免疫调控特性可为多种非肿瘤性疾病，如病毒感染和神经退行性疾病，提供新的治疗策略。文章的创新性在于系统提出拓展 NK 细胞免疫学应用的新方向，同时揭示当前临床转化仍面临机制理解与精准调控的挑战。

---

## 66. KEYLYNK-009：帕博利珠单抗联合奥拉帕利在局部复发不可切除或转移性三阴性乳腺癌中的应用及一线帕博利珠单抗联合化疗获益分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405563)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41405563
**DOI：** 10.1158/1078-0432.CCR-25-1818

### 第一部分 原文与翻译

**英文原标题：** KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy.

> **英文摘要：**
> PURPOSE: Pembrolizumab plus olaparib versus pembrolizumab plus chemotherapy was evaluated as post-induction therapy for patients with PD-L1‒unselected locally recurrent inoperable/metastatic triple-negative breast cancer (TNBC) who derived clinical benefit from first-line pembrolizumab plus platinum-based chemotherapy induction therapy.
> 
> METHODS: In this phase 2 study (NCT04191135), participants with previously untreated locally recurrent inoperable/metastatic TNBC received first-line pembrolizumab 200 mg Q3W plus platinum-based chemotherapy. Participants with complete/partial response or stable disease (per RECIST v1.1) were randomized 1:1 to pembrolizumab 200 mg Q3W plus olaparib 300 mg BID or pembrolizumab plus chemotherapy. PFS and OS were primary endpoints.
> 
> RESULTS: Of 460 participants receiving induction treatment, 271 were randomized to post-induction therapy. Median PFS was 5.5 months in the pembrolizumab plus olaparib group versus 5.6 months in the pembrolizumab plus chemotherapy group (HR, 0.98; 95% CI, 0.72‒1.33; P=0.4556). Median OS was 25.1 versus 23.4 months, respectively (HR, 0.95; 95% CI, 0.64‒1.40). In participants with tumor BRCA1/BRCA2 mutations (tBRCAm), HRs for PFS (HR, 0.70; 95% CI, 0.33‒1.48) and OS (0.81; 95% CI, 0.28‒2.37) favored pembrolizumab plus olaparib. Treatment-related adverse events occurred in 84.4% and 96.2% of participants receiving pembrolizumab plus olaparib and pembrolizumab plus chemotherapy, respectively.
> 
> CONCLUSION: Although the primary endpoint was not met, post-induction pembrolizumab plus olaparib therapy resulted in similar PFS and OS compared with pembrolizumab plus chemotherapy in this setting. The positive trend for PFS and OS in participants with tBRCAm suggests a potential non-chemotherapy strategy for maintaining clinical benefit attained with first-line pembrolizumab plus chemotherapy induction treatment. No new safety signals were identified.

> **中文摘要：**
> 研究目的：评估在未选择PD-L1状态的局部复发不可切除或转移性三阴性乳腺癌（TNBC）患者中，帕博利珠单抗联合奥拉帕利与帕博利珠单抗联合化疗作为诱导治疗后的维持方案的疗效。这些患者均在一线接受帕博利珠单抗联合含铂化疗诱导治疗并获得临床获益。
> 
> 研究方法：在这项Ⅱ期研究（NCT04191135）中，未经治疗的局部复发不可切除/转移性TNBC患者首先接受帕博利珠单抗200 mg，每3周一次，联合含铂化疗。根据RECIST v1.1评估达到完全缓解、部分缓解或疾病稳定的患者，按1:1比例随机分配至帕博利珠单抗200 mg每3周一次联合奥拉帕利300 mg每日两次组，或帕博利珠单抗联合化疗组。无进展生存期（PFS）和总生存期（OS）为主要终点。
> 
> 研究结果：在接受诱导治疗的460例受试者中，271例被随机分配接受维持治疗。帕博利珠单抗联合奥拉帕利组的中位PFS为5.5个月，帕博利珠单抗联合化疗组为5.6个月（风险比[HR]：0.98；95%置信区间[CI]：0.72‒1.33；P=0.4556）。两组的中位OS分别为25.1个月与23.4个月（HR：0.95；95% CI：0.64‒1.40）。在携带肿瘤BRCA1/BRCA2突变（tBRCAm）的患者中，PFS（HR：0.70；95% CI：0.33‒1.48）及OS（HR：0.81；95% CI：0.28‒2.37）均倾向于帕博利珠单抗联合奥拉帕利组。治疗相关不良事件的发生率分别为帕博利珠单抗联合奥拉帕利组84.4%，帕博利珠单抗联合化疗组96.2%。
> 
> 结论：尽管主要终点未达到，但在该研究人群中，诱导治疗后帕博利珠单抗联合奥拉帕利方案在PFS和OS方面与帕博利珠单抗联合化疗相当。在tBRCAm患者中PFS和OS的积极趋势提示，帕博利珠单抗联合奥拉帕利可能为维持一线帕博利珠单抗联合化疗疗效提供一种潜在的非化疗策略。未观察到新的安全性信号。

### 第二部分 AI 大师评价

本研究旨在探索帕博利珠单抗联合奥拉帕利作为诱导后维持治疗方案在晚期三阴性乳腺癌患者中的有效性与安全性。结果显示两组的无进展生存期和总生存期相当，但在携带BRCA突变的患者中存在疗效趋优。该研究为免化疗维持策略在特定分子亚型TNBC中的可行性提供了早期临床依据。尽管未达到主要终点，但显示出新的治疗方向和良好的安全性，为精准免疫联合PARP抑制治疗奠定基础。

---

## 67. 抗BCMA 与 抗GPRC5D 双特异性抗体治疗多发性骨髓瘤患者中选择性B细胞亚群耗竭导致感染风险升高

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405507)
**期刊：** Blood
**PMID：** 41405507
**DOI：** 10.1182/blood.2025029572

### 第一部分 原文与翻译

**英文原标题：** Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.

> **英文摘要：**
> Infections remain a key challenge during treatment of multiple myeloma (MM) patients with anti-BCMA and -GPRC5D bispecific antibodies (bsAbs). However, the underlying mechanism behind different rates and severity of infections induced by the two bsAbs remains poorly understood. Single-cell RNA-sequencing performed in bone marrow aspirates of 11 MM patients and 8 healthy donors revealed BCMA expression on mature B cells and, surprisingly, in small pre-B cells within B-cell precursors. By contrast, GPRC5D expression was restricted to normal and malignant plasma cells (PCs). Next-generation flow cytometry immune profiling showed that anti-BCMA bsAbs severely depleted bone marrow (BM) mature B cells (4.9%→0%; p<0.001) and normal PCs (0.17% → <0.0002%; p<0.001) during treatment of 62 relapsed MM patients. This was observed in early and late time points of therapy. Additional flow cytometry (N=31) and single-cell RNA-sequencing studies (N=8) demonstrated that, in contrast to anti-GPRC5D, anti-BCMA bsAbs also depleted immature and small pre-B cells. The MIcγ1 mouse model was used as a negative control of BCMA expression in all stages of the B-cell lineage, which confirmed no depletion of any B-cell subset after anti-BCMA treatment. In conclusion, we show that while GPRC5D bsAbs selectively target PCs, anti-BCMA bsAbs target both PCs and B cells from the small pre-B stage onwards. Our study provides mechanistic insight into the increased infection risk with anti-BCMA therapy and lays a foundation for individualized bsAb strategies in MM. Moreover, dual targeting of B cells and PCs may have therapeutic potential in other B cell malignancies or autoimmune diseases.

> **中文摘要：**
> 感染仍然是使用抗BCMA和抗GPRC5D双特异性抗体（bsAbs）治疗多发性骨髓瘤（MM）患者时面临的主要挑战。然而，由两种bsAbs引起的感染发生率和严重程度差异的潜在机制尚不清楚。对11例MM患者和8名健康供者的骨髓抽吸样本进行单细胞RNA测序显示，BCMA在成熟B细胞以及令人意外的小型前B细胞（即B细胞前体细胞内的一个阶段）中表达。相比之下，GPRC5D的表达仅限于正常和恶性浆细胞（PCs）。新一代流式细胞术免疫谱分析显示，在62例复发性MM患者的治疗过程中，抗BCMA bsAbs显著耗竭了骨髓（BM）成熟B细胞（4.9%→0%；p<0.001）和正常浆细胞（0.17%→<0.0002%；p<0.001）。这种现象在治疗早期和晚期时间点均可观察到。进一步的流式细胞分析（N=31）和单细胞RNA测序研究（N=8）证实，与抗GPRC5D不同，抗BCMA bsAbs还会耗竭未成熟和小型前B细胞。MIcγ1小鼠模型被用作在B细胞谱系各阶段均不表达BCMA的阴性对照，结果证实抗BCMA治疗后未见任何B细胞亚群被耗竭。总结而言，我们的研究表明，尽管GPRC5D bsAbs选择性靶向浆细胞，抗BCMA bsAbs则从小型前B细胞阶段起同时靶向浆细胞和B细胞。本研究为抗BCMA治疗相关感染风险增加提供了机制学见解，并为MM个体化双特异性抗体治疗策略奠定了基础。此外，同时靶向B细胞和浆细胞的方案可能在其他B细胞恶性肿瘤或自身免疫性疾病中具有潜在治疗价值。

### 第二部分 AI 大师评价

该研究通过单细胞RNA测序和流式细胞术系统比较了抗BCMA与抗GPRC5D双特异性抗体在多发性骨髓瘤患者中导致感染风险差异的细胞学基础。研究发现抗BCMA治疗不仅耗竭浆细胞，还广泛破坏从小型前B阶段起的B细胞亚群，从而揭示感染风险上升的机制。相比之下，抗GPRC5D治疗仅限于靶向浆细胞。该工作首次系统阐明了不同bsAb在骨髓B细胞谱系中的作用差异，为优化双抗策略及其安全性评估提供新思路，然而样本量相对有限，后续需进一步验证其临床关联性。

---

## 68. 糖胺聚糖型胚胎癌相关软骨素硫酸盐是急性髓系白血病抗体偶联药物治疗的新型靶点。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405498)
**期刊：** Blood
**PMID：** 41405498
**DOI：** 10.1182/blood.2024028147

### 第一部分 原文与翻译

**英文原标题：** The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML.

> **英文摘要：**
> Antibody-drug conjugates (ADCs) have emerged as promising targeted therapies in acute myeloid leukemia (AML). However, most ADCs exhibit off-target binding to normal hematopoietic stem and myeloid progenitor cells, resulting in adverse hemato-toxicity and narrow therapeutic windows, limiting their clinical application to young and fit AML patients eligible for intensive curative therapies. Proteoglycans with high levels of the glycosaminoglycan oncofetal chondroitin sulfate (ofCS), are abundantly expressed in solid cancers while being absent or lowly expressed in normal adult tissues. Here, we report high ofCS levels on bone marrow (BM) cells of AML patients and AML patient-derived xenografts (PDXs), while BM cells of healthy subjects showed low or undetectable ofCS levels. Consistently, an anti-ofCS antibody demonstrated binding and internalization into AML cells, and anti-ofCS ADCs effectively killed AML cells in vitro. Moreover, anti-ofCS ADC treatment significantly prolonged survival of AML PDXs compared to controls and was associated with low toxicity. Hence, anti-ofCS ADC could represent an effective therapy with acceptable toxicity applicable for all AML patients, including those ineligible or unresponsive to current intensive curative therapies. In conclusion, our study for the first time demonstrates that a glycosaminoglycan like ofCS represents a druggable target for development of effective antibody-based AML therapies.

> **中文摘要：**
> 抗体药物偶联物（ADCs）已成为急性髓系白血病（AML）中一种极具前景的靶向治疗策略。然而，大多数ADC对正常造血干细胞和髓系祖细胞存在非特异性结合，导致不良的血液毒性及狭窄的治疗窗，从而将其临床应用限制在适合接受强化治愈性治疗的年轻或体能良好的AML患者。富含糖胺聚糖型胚胎癌相关软骨素硫酸盐（ofCS）的蛋白聚糖在实体瘤中高度表达，而在正常成人组织中则缺乏或表达水平极低。本研究报道，AML患者及患者来源的异种移植（PDX）骨髓细胞中ofCS水平较高，而健康供体的骨髓细胞ofCS水平较低或不可检测。与此同时，抗ofCS抗体可与AML细胞结合并被其内化，抗ofCS ADC在体外有效杀伤AML细胞。此外，与对照组相比，抗ofCS ADC治疗显著延长了AML PDX模型的生存期，并且毒性较低。因此，抗ofCS ADC可能成为一种具有可接受毒性的有效治疗选择，适用于所有AML患者，包括那些不适合或对现有强化治愈性疗法无反应的患者。总之，本研究首次证实，类似ofCS的糖胺聚糖可作为可药物化靶点，为开发基于抗体的AML有效治疗提供了新方向。

### 第二部分 AI 大师评价

该研究旨在发现急性髓系白血病（AML）新的抗体药物偶联物靶点。作者通过检测发现，胚胎癌相关软骨素硫酸盐（ofCS）在AML细胞中高表达，而在健康骨髓中几乎不可检测。基于此，研究构建了抗ofCS ADC并验证其体外杀伤作用及AML异种移植模型中的延寿效果，且毒性较低。研究创新性在于首次揭示糖胺聚糖ofCS的可药物化潜力，为广泛AML患者（包括不适合强化治疗者）提供了新的精准治疗方向。其局限性在于仍需进一步验证临床安全性与疗效。

---

## 69. 自体移植前基于PD-1的联合治疗与经典霍奇金淋巴瘤患者改善的预后相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405496)
**期刊：** Blood
**PMID：** 41405496
**DOI：** 10.1182/blood.2025030151

### 第一部分 原文与翻译

**英文原标题：** PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

> **英文摘要：**
> Combination therapy incorporating PD-1 blockade results in unprecedented response rates in both frontline and relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). Prior retrospective studies have suggested benefit for PD-1 blockade pre-ASCT but included few patients receiving PD-1 blockade with cytotoxic chemotherapy. To explore the impact of anti-PD-1 based salvage on outcomes for patients with R/R cHL, we retrospectively reviewed 1280 patients with R/R cHL who underwent ASCT from 2010-2022 at 6 transplant centers, none of whom received PD-1 blockade as part of frontline therapy. 25% received a PD-1 inhibitor at any point prior to ASCT (10% in conjunction with chemotherapy), 28% received salvage BV without PD-1 blockade, and the rest received salvage chemotherapy alone. Patients who received PD-1 inhibitors at any point before ASCT had a significantly higher 2-year PFS compared to patients who received BV without PD-1 inhibitors or patients receiving chemotherapy alone (88.2%, 70.2%, 67.4%, p < 0.0001). When restricted to patients in complete response (CR) pre-ASCT, the benefit of PD-1 blockade remained significant. PD-1 blockade pre-ASCT is independently associated with superior post-ASCT outcomes and patients proceeding to ASCT should be treated with PD-1-based salvage.

> **中文摘要：**
> 将PD-1阻断纳入的联合治疗在初治及复发/难治性（R/R）经典型霍奇金淋巴瘤（cHL）中可导致前所未有的应答率。以往的回顾性研究提示在自体造血干细胞移植（ASCT）前采用PD-1阻断具有益处，但纳入的同时接受细胞毒性化疗及PD-1阻断的患者较少。为探讨基于抗PD-1的挽救治疗对R/R cHL患者预后的影响，我们回顾性分析了2010年至2022年间在6个移植中心接受ASCT的1280例R/R cHL患者，这些患者均未在一线治疗中接受PD-1阻断。共有25%的患者在ASCT前任何阶段接受过PD-1抑制剂治疗（其中10%同时接受化疗），28%在无PD-1阻断的情况下接受了挽救性BV治疗，其余患者仅接受了挽救性化疗。与仅接受BV且无PD-1抑制剂或仅接受化疗的患者相比，任何阶段在ASCT前接受PD-1抑制剂的患者其两年无进展生存率（PFS）显著更高（分别为88.2%、70.2%、67.4%，p < 0.0001）。当分析限定于ASCT前达到完全缓解（CR）的患者时，PD-1阻断的益处依然显著。ASCT前的PD-1阻断与ASCT后的优越结局独立相关，提示应进行ASCT的患者应接受基于PD-1的挽救治疗。

### 第二部分 AI 大师评价

本研究通过多中心大规模回顾性分析，评估了自体移植前基于PD-1的挽救治疗对复发/难治性经典型霍奇金淋巴瘤患者预后的影响。结果显示，接受PD-1抑制剂治疗的患者移植后的两年无进展生存率显著提高，且这一益处在完全缓解者中依然存在。研究揭示了PD-1联合治疗在移植前治疗策略中的潜在价值，为临床优化复发/难治性霍奇金淋巴瘤的管理提供了重要依据。不过，作为回顾性研究，其因患者选择偏倚和治疗异质性仍具一定局限。

---

## 70. 伊布替尼治疗伴或不伴TP53异常的慢性淋巴细胞白血病十年研究：研究者发起的II期试验最终报告

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405491)
**期刊：** Blood
**PMID：** 41405491
**DOI：** 10.1182/blood.2025029971

### 第一部分 原文与翻译

**英文原标题：** A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.

> **英文摘要：**
> BTK inhibitors improve outcomes for patients with chronic lymphocytic leukemia (CLL). Long-term data with continuous therapy are limited. With a median follow-up of 10.0 years, we report final results on 84 patients with TP53 aberrations (del(17p) or TP53 mutation) or ≥65 years of age treated with 420mg of single-agent ibrutinib daily until progression or unacceptable toxicity. 52 (61.9%) patients were previously untreated, 56 (66.7%) had unmutated IGHV, and 53 (63.1%) had TP53 aberrations, including 34 who were treatment-naive. As of July 31, 2024, 9 (10.7%) patients continued ibrutinib, 39 (46.4%) discontinued ibrutinib for progressive disease, 31 (36.9%) for adverse events, and 5 (5.9%) withdrew consent. The median progression-free survival (PFS) was 7.2 years; median overall survival (OS) was not reached. In patients with and without TP53 aberrations, median PFS was 5.6 years and not reached, and 10-year OS was 51.3% and 75.3%, respectively. The estimated 10-year PFS and OS for patients with TP53-aberrant CLL treated in first line was 38.6% and 65.7%, respectively. Minimal residual disease (MRD) was quantified by peripheral blood flow cytometry annually. Undetectable MRD (at 10-4) was achieved in 13 (15.5%) patients after a median of 5 years. Twelve patients maintained uMRD, the longest observation ongoing at 8.0 years. Seventeen (42.5%) patients with best response of high MRD (>10-2) remained progression-free for over 5 years. These results highlight durable benefits and deepening responses with ibrutinib, including in high-risk CLL. Whether patients maintaining uMRD for years can safely discontinue therapy should be assessed prospectively. Clinicaltrials.gov: NCT01500733.

> **中文摘要：**
> 布鲁顿酪氨酸激酶（BTK）抑制剂可改善慢性淋巴细胞白血病（CLL）患者的预后。其持续治疗的长期数据仍然有限。本研究中位随访10.0年，报告了84例接受伊布替尼单药治疗（每日420毫克，直至疾病进展或出现不可接受毒性）的患者的最终结果，这些患者包括具有TP53异常［del(17p)或TP53突变］或年龄≥65岁的个体。其中，52例（61.9%）为初治患者，56例（66.7%）为IGHV未突变型，53例（63.1%）存在TP53异常，包括34例初治者。截至2024年7月31日，9例（10.7%）患者仍在接受伊布替尼治疗，39例（46.4%）因疾病进展停药，31例（36.9%）因不良事件停药，5例（5.9%）自行退出。中位无进展生存期（PFS）为7.2年；中位总生存期（OS）尚未达到。在伴/不伴TP53异常患者中，中位PFS分别为5.6年和未达到，10年OS分别为51.3%和75.3%。在初治的TP53异常CLL患者中，估算的10年PFS和OS分别为38.6%和65.7%。每年通过外周血流式细胞术测定微小残留病灶（MRD）。在中位5年后，13例（15.5%）患者达到MRD不可检出水平（10⁻⁴）；其中12例维持uMRD状态，最长持续观察达8.0年。17例（42.5%）MRD高水平（>10⁻²）的患者在5年以上仍无进展。这些结果突显出伊布替尼在CLL治疗中的持久获益与反应加深效应，即使在高危患者中亦然。对于长期维持uMRD状态的患者能否安全停药，仍需前瞻性研究验证。临床试验注册号：NCT01500733。

### 第二部分 AI 大师评价

本研究为伊布替尼在CLL治疗中的十年随访最终报告，系统评估了TP53异常及非异常患者的长期疗效与生存结果。结果显示，伊布替尼在不同风险层级人群中均能带来持久获益，部分患者可获得深度分子缓解并长期维持无进展状态。研究突出了BTK抑制剂的长期安全性与疗效稳定性，同时也提出了uMRD患者是否可停药的关键科学问题。其优势在于超长随访与细致的MRD动态监测，但作为单臂研究仍受样本量及无对照设计限制。

---

## 71. CD38在骨髓增殖性肿瘤纤维化进展过程中单核细胞中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405487)
**期刊：** Blood
**PMID：** 41405487
**DOI：** 10.1182/blood.2025028703

### 第一部分 原文与翻译

**英文原标题：** The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.

> **英文摘要：**
> Proinflammatory signaling is a hallmark of myeloproliferative neoplasms (MPNs). Several studies have shown that monocytes are a major source of proinflammatory cytokines and monocyte-derived fibrocytes play a pivotal role in the pathogenesis of myelofibrosis (MF). To further explore the role of monocytes in MF, we generated inducible NrasG12D/+Jak2V617F/+ (NJ) mice. Recipients transplanted with NJ BM cells developed MF with an early onset of anemia and monocytosis. In vitro, NJ recipients' BM nucleated cells exhibited increased quantity of CD45+CollagenI+ fibrocytes, which were mainly derived from the Ly6chigh monocytes. RNA sequencing identified a significant elevated expression of CD38 (a nicotinamide adenine dinucleotide (NAD)+ hydrolase) in Ly6chigh monocytes from NJ mice, which results in pronounced lower level of NAD+. In humans, CD14+ monocytes from MF patients showed significantly higher expression of CD38 than controls and monocytes from polycythemia vera (PV) patients with grade 1 fibrosis had higher CD38 expression than those without fibrosis. Finally, boosting NAD+ via pharmacological CD38 targeting or NAD+ precursor supplementation inhibited the differentiation of fibrocytes in vitro and targeting CD38 can effectively prevent the onset of fibrosis in vivo. Collectively, our findings shed light on the role of CD38 in monocytes and suggest potential clinical applications such as use of CD38 as a biomarker of fibrotic progression and potential clinical utility of CD38 inhibition in patients with MF.

> **中文摘要：**
> 促炎性信号是骨髓增殖性肿瘤（MPNs）的标志。多项研究表明，单核细胞是促炎细胞因子的主要来源，而单核细胞来源的成纤维细胞在骨髓纤维化（MF）的发病机制中发挥关键作用。为进一步探讨单核细胞在MF中的作用，我们构建了可诱导的NrasG12D/+Jak2V617F/+（NJ）小鼠。接受NJ骨髓细胞移植的受体出现了早发性贫血和单核细胞增多，并发展为MF。在体外实验中，NJ受体的骨髓有核细胞中CD45+CollagenI+成纤维细胞数量增加，这些细胞主要来源于Ly6chigh单核细胞。RNA测序结果显示，NJ小鼠的Ly6chigh单核细胞中CD38（一种烟酰胺腺嘌呤二核苷酸（NAD+）水解酶）的表达显著升高，导致NAD+水平明显降低。在人类样本中，MF患者的CD14+单核细胞中CD38表达显著高于对照组；而伴有1级纤维化的真性红细胞增多症（PV）患者的单核细胞中CD38表达也高于无纤维化者。最后，通过药物性靶向CD38或补充NAD+前体以提升NAD+水平，可在体外抑制成纤维细胞分化，并且在体内靶向CD38可有效预防纤维化的发生。综上所述，我们的研究揭示了CD38在单核细胞中的作用，并提示其可作为纤维化进展的生物标志物及MF患者中CD38抑制的潜在临床应用价值。

### 第二部分 AI 大师评价

该研究聚焦于CD38在骨髓增殖性肿瘤纤维化进程中单核细胞的作用，使用了双突变小鼠模型和人类样本验证。研究发现，CD38的上调导致NAD+水平下降，促进成纤维细胞分化，从而推动纤维化发展。通过药理学抑制或代谢干预恢复NAD+水平，可逆转这一过程。这一发现揭示了单核细胞CD38在骨髓纤维化中的关键病理机制，并为靶向CD38的抗纤维化治疗提供了理论和实验依据。尽管结果令人鼓舞，但仍需进一步评估长期干预的安全性和有效性。

---

## 72. 回复：原发性硬化性胆管炎（PSC）患者的肝细胞癌（HCC）竞争风险与监测阈值

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405465)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41405465
**DOI：** 10.1097/HEP.0000000000001651

### 第一部分 原文与翻译

**英文原标题：** Reply: Competing risk and surveillance thresholds for HCC in Patients with PSC.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文为对相关研究的回复，聚焦于原发性硬化性胆管炎患者中肝细胞癌风险评估及监测阈值确定问题。尽管正文未提供摘要，但标题显示其讨论竞争风险模型与筛查策略的适用性。此类研究有助于改进PSC患者的HCC早期检测方案，提升风险分层的精确度。然而，作为回复性文章，其创新性主要体现在学术讨论与方法论补充，而非原始数据分析。

---

## 73. 利用跨膜水交换磁共振成像的细胞死亡早期检测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405452)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41405452
**DOI：** 10.1002/advs.202513317

### 第一部分 原文与翻译

**英文原标题：** Early Detection of Cell Death Using Transmembrane Water Exchange Magnetic Resonance Imaging.

> **英文摘要：**
> Cell death plays a key role in cancer progression and treatment. After its onset, cell membrane integrity is often compromised. Here, it is shown in cells, animals and humans that the transmembrane water exchange rate, measured using magnetic resonance filter-exchange spectroscopy (FEXSY) or imaging (FEXI), and quantified by the apparent exchange rate (AXR), is an early biomarker of cell death. AXR measurements detect the onset of cell death in vivo earlier than diffusion-weighted MRI (DWI) and in vitro with similar sensitivity as flow cytometry. C magnetic resonance imaging (MRI) measurements of the malate/fumarate ratio (MFR), following injection of hyperpolarized [1,4-C]fumarate, in tumors displaying diffuse necrosis, are correlated with AXR. AXR detects early treatment response in colorectal and lymphoma tumor models while the apparent diffusion coefficient (ADC) measured by DWI remains unchanged. AXR measurements in human uterine fibroids show sensitivity to post-treatment changes soon after embolization, demonstrating clinical translatability of the method.

> **中文摘要：**
> 细胞死亡在癌症的进展与治疗中起着关键作用。细胞死亡开始后，其细胞膜完整性常受到破坏。本研究在细胞、动物及人体中表明，通过磁共振滤波交换光谱（FEXSY）或成像（FEXI）测得并以表观交换率（AXR）量化的跨膜水交换速率，是细胞死亡的早期生物标志物。AXR 测量能在体内比弥散加权磁共振成像（DWI）更早检测到细胞死亡的发生，并且在体外与流式细胞术具有相似的敏感性。利用超极化 [1,4-C] 延胡索酸注射后，在表现出弥漫性坏死的肿瘤中测得的苹果酸/延胡索酸比值（MFR）磁共振成像结果与 AXR 存在相关性。AXR 在结直肠癌和淋巴瘤肿瘤模型中能够检测到早期治疗反应，而 DWI 测得的表观扩散系数（ADC）仍保持不变。在人体子宫肌瘤栓塞治疗后不久的 AXR 测量也能灵敏反映治疗变化，显示该方法具有良好的临床可转化性。

### 第二部分 AI 大师评价

该研究旨在探索跨膜水交换磁共振成像（FEXSY/FEXI）作为细胞死亡早期检测生物标志物的可行性。作者通过细胞实验、动物模型及人体研究，验证了表观交换率（AXR）在检测细胞死亡方面的高敏感性，并较弥散加权成像（DWI）更早捕捉到细胞死亡信号。研究进一步展示了 AXR 与代谢标志物 MFR 的关联，以及其在结直肠癌、淋巴瘤和子宫肌瘤中的应用潜力。该方法具有创新性和较强的临床转化潜力，但其在不同肿瘤类型及复杂临床场景下的普适性仍需进一步研究。

---

## 74. 通过硒纳米颗粒激活GPX1重编程M2b型巨噬细胞可减轻狼疮性肾炎

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405450)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41405450
**DOI：** 10.1002/advs.202519981

### 第一部分 原文与翻译

**英文原标题：** Reprogramming M2b Macrophages via GPX1 Activation by Selenium Nanoparticles Attenuates Lupus Nephritis.

> **英文摘要：**
> Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), is largely driven by dysregulated macrophage responses. However, the heterogeneity of macrophages hinders the development of targeted therapies for LN. Here, through single-cell analysis and clinical specimen validation, it is found that pro-inflammatory M2b macrophages are increased in the kidneys of patients with LN and are strongly associated with clinical indicators. To target and modulate M2b macrophages, mannose-functionalized selenium nanoparticles are engineered that can selectively suppress M2b polarization and activation by reducing reactive oxygen species (ROS), restoring mitochondrial function, and inducing selenoprotein glutathione peroxidase 1 (GPX1). In vivo, SeZM NPs accumulate in the kidneys of lupus mice and reduce M2b-derived pro-inflammatory cytokines, preserving renal structure and function. Together, these findings highlight pro-inflammatory M2b macrophages as pathogenic drivers of LN and demonstrate the translational potential of selenium-based nanotherapy.

> **中文摘要：**
> 狼疮性肾炎（LN）是系统性红斑狼疮（SLE）的一种严重并发症，其主要由失调的巨噬细胞反应驱动。然而，巨噬细胞的异质性阻碍了LN靶向治疗的发展。在本研究中，通过单细胞分析和临床样本验证发现，促炎性的M2b型巨噬细胞在LN患者肾脏中显著增加，并且与临床指标密切相关。为靶向调节M2b型巨噬细胞，研究者设计了具有甘露糖功能化的硒纳米颗粒，可通过减少活性氧（ROS）、恢复线粒体功能并诱导硒蛋白谷胱甘肽过氧化物酶1（GPX1）来选择性抑制M2b型极化与活化。在体内实验中，SeZM纳米颗粒积聚于狼疮小鼠的肾脏中，减少了M2b来源的促炎性细胞因子，进而保护了肾脏结构和功能。总体而言，这些发现强调了促炎性M2b型巨噬细胞在LN发病中的关键作用，并展示了基于硒的纳米疗法的转化潜力。

### 第二部分 AI 大师评价

该研究聚焦于狼疮性肾炎中的巨噬细胞亚型调控，通过单细胞分析揭示M2b型巨噬细胞的促炎特性与疾病关联。研究采用甘露糖修饰的硒纳米颗粒靶向激活GPX1，从而重编程M2b型巨噬细胞的功能。实验结果表明，该策略可减少炎症因子释放并保护肾功能，体现了纳米医学与免疫调控的交叉创新。其主要创新在于提出硒基纳米材料介导的免疫重编程概念，但仍需进一步研究长期安全性与临床可转化性。

---

## 75. EIF1AX核仁凝聚体增强子宫内膜癌治疗中的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405406)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41405406
**DOI：** 10.1002/advs.202504238

### 第一部分 原文与翻译

**英文原标题：** EIF1AX Nucleolar Condensates Enhance Susceptibilities for the Management of Endometrial Cancer.

> **英文摘要：**
> Endometrial cancer harboring TP53 aberrations presents a significant therapeutic challenge due to the lack of druggable targets. A promising strategy involves inducing senescence in cancer cells followed by targeted elimination using senolytic agents. The preliminary findings indicated that the aberrant subcellular localization of EIF1AX in endometrial cancer is significantly correlated with a poor prognosis. In this study, a compound library is employed to screen for therapeutic agents that induce the nuclear localization of EIF1AX in endometrial cancer cells, followed by a CRISPR library screen to identify senolytic compounds. The results demonstrated that the combination of 2,5-MeC and dacinostat effectively inhibited tumor growth. Mechanistically, co-immunoprecipitation mass spectrometry and cleavage under targets and tagmentation sequencing analyses demonstrated that 2,5-MeC acts as a potent inducer of EIF1AX nucleolar translocation. This translocation promoted senescence by recruiting DDX21 to form nucleolar aggregates, which suppressed rDNA transcription. Additionally, RNA sequencing and antibody array analyses revealed that the synthetic lethality of 2,5-MeC and dacinostat is mediated through the activation of the JNK/MAPK signaling pathway. Collectively, these findings highlight a novel therapeutic strategy for TP53-aberrant endometrial cancer.

> **中文摘要：**
> 携带TP53异常的子宫内膜癌由于缺乏可药物靶向的分子而在治疗上面临重大挑战。一种有前景的策略是诱导癌细胞进入衰老状态，随后利用清除衰老细胞的药物进行靶向消除。初步研究结果显示，EIF1AX在子宫内膜癌中的异常亚细胞定位与预后不良显著相关。本研究采用化合物库筛选可诱导EIF1AX在子宫内膜癌细胞中核定位的治疗候选分子，随后通过CRISPR文库筛选识别清除衰老细胞的化合物。结果显示，2,5-MeC与dacinostat的联合应用能有效抑制肿瘤生长。从机制上看，共免疫沉淀质谱与CUT&Tag测序分析表明，2,5-MeC是EIF1AX核仁转位的强效诱导因子。该转位通过募集DDX21形成核仁聚集体，从而促进细胞衰老并抑制rDNA转录。此外，RNA测序与抗体芯片分析揭示，2,5-MeC与dacinostat的合成致死作用通过激活JNK/MAPK信号通路介导。总体而言，这些结果揭示了一种针对TP53异常子宫内膜癌的新型治疗策略。

### 第二部分 AI 大师评价

本研究针对TP53突变子宫内膜癌治疗靶点缺乏的难题，提出通过诱导EIF1AX核仁转位及细胞衰老的新策略。作者利用化合物库与CRISPR筛选相结合，鉴定出2,5-MeC与dacinostat的协同作用，显著抑制肿瘤生长。从机制层面揭示EIF1AX-DDX21复合体在核仁形成及rDNA抑制中的作用，并指出JNK/MAPK通路在合成致死中的调控作用。该研究为TP53异常子宫内膜癌提供了新的药理学干预思路，但仍需进一步验证其体内稳定性及临床可行性。

---

## 76. 互斥分析显示 DUSP9 负向调控 PD-L1 表达，并作为靶点增强抗 PD-1 疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405398)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41405398
**DOI：** 10.1002/advs.202514347

### 第一部分 原文与翻译

**英文原标题：** Mutual Exclusion Analysis Shows that DUSP9 Negatively Regulates PD-L1 Expression and Acts as a Target to Enhance Anti-PD-1 Efficacy.

> **英文摘要：**
> The expression level of PD-L1 is one of the most widely used predictive markers of immune checkpoint blockade (ICB) efficacy in the clinic, suggesting the importance of regulating PD-L1 expression. However, no published reports have addressed the systematic exploration of the regulation of immune checkpoint molecules from the perspective of mutual exclusion (ME) in gene expression. The ME analysis, based on gene plasticity, provides a novel perspective on the intergenic regulatory paradigm. Here, multiple negative regulators of PD-L1 expression are identified, and dual-specificity phosphatase 9 (DUSP9) is selected for intensive study. DUSP9 negatively regulates PD-L1 expression in multiple tumor cells, and mechanistically, DUSP9 dephosphorylates STAT3 to mediate the inhibitory role. In syngeneic tumor models, the combination of DUSP9 targeting and PD-1 antibody can enhance therapeutic sensitivity. The clinical data demonstrated that elevated DUSP9 expression is correlated with diminished PD-1/PD-L1 antibody response rates. Consequently, DUSP9 emerges as a promising target for enhancing treatment response in combination with PD-1 antibody, and functions as a potential marker for predicting the efficacy of tumor immunotherapy. This research demonstrates an efficient method for identifying negative regulators of highly plastic genes (HPGs), which can predict immunotherapy responses and identify new targets for combination therapy with ICB.

> **中文摘要：**
> PD-L1 的表达水平是临床上最广泛应用的免疫检查点抑制（ICB）疗效预测标志物之一，这提示调控 PD-L1 表达具有重要意义。然而，目前尚无关于从基因表达互斥（ME）的角度系统探讨免疫检查点分子调控的发表报道。基于基因可塑性的 ME 分析提供了一种研究基因间调控范式的新视角。在本研究中，作者鉴定了多种 PD-L1 表达的负性调控因子，并选择双特异性磷酸酶 9（DUSP9）进行深入研究。DUSP9 在多种肿瘤细胞中负向调控 PD-L1 表达，在机制上，DUSP9 通过去磷酸化 STAT3 来介导其抑制作用。在同系肿瘤模型中，靶向 DUSP9 联合 PD-1 抗体可提高治疗敏感性。临床数据表明，DUSP9 表达升高与 PD-1/PD-L1 抗体应答率降低相关。因此，DUSP9 成为增强 PD-1 抗体治疗反应的有前景靶点，同时也是预测肿瘤免疫治疗疗效的潜在标志物。本研究提出了一种高效方法，可识别高可塑性基因（HPGs）的负调控因子，从而预测免疫治疗反应并发现免疫检查点抑制联合治疗的新靶点。

### 第二部分 AI 大师评价

本研究通过创新性地引入基因表达互斥分析，系统探索了 PD-L1 表达的负性调控网络，发现 DUSP9 作为关键抑制因子可去磷酸化 STAT3 并降低 PD-L1 水平，从而增强 PD-1 抗体疗效。研究不仅揭示了 DUSP9 在免疫逃逸中的新作用机制，也为联合免疫治疗提供了新的分子靶点。该工作方法学上具有较高可推广性，但仍需更多临床验证以确定 DUSP9 靶向策略的安全性和有效性。

---

## 77. 从样本到混合现实：用于三维细胞培养疾病模型高级三维空间组学分析的转化性三维 MALDI 成像平台

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405385)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41405385
**DOI：** 10.1002/advs.202516098

### 第一部分 原文与翻译

**英文原标题：** From Sample to Mixed Reality: A Translational 3D MALDI Imaging Platform for Advanced 3D Spatial Omics Analysis of 3D Cell Culture Disease Models.

> **英文摘要：**
> Human 3D cell cultures, including spheroids and organoids, are essential biological models for translational pharmaceutical and biomedical research. However, their 3D analysis using 2D- matrix-assisted laser desorption/ionization (MALDI) imaging-based spatial metabolomics remains challenging, since end-to-end solutions for 3D-enabling sample preparation, 3D-data processing, 3D-rendering, and 3D-user interaction are lacking. Here, a 3D-MALDI imaging platform and resource that advances each of three pillars is presented: i) the sample preparation introduces custom-designed molds for precise and reproducible embedding and cryosectioning of multiple spheroids and organoids, a substantial improvement over ad hoc or single-sample sectioning workflows; ii) the integrated computational framework that facilitates the generation of high-fidelity volumetric datasets that enable voxel-based analysis for feature discovery, surpassing traditional slice-based 2D analysis; iii) the mixed reality tool enables immersive spatial exploration of molecular distributions in 3D, extending user engagement beyond static 3D renderings. The versatility of the platform is illustrated by its translation to a clinical framework for the molecular profiling of patient-derived colon cancer organoids. Collectively, this integrated approach enables spatial metabolomic analysis in 3D, offers increased throughput, and paves the way for next-generation molecular diagnostics and personalized medicine applications.

> **中文摘要：**
> 包括球状体和类器官在内的人三维细胞培养，是转化性药物学与生物医学研究中至关重要的生物模型。然而，利用基于二维基质辅助激光解吸/电离（MALDI）成像的空间代谢组学对其进行三维分析仍具挑战性，因为目前缺乏覆盖样本制备、三维数据处理、三维渲染及三维用户交互的端到端整体解决方案。本研究提出了一种推动上述三大关键环节进展的三维 MALDI 成像平台与资源：i）在样本制备方面，引入特制模具，可实现多球状体与类器官的精确、可重复的包埋与冷冻切片，显著优于以往的临时或单样本切片流程；ii）在计算框架方面，整合的算法体系可生成高保真体积数据集，支持基于体素的特征发现分析，超越传统基于切片的二维分析；iii）在用户交互方面，混合现实工具使分子分布的三维沉浸式空间探查成为可能，拓展了用户在静态三维渲染之外的交互体验。该平台的通用性还通过将其应用于患者来源结肠癌类器官的分子特征分析临床框架得到验证。总体而言，该一体化方法实现了三维空间代谢组学分析，提高了分析通量，并为下一代分子诊断与个体化医学应用铺平了道路。

### 第二部分 AI 大师评价

本研究旨在构建并验证一个涵盖样本制备、数据处理和混合现实交互的三维 MALDI 成像综合平台，用于三维细胞培养模型的空间组学研究。该平台利用定制模具实现多样本精确切片，结合高保真体积数据与混合现实可视化，显著提升了三维代谢特征分析的分辨率和交互深度。研究成果展示了其在结直肠癌类器官分子表征中的潜在临床转化应用，体现出强大的技术创新性与跨学科融合性。但在广泛临床应用之前，仍需进一步标准化流程和验证其稳健性。

---

## 78. 超越催化治疗：铜-芍药苷纳米酶通过破坏Fascin介导的肌动蛋白束缚抑制肿瘤生长与转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405370)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41405370
**DOI：** 10.1002/advs.202512186

### 第一部分 原文与翻译

**英文原标题：** Beyond Catalytic Therapy: Copper-Paeonol Nanozymes Disrupt Fascin-Mediated Actin Bundling to Suppress Tumor Growth and Metastasis.

> **英文摘要：**
> Fascin, an actin-bundling protein universally upregulated in metastatic tumors, drives tumor migration and invasion by promoting filopodia and invadopodia formation, establishing it as a pivotal therapeutic target. Herein, copper-paeonol nanozymes (CuPaeNs) is engineered through metal-phenolic complexation, mimicking natural enzyme metal-coordination microenvironments to confer peroxidase-like activity. This enzymatic capability drives the conversion of tumor-associated HO into cytotoxic hydroxyl radicals, inducing oxidative damage in malignant cells. Notably, beyond inducing tumor catalytic therapy via targeted ROS generation, CuPaeNs directly disrupted the actin-bundling activity of fascin, as evidenced by molecular docking, isothermal titration calorimetry, co-immunoprecipitation, and immunofluorescence assays. Transcriptomic and biochemical analyses further revealed that CuPaeNs suppressed melanoma glycolysis by blocking the fascin-YAP1-PFKFB3 signaling axis. This study establishes metal-phenolic nanozymes as a dual-functional strategy that simultaneously triggers ROS overproduction to amplify tumor oxidative stress and disrupts fascin-mediated metastasis, thereby modulating tumor metabolic reprogramming. This coordinated intervention establishes a novel treatment framework for malignancies characterized by fascin overexpression.

> **中文摘要：**
> Fascin是一种在转移性肿瘤中普遍上调的肌动蛋白束缚蛋白，通过促进丝状伪足和侵袭伪足的形成来驱动肿瘤迁移和侵袭，使其成为关键的治疗靶点。本研究中，通过金属-酚复合策略构建了铜-芍药苷纳米酶（CuPaeNs），该材料模拟天然酶的金属配位微环境，从而赋予其过氧化物酶样活性。这种酶促能力可将肿瘤相关的过氧化氢转化为具有细胞毒性的羟基自由基，从而诱导恶性细胞的氧化损伤。值得注意的是，CuPaeNs不仅通过靶向活性氧（ROS）生成诱导肿瘤的催化治疗，还可直接破坏Fascin的肌动蛋白束缚活性，这一点通过分子对接、等温滴定量热法、共免疫沉淀及免疫荧光分析得到证实。转录组学和生化分析进一步揭示，CuPaeNs通过阻断Fascin-YAP1-PFKFB3信号轴抑制黑色素瘤的糖酵解。本研究确立了金属-酚纳米酶作为一种双功能策略：一方面诱导ROS过量生成以增强肿瘤氧化应激，另一方面破坏Fascin介导的转移过程，从而调控肿瘤代谢重编程。这种协同干预为Fascin高表达的恶性肿瘤提供了一种新的治疗框架。

### 第二部分 AI 大师评价

该研究针对Fascin作为肿瘤转移的核心驱动因子，设计了具有过氧化物酶样活性的铜-芍药苷纳米酶（CuPaeNs），实现了肿瘤氧化应激增强与Fascin介导的细胞骨架干扰的双重治疗机制。作者通过分子、热力学及细胞实验多层验证了其作用机制，并揭示其对糖酵解信号通路的抑制效应。研究创新性在于提出了“催化治疗+骨架信号干扰”的整合策略，为Fascin高表达肿瘤提供了全新的治疗思路。局限性可能在于对体内长期安全性及药物递送稳定性的进一步验证仍需深化。

---

## 79. A20通过对IKK-β的单泛素化促进结直肠癌对奥沙利铂的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405367)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41405367
**DOI：** 10.1002/advs.202514486

### 第一部分 原文与翻译

**英文原标题：** A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β.

> **英文摘要：**
> The ubiquitin-editing enzyme A20 is essential for maintaining inflammatory homeostasis, yet its role in chemoresistance remains unclear. To investigate how A20 regulates oxaliplatin resistance in colorectal cancer (CRC), with a focus on A20-mediated IKK-β monoubiquitylation at K163. A prospective, randomized Phase III study is conducted in patients with locally advanced CRC who received either oxaliplatin+capecitabine neoadjuvant chemoradiotherapy (oxaliplatin-NACRT) or capecitabine-only neoadjuvant chemoradiotherapy (non-oxaliplatin-NACRT). Preoperative biopsy and matched surgical specimens are evaluated by immunohistochemistry to determine A20's association with oxaliplatin response. In oxaliplatin-NACRT group, patients achieving pathological complete response (pCR) displayed lower A20 expression than non-pCR patients, whereas no difference is observed in non-oxaliplatin-NACRT group. Two additional independent cohorts confirmed A20 downregulation in human CRC tissues, and reduced A20 expression correlated with poorer survival and oxaliplatin resistance. Mechanistically, A20 monoubiquitylates IKK-β via its fourth zinc-finger domain, promoting IKK-β degradation and suppressing NF-κB nuclear translocation. A20 knockdown or expression of the IKK-β K163R mutant induced oxaliplatin resistance in mouse xenografts. Clinically, A20 expression are negatively associated with IKK-β and its downstream targets. A20 depletion promotes oxaliplatin resistance in CRC by stabilizing IKK-β. the results uncover an essential role of the A20-IKK-β axis in oxaliplatin resistance of CRC.

> **中文摘要：**
> 泛素编辑酶A20在维持炎症稳态中起关键作用，但其在化疗耐药中的作用尚不明确。为探究A20如何调控结直肠癌（CRC）对奥沙利铂的耐药性，研究重点放在A20介导的IKK-β在K163位点的单泛素化上。研究开展了一项前瞻性、随机的Ⅲ期临床试验，纳入局部晚期CRC患者，这些患者接受了奥沙利铂联合卡培他滨的新辅助放化疗（oxaliplatin-NACRT）或仅卡培他滨的新辅助放化疗（non-oxaliplatin-NACRT）。通过免疫组化评估术前活检和配对手术标本，以确定A20与奥沙利铂反应之间的关联。在oxaliplatin-NACRT组中，获得病理完全缓解（pCR）的患者A20表达低于非pCR患者，而non-oxaliplatin-NACRT组中未观察到差异。另有两个独立队列进一步确认了人类CRC组织中A20下调的现象，并显示A20表达降低与预后不良及奥沙利铂耐药相关。在机制上，A20通过其第四个锌指结构域对IKK-β进行单泛素化，促进IKK-β降解并抑制NF-κB的核转位。敲低A20或表达IKK-β K163R突变体可在小鼠异种移植模型中诱导奥沙利铂耐药。从临床角度看，A20的表达水平与IKK-β及其下游靶标呈负相关。A20的缺失通过稳定IKK-β促进CRC对奥沙利铂的耐药性。这些结果揭示了A20-IKK-β轴在CRC奥沙利铂耐药中的重要作用。

### 第二部分 AI 大师评价

该研究系统探讨了A20在结直肠癌中调控奥沙利铂敏感性的作用机制。通过临床Ⅲ期试验及多队列验证，研究发现A20的下调与化疗耐药及不良预后密切相关，并阐明A20通过单泛素化介导IKK-β降解及抑制NF-κB信号的分子机制。动物实验验证了A20敲低或IKK-β突变可诱导耐药性，增强了机制的可信度。研究揭示了A20-IKK-β轴作为潜在化疗敏感性调控靶点的临床意义，为个体化治疗提供了新的方向。

---

## 80. AASLD-AST 成人肝移植实践指南：受者评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41405234)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41405234
**DOI：** 10.1097/HEP.0000000000001644

### 第一部分 原文与翻译

**英文原标题：** AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation.

> **英文摘要：**
> BACKGROUND AND AIMS: Liver transplant is a specialized treatment for a spectrum of indications that use a scarce resource. Transplant is guided by principles of justice, equity and benefit with a constant conflict between competing interests. Organs are a national resource with a goal of equitable distribution across sites. An AASLD guideline for the evaluation and selection of appropriate transplant candidates has been available since 2005.
> 
> METHODS: A multidisciplinary writing group of liver transplant experts and a librarian convened over 24 months. The writing group reviewed the literature, generated guideline recommendations and rated the level of evidence for each recommendation based on the Oxford Center for Evidence-Based Medicine. The group categorized the strength of recommendations based on the level of evidence, risk-benefit ratio, and patient preferences.
> 
> CONCLUSIONS: Liver transplant is a lifesaving procedure that should be offered to selected patients with clear indications and a reasonable prospect of benefit. The evaluation is designed to identify those in need, to outline hurdles to a successful outcome, and to develop an effective transplant plan. The goal of this document is to provide a template for this process.

> **中文摘要：**
> 背景与目的：肝移植是一种针对多种适应证的专科治疗方式，涉及稀缺资源的使用。移植实践由公正、平等与受益的原则引导，但这些原则之间常存在利益冲突。供体器官是一种国家资源，其目标是实现各地区之间的公平分配。AASLD 自 2005 年起已提供针对肝移植候选者评估与选择的指南。
> 
> 方法：一个由肝移植专家及图书馆员组成的多学科写作组在 24 个月内召开会议。该写作组审查了相关文献，生成了指南建议，并基于牛津循证医学中心的标准评定每条建议的证据等级。研究小组还根据证据水平、风险-收益比及患者偏好对建议的强度进行了分类。
> 
> 结论：肝移植是一种可挽救生命的操作，应提供给具有明确适应证且有合理获益前景的特定患者。评估的目标是识别真正需要移植的患者，明确成功移植的潜在障碍，并制定有效的移植计划。本文件旨在为这一过程提供规范化模板。

### 第二部分 AI 大师评价

本文旨在更新并规范成人肝移植候选者评估的实践指南，强调公平、公正和最大受益的基本原则。研究团队通过多学科专家协作、系统性文献回顾及循证分级体系，提出了基于证据与患者偏好的推荐框架。该指南强化了评估流程的标准化与科学性，有助于优化器官分配与移植决策。其创新性在于整合了最新循证标准，但未来仍需在不同医疗体系中验证其实用性与适用性。

---

## 81. 多梯度置换生存分析识别出与癌症患者预后稳定相关的有丝分裂与免疫特征。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41404730)
**期刊：** eLife
**PMID：** 41404730
**DOI：** 10.7554/eLife.101619

### 第一部分 原文与翻译

**英文原标题：** Multi-gradient permutation survival analysis identifies mitosis and immune signatures steadily associated with cancer patient prognosis.

> **英文摘要：**
> The inconsistency of the association between genes and cancer prognosis is often attributed to many variables that contribute to patient survival. Whether there exist the enes Stadily ssociated with Pognosis (GEARs) and functions remains largely elusive. Here, we developed a novel method named 'ulti-gradint Perutatin Suvival Analsis' (MEMORY) to screen the GEARs by using RNA-seq data from the TCGA database. We employed a network construction approach to identify hub genes from GEARs and utilized them for cancer classification. In the case of lung adenocarcinoma (LUAD), the GEARs were found to be related to mitosis. Our analysis suggested that LUAD cell lines carrying  mutations exhibit increased drug resistance. For breast invasive carcinoma (BRCA), the GEARs were related to immunity. Further analysis revealed that  mutation might regulate immune infiltration through the EMT process. Moreover, we explored the prognostic relevance of mitosis and immunity through their respective scores and demonstrated it as valuable biomarkers for predicting patient prognosis. In summary, our study offered significant biological insights into GEARs and highlights their potentials as robust prognostic indicators across diverse cancer types.

> **中文摘要：**
> 基因与癌症预后之间关联的不一致性通常归因于影响患者生存的多个变量。是否存在与预后稳定相关的基因及其功能（GEARs）仍然 largely 未知。本研究开发了一种名为“多梯度置换生存分析”（MEMORY）的新方法，利用 TCGA 数据库的 RNA-seq 数据筛选 GEARs。我们采用网络构建方法从 GEARs 中识别枢纽基因，并将其用于癌症分类。在肺腺癌（LUAD）中，发现 GEARs 与有丝分裂相关。分析显示，携带某些突变的 LUAD 细胞系表现出更强的耐药性。在乳腺浸润性癌（BRCA）中，GEARs 与免疫相关。进一步分析表明，某些突变可能通过 EMT 过程调控免疫浸润。此外，我们通过计算有丝分裂和免疫的相关评分，探讨了其与预后的关联，并证明它们可作为预测患者预后的有价值生物标志物。综上所述，本研究为 GEARs 提供了重要的生物学见解，强调了其作为多种癌症中稳健预后指标的潜力。

### 第二部分 AI 大师评价

该研究旨在解决基因与癌症预后关联不稳定的问题，提出了基于多梯度置换的生存分析新方法 MEMORY，用于筛选与预后持续相关的基因（GEARs）。研究结合 TCGA 数据和网络分析，揭示了肺腺癌中与有丝分裂相关的 GEARs 以及乳腺癌中与免疫相关的 GEARs，进一步探索了突变与耐药性及免疫浸润的关系。研究结果验证了有丝分裂和免疫评分在预后预测中的生物学价值。该工作方法创新、数据充分，为跨癌种的稳健预后生物标志物研究提供了新视角，但仍需更多实验验证其机制和临床可转化性。

---

## 82. 基于日本临床基因组数据库的肿瘤样本测序生殖系致病变异预测模型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41403154)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41403154
**DOI：** 10.1158/1078-0432.CCR-25-2985

### 第一部分 原文与翻译

**英文原标题：** Germline pathogenic variant prediction model for tumor-only sequencing based on Japanese clinicogenomic database.

> **英文摘要：**
> PURPOSE: Germline pathogenic variants (GPVs) are frequently identified as secondary findings in cancer gene panel testing. Due to limited data on germline conversion rates (GCRs) in the Japanese population, clinical decisions have relied on ESMO criteria. We aimed to develop a variant-level GCR prediction algorithm using Japanese tumor-normal matched panel database and compare its utility with existing standards.
> 
> PATIENTS AND METHODS: We analyzed 7,078 Japanese cases from the NCC Oncopanel dataset, focusing on 32 hereditary cancer genes. Clinical features, sample information, sequence results, and minor allele frequency (MAF) in healthy populations were incorporated int a machine learning model and nomogram. Clinical utility was assessed via decision curve analysis and validated using GenMineTOP dataset.
> 
> RESULTS: Among 3,372 cases (mean age 61; 51% male), 4,905 pathogenic variants were identified, including 491 GPVs (GCR: 10%). High disease-specific GCRs were observed in BAP1 (11% in ocular tumors), BRCA1 and/or BRCA2 (13-16% in ovarian/peritoneal cancers), and NF1 (16% in peripheral nerve tumors). Genes with >50% GCRs included RAD51C, BRCA1, PALB2, CHEK2, RET, BRCA2, and PMS2. Significant predictors included age <30, multiple cancers, gene type, cancer type, MAF, relative variant allele frequency to tumor purity, and tumor allele ratio (TAR). The model achieved a c-index of 0.96-0.97, outperforming ESMO (0.88), with a 1.2% net benefit at a 5% threshold. The results were confirmed using GenMineTOP dataset.
> 
> CONCLUSIONS: Variant-level prediction models for Japanese cancer patients incorporating TAR and MAF offer improved GPV prediction over gene-level approaches and support clinical decision-making and personalized medicine.

> **中文摘要：**
> 研究目的：生殖系致病变异（GPV）常作为癌症基因面板检测的次要发现被识别。由于日本人群中有关生殖系转化率（GCR）的数据有限，临床决策一直依赖于ESMO标准。本研究旨在利用日本肿瘤-正常匹配面板数据库开发基于变异水平的GCR预测算法，并与现有标准的实用性进行比较。
> 
> 研究对象与方法：我们分析了来自NCC Oncopanel数据集的7078例日本病例，重点关注32个遗传性癌症相关基因。研究将临床特征、样本信息、测序结果以及健康人群中的次要等位基因频率（MAF）纳入机器学习模型及列线图。通过决策曲线分析评估模型的临床实用性，并使用GenMineTOP数据集进行验证。
> 
> 研究结果：在3372例病例（平均年龄61岁；男性占51%）中，共识别出4905个致病变异，其中包含491个GPV（GCR为10%）。特定疾病中显示出较高的GCR，例如BAP1（眼部肿瘤中为11%）、BRCA1和/或BRCA2（卵巢/腹膜癌中为13–16%）、以及NF1（外周神经肿瘤中为16%）。GCR超过50%的基因包括RAD51C、BRCA1、PALB2、CHEK2、RET、BRCA2和PMS2。显著预测因素包括年龄<30岁、多发癌症、基因类型、癌症类型、MAF、相对于肿瘤纯度的变异等位基因频率以及肿瘤等位基因比（TAR）。该模型达到0.96–0.97的c指数，优于ESMO标准（0.88），在5%阈值下净获益为1.2%。使用GenMineTOP数据集的结果验证了其可靠性。
> 
> 结论：在日本癌症患者中，纳入TAR和MAF的变异级别预测模型相比基因级分析方法，在GPV预测方面具有更高的准确度，可支持临床决策与个体化医疗的实施。

### 第二部分 AI 大师评价

该研究基于日本大规模临床基因组数据库开发了一个生殖系致病变异预测模型，重点在于提高仅使用肿瘤测序数据时的判定准确性。研究以机器学习方法综合考虑MAF、TAR、基因和肿瘤类型等多因素，模型性能显著优于现有ESMO标准。结果验证了模型的稳健性和临床潜力，有助于在日本人群中实现更精准的生殖系变异预测。其创新性在于从变异层面建立GCR预测算法，但仍可能受样本来源与种族特异性限制。

---

## 83. 综合并发症指数作为胰腺外科发病率结局指标的结构效度与信度研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41403005)
**期刊：** Annals of surgery
**PMID：** 41403005
**DOI：** 10.1097/SLA.0000000000007002

### 第一部分 原文与翻译

**英文原标题：** Construct Validity and Reliability of the Comprehensive Complication Index as a Morbidity Outcome Measure in Pancreatic Surgery.

> **英文摘要：**
> OBJECTIVE: To assess the reliability and construct validity of the CCI®️ following pancreatic surgery.
> 
> SUMMARY BACKGROUND DATA: The Comprehensive Complication Index (CCI®️) is the only validated metric that quantifies cumulative morbidity, with a continuous score ranging from 0 (no complications) to 100 (death).
> 
> METHODS: To address construct validity, we assessed patients undergoing elective pancreatic surgery for any disease at five Italian centers enrolled in a randomized controlled trial (NCT04438447) and a prospective cohort study (NCT04431076). The severity of 90-day complications was assessed using the CCI®️. We tested 10 a priori construct validity hypotheses through linear regression. Regression coefficients represented the between-group mean difference in CCI®️, with an effect size ≥0.2 considered potentially meaningful. Validity was deemed adequate if >75% of the hypotheses were supported. To address reliability, three independent raters among six centers assessed the CCI®️ from 100 anonymous case vignettes to evaluate inter-rater and inter-center reliability through intraclass correlation coefficient (ICC) and standard error of measurement (SEM).
> 
> RESULTS: 797 patients were included (66±11 y, 50% female, 60% malignancy). The construct validity was supported by data, with 9/10 a priori hypotheses confirmed (90%). The CCI®️ showed excellent inter-rater (ICC=0.96, 95%CI: 0.95-0.97), high inter-center reliability (ICC >0.75 in each center), with a SEM ranging from 2.73 to 6.38.
> 
> CONCLUSIONS: This study supports CCI®️as a valid and reliable measure of morbidity after pancreatic surgery, supporting its use in both clinical practice and comparative effectiveness research.

> **中文摘要：**
> 研究目的：评估胰腺手术后综合并发症指数（CCI®️）的信度与结构效度。
> 
> 背景摘要：综合并发症指数（CCI®️）是目前唯一经验证的指标，可量化累积发病率，其连续评分范围为0（无并发症）至100（死亡）。
> 
> 方法：为验证结构效度，我们分析了在五个意大利中心接受择期胰腺手术的患者，这些患者均纳入一项随机对照试验（NCT04438447）及一项前瞻性队列研究（NCT04431076）。使用CCI®️评估术后90天内并发症的严重程度。研究采用线性回归检验10项预设的结构效度假设，回归系数表示各组间CCI®️均值差异，当效应量≥0.2时被认为具有潜在意义。若假设验证率超过75%，则认为效度良好。为评估信度，来自六个中心的三名独立评估者对100个匿名病例摘要的CCI®️进行评分，并通过组内相关系数（ICC）及测量标准误（SEM）评估评估者间及中心间信度。
> 
> 结果：共纳入797例患者（平均年龄66±11岁，女性占50%，恶性肿瘤占60%）。研究数据显示结构效度得到支持，10项假设中有9项得到验证（90%）。CCI®️在评估者间具有极高一致性（ICC=0.96，95%CI：0.95–0.97），各中心间信度亦高（每中心ICC>0.75），SEM范围为2.73至6.38。
> 
> 结论：本研究表明，CCI®️在胰腺手术后发病率评估中具有良好的效度与信度，支持其在临床实践及比较效果研究中的应用。

### 第二部分 AI 大师评价

该研究系统评估了综合并发症指数在胰腺外科中的结构效度与信度，采用多中心数据与严格的统计验证方法。结果显示CCI总体表现出优异的可重复性与一致性，验证假设的支持率达90%，在不同中心与评估者间均保持高一致性。此研究为CCI在胰腺外科发病率量化中的标准化应用提供了强有力证据，其创新点在于结合随机对照试验和前瞻性队列的多层验证，但局限性可能在于地域集中与病例类型差异带来的外推性影响。

---

## 84. 在晚期黑色素瘤治疗过程中对过继细胞转移产物的T细胞受体库进行描绘与监测。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402893)
**期刊：** Genome medicine
**PMID：** 41402893
**DOI：** 10.1186/s13073-025-01583-w

### 第一部分 原文与翻译

**英文原标题：** Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究旨在探索晚期黑色素瘤患者过继细胞治疗过程中T细胞受体库的特征及动态变化。通过对过继转移细胞产物的T细胞谱系进行监测，研究者可能试图揭示免疫应答的演化轨迹及治疗效果相关的免疫标志物。该工作体现了精准免疫监测在细胞治疗中的关键作用，为优化个体化免疫治疗策略提供了潜在依据。尽管摘要缺失，但从标题可见其技术深度与临床转化价值值得关注。

---

## 85. 氨基酸代谢：癌症治疗的潜在靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402797)
**期刊：** Molecular cancer
**PMID：** 41402797
**DOI：** 10.1186/s12943-025-02523-3

### 第一部分 原文与翻译

**英文原标题：** Amino acids metabolism: a potential target for cancer treatment.

> **英文摘要：**
> Metabolic reprogramming of amino acids has been recognized as a significant characteristic in various types of cancers. Numerous studies have indicated that the metabolic reprogramming of amino acids in tumors significantly supports certain malignant behaviors, including tumor proliferation, survival, invasion, and even immune escape. Amino acids can provide biomolecules such as nucleotides and glutathione (GSH) for tumors, and the bioavailability of amino acids influences tumor progression. Meanwhile, as essential metabolites, amino acids are closely associated with immune cell activation and can contribute to tumor immune processes by modulating the function of immune cells. Thus, targeting amino acids metabolism has emerged as a promising therapeutic strategy. Herein, we provide an overview of the effects of amino acids on the central carbon cycle and autophagy. We also provide an in-depth review of potential therapies for cancer treatment associated with amino acids, including metabolic enzymes of amino acids, dietary therapy of amino acids, and so on. Furthermore, we summarize some current nano-systems relevant to amino acids. This review aims to offer a theoretical foundation for understanding amino acids metabolism in cancer and identifying potential therapeutic strategies.

> **中文摘要：**
> 氨基酸的代谢重编程已被认为是多种癌症的重要特征。大量研究表明，肿瘤中氨基酸代谢的重编程在很大程度上支持了某些恶性行为，包括肿瘤的增殖、生存、侵袭，甚至免疫逃逸。氨基酸可为肿瘤提供核苷酸和谷胱甘肽（GSH）等生物分子，而氨基酸的生物利用度会影响肿瘤的进展。同时，作为关键代谢产物，氨基酸与免疫细胞的激活密切相关，并可通过调控免疫细胞的功能参与肿瘤的免疫过程。因此，靶向氨基酸代谢已成为一种有前景的治疗策略。本文概述了氨基酸对中心碳循环和自噬的影响。此外，我们深入回顾了与氨基酸相关的潜在癌症治疗策略，包括氨基酸代谢酶和氨基酸膳食治疗等。同时，我们还总结了一些与氨基酸相关的当前纳米系统。本综述旨在为理解癌症中的氨基酸代谢及识别潜在治疗策略提供理论基础。

### 第二部分 AI 大师评价

该综述系统总结了氨基酸代谢在癌症发生发展中的关键作用，强调其与肿瘤生长、免疫调控及治疗潜能的密切关联。作者不仅回顾了氨基酸代谢与自噬、碳循环的联系，还探讨了靶向代谢酶、膳食干预及纳米系统等疗法的研究进展。文章在提出氨基酸代谢作为靶点的同时，为未来精准代谢治疗提供了理论依据。其创新性在于多维整合代谢与免疫角度的治疗思路，但仍需更多临床证据验证其可行性。

---

## 86. YTHDC2通过铜死亡机制抑制肺癌对EGFR-TKI的耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402633)
**期刊：** Oncogene
**PMID：** 41402633
**DOI：** 10.1038/s41388-025-03660-1

### 第一部分 原文与翻译

**英文原标题：** YTHDC2 inhibits the resistance of lung cancer to EGFR-TKI through cuproptosis.

> **英文摘要：**
> While third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as osimertinib, have significantly improved patient survival in non-small cell lung cancer (NSCLC), acquired resistance remains a major clinical challenge, and its underlying mechanisms are incompletely understood. In this study, we demonstrate that YTHDC2 expression is significantly downregulated in osimertinib-resistant patient-derived xenograft (PDX) tissues and lung cancer cell lines compared to their osimertinib-sensitive counterparts. Further investigation revealed that YTHDC2 overcomes osimertinib resistance in lung cancer cells by promoting cuproptosis. Mechanistically, YTHDC2 binds to mA-modified sites (specifically at nucleotides A1223 and A2824) within the mRNA of the copper transporter SLC31A1 in an mA-dependent manner. This interaction enhances SLC31A1 mRNA stability and protein expression, thereby increasing intracellular copper transport and inducing cuproptosis in tumor cells. Additionally, we found that the copper ionophore disulfiram (DSF) overcame osimertinib resistance by augmenting YTHDC2 expression. Collectively, our findings elucidate a novel YTHDC2-SLC31A1-cuproptosis axis as a key mechanism underlying EGFR-TKI resistance and propose new therapeutic strategies for its reversal.

> **中文摘要：**
> 尽管第三代EGFR酪氨酸激酶抑制剂（EGFR-TKIs），如奥希替尼，已显著改善非小细胞肺癌（NSCLC）患者的生存，但获得性耐药仍是主要临床难题，其潜在机制尚未完全阐明。在本研究中，我们发现，与对奥希替尼敏感的肺癌患者来源移植瘤（PDX）组织及肺癌细胞系相比，奥希替尼耐药样本中YTHDC2的表达显著下调。进一步研究表明，YTHDC2通过促进铜死亡（cuproptosis）来克服肺癌细胞的奥希替尼耐药。从机制上看，YTHDC2以m6A依赖的方式结合于铜转运蛋白SLC31A1 mRNA中的m6A修饰位点（具体位于核苷酸A1223和A2824），该相互作用增强了SLC31A1 mRNA的稳定性和蛋白表达，从而提高细胞内铜的转运并诱导肿瘤细胞发生铜死亡。此外，我们发现铜离子载体双硫仑（DSF）可通过上调YTHDC2表达来克服奥希替尼耐药。综上所述，本研究揭示了YTHDC2-SLC31A1-铜死亡轴作为EGFR-TKI耐药的关键机制，并提出了逆转耐药的新型治疗策略。

### 第二部分 AI 大师评价

该研究聚焦EGFR-TKI耐药这一肺癌治疗难题，系统揭示了m6A识别蛋白YTHDC2在调控铜离子稳态和铜死亡过程中的关键作用。通过分子层面验证YTHDC2-SLC31A1信号通路在奥希替尼耐药转化中的机制，该工作提出了DSF通过上调YTHDC2逆转耐药的新思路。研究创新性地将表观转录修饰与铜死亡机制相结合，为非小细胞肺癌靶向药物耐药提供了潜在干预靶点与转化路径。其局限性在于目前主要基于细胞与PDX模型，仍需进一步临床验证。

---

## 87. 靶向糖链的癌症免疫治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402488)
**期刊：** Nature biotechnology
**PMID：** 41402488
**DOI：** 10.1038/s41587-025-02924-1

### 第一部分 原文与翻译

**英文原标题：** Targeting glycans for cancer immunotherapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究聚焦于利用糖类修饰和糖链分子作为癌症免疫治疗的新靶点，体现出对肿瘤免疫微环境和糖生物学交叉机制的前沿探索。尽管暂无摘要信息，标题暗示其旨在通过识别或调控糖链结构来增强免疫系统识别癌细胞的能力。这一方向有望拓展免疫治疗的新途径，但仍需系统性验证其在不同肿瘤类型中的机制与安全性。

---

## 88. 用于糖型免疫检查点阻断的抗体-凝集素嵌合体

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402487)
**期刊：** Nature biotechnology
**PMID：** 41402487
**DOI：** 10.1038/s41587-025-02884-6

### 第一部分 原文与翻译

**英文原标题：** Antibody-lectin chimeras for glyco-immune checkpoint blockade.

> **英文摘要：**
> Despite the curative potential of checkpoint blockade immunotherapy, many patients remain unresponsive to existing treatments. Glyco-immune checkpoints, which involve interactions of cell-surface glycans with lectin, or glycan-binding, immunoreceptors, have emerged as prominent mechanisms of immune evasion and therapeutic resistance in cancer. Here, we describe antibody-lectin chimeras (AbLecs), a modular system for glyco-immune checkpoint blockade. AbLecs are bispecific antibody-like molecules comprising a cell-targeting antibody domain and a lectin 'decoy receptor' domain that directly binds glycans and blocks their ability to engage inhibitory lectin receptors. AbLecs potentiate cancer cell destruction by primary human immune cells in vitro and reduce tumour burden in a humanized, immunocompetent mouse model, outperforming most existing therapies and combinations tested. By targeting a distinct axis of immunological regulation, AbLecs synergize with blockade of established immune checkpoints. AbLecs can be readily designed to target numerous tumours and immune cell subsets as well as glyco-immune checkpoints, thus representing a potential modality for cancer immunotherapy.

> **中文摘要：**
> 尽管检查点阻断免疫治疗具有治愈潜力，但许多患者对现有治疗仍无反应。糖型免疫检查点涉及细胞表面糖链与凝集素或糖结合型免疫受体的相互作用，已成为癌症中免疫逃逸和治疗耐受的重要机制。在本研究中，我们介绍了一种用于糖型免疫检查点阻断的模块化体系——抗体-凝集素嵌合体（AbLecs）。AbLecs 是双特异性、抗体样分子，由识别细胞的抗体结构域和直接结合糖链并阻断其与抑制性凝集素受体相互作用的凝集素“诱饵受体”结构域组成。AbLecs 在体外可增强人类初级免疫细胞对癌细胞的杀伤作用，并在人源化且免疫功能健全的小鼠模型中显著减少肿瘤负荷，其疗效优于多数已测试的单药及联合疗法。通过靶向一种独特的免疫调控轴，AbLecs 可与既有免疫检查点阻断产生协同效应。AbLecs 可灵活设计以靶向多种肿瘤类型和免疫细胞亚群及其糖型免疫检查点，因此代表了一种具有潜力的癌症免疫治疗新策略。

### 第二部分 AI 大师评价

该研究旨在开发一种创新的抗体-凝集素嵌合体（AbLecs）体系，用于阻断糖型免疫检查点，从而增强抗肿瘤免疫反应。研究者通过构建同时具备抗体靶向性与凝集素结合功能的双特异性分子，实现了对肿瘤免疫逃逸的新途径干预。实验显示，AbLecs 在体内外均显著增强免疫细胞的杀伤能力，并优于现有免疫疗法。该工作在机制与应用层面均具有开创性，但其在多样化肿瘤免疫微环境中的长期安全性与可扩展性仍需进一步验证。

---

## 89. 膜嵌入型人T细胞受体-CD3复合物的静息态与配体结合态

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402338)
**期刊：** Nature communications
**PMID：** 41402338
**DOI：** 10.1038/s41467-025-66939-7

### 第一部分 原文与翻译

**英文原标题：** The resting and ligand-bound states of the membrane-embedded human T-cell receptor-CD3 complex.

> **英文摘要：**
> The T-cell receptor (TCR) initiates T-lymphocyte activation, but the mechanism of TCR activation remains uncertain. Here, we present cryogenic electron microscopy structures for the unliganded and human leukocyte antigen (HLA)-bound human TCR-CD3 complex in nanodiscs that provide a native-like lipid environment. Distinct from the open and extended conformation seen in detergent, the unliganded TCR-CD3 in nanodiscs adopts two related closed and compacted conformations that represent its physiologic resting state in vivo. By contrast, the HLA-bound complex adopts the open and extended conformation, and conformation-locking disulfide mutants show that ectodomain opening is necessary for maximal ligand-dependent T-cell activation. These structures also reveal conformation-dependent protein-lipid and glycan-glycan interactions within the TCR. Together, these results establish allosteric conformational change during TCR activation, reveal avenues for immunotherapeutic engineering, and highlight the importance of native-like lipid environments for membrane protein structure determination.

> **中文摘要：**
> T细胞受体（TCR）启动T淋巴细胞的活化，但其活化机制仍不明确。在本研究中，我们展示了在提供类原生脂质环境的纳米盘中，无配体及人类白细胞抗原（HLA）结合的人TCR-CD3复合物的冷冻电子显微镜结构。与在洗涤剂中观察到的开放和延伸构象不同，纳米盘中的无配体TCR-CD3呈现两种相关的闭合且紧缩的构象，代表其在体内的生理静息状态。相比之下，HLA结合复合物采用开放和延伸的构象，而构象锁定的二硫键突变体表明，胞外结构域的开放对于实现最大化的配体依赖性T细胞活化是必要的。这些结构还揭示了TCR内部的构象依赖性蛋白-脂质及糖链-糖链相互作用。总体而言，这些结果确立了TCR活化过程中的变构构象变化，揭示了免疫治疗工程化的新途径，并强调了类原生脂质环境对膜蛋白结构解析的重要性。

### 第二部分 AI 大师评价

本研究通过高分辨率冷冻电镜结构解析，首次系统揭示了人TCR-CD3复合物在原生环境中静息态与配体结合态的动态转变。研究显示，TCR的活化涉及细胞外结构域的变构性开合以及脂质与糖基间的构象依赖性互作。该发现不仅阐明了TCR信号传导的分子基础，也为免疫受体工程和精准免疫治疗提供了结构学依据。其创新性在于采用纳米盘系统重建类原生膜环境，但在时间动态和细胞内信号层面的机制仍需进一步研究。

---

## 90. 多层次转录调控的糖原代谢机制协调雄性小鼠白脂肪细胞的产热性重塑

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402325)
**期刊：** Nature communications
**PMID：** 41402325
**DOI：** 10.1038/s41467-025-67515-9

### 第一部分 原文与翻译

**英文原标题：** Multi-layered transcriptional control of glycogen metabolism coordinates thermogenic remodeling of white adipocytes in male mice.

> **英文摘要：**
> Thermogenic activation of subcutaneous white adipocytes requires glycogen synthesis and turnover. Here we show that β-adrenergic stimulation induces a distinct glycogen metabolism gene program in inguinal white adipose tissue in a cell-autonomous and adipocyte-specific manner. Among these, Gys2 and Ppp1r3c are rapidly induced following acute β3-adrenergic receptor activation. We identify Gys2 as a direct transcriptional target of PKA-CREB signaling. In contrast, sustained expression of glycogen metabolism genes under chronic β3-adrenergic activation requires the coactivator PGC1α, whose loss blunts glycogen accumulation and thermogenic capacity. Mechanistically, PGC1α cooperates with estrogen-related receptors (ERRs) to regulate chromatin accessibility and gene transcription. Although deletion of ERRα is compensated by ERRγ, combined deletion of ERRα/β/γ abolishes expression of glycogen metabolism and thermogenic genes. Chromatin profiling confirm that ERRs directly control the glycogen metabolic program in beige adipocytes. Together, our results identify a multilayered transcriptional axis that sustains glycogen metabolism during β-adrenergic activation in male mice.

> **中文摘要：**
> 皮下白脂肪细胞的产热激活需要糖原的合成与周转。在本研究中，我们发现β-肾上腺素能刺激以细胞自律且脂肪细胞特异的方式，在腹股沟白色脂肪组织中诱导出一种独特的糖原代谢基因表达程序。其中，Gys2 和 Ppp1r3c 在急性 β3-肾上腺素能受体激活后迅速上调。我们鉴定出 Gys2 是 PKA-CREB 信号通路的直接转录靶基因。相比之下，在慢性 β3-肾上腺素能激活条件下，糖原代谢基因的持续表达依赖于共激活因子 PGC1α，其缺失会削弱糖原积累及产热能力。从机制上看，PGC1α 与雌激素相关受体（ERRs）协同调控染色质可及性和基因转录。虽然 ERRα 的缺失可由 ERRγ 补偿，但当 ERRα/β/γ 同时缺失时，糖原代谢及产热相关基因的表达被完全抑制。染色质组分析结果确认 ERRs 直接控制米色脂肪细胞中的糖原代谢程序。综上所述，我们的研究揭示了一条在雄性小鼠 β-肾上腺素能激活过程中维持糖原代谢的多层次转录调控轴。

### 第二部分 AI 大师评价

本研究聚焦于雄性小鼠白脂肪细胞在β-肾上腺素能激活下的糖原代谢及产热重塑，通过分子及染色质水平的分析，揭示了Gys2作为PKA-CREB信号的直接靶点，以及PGC1α与ERR家族的协同调控机制。研究创新地描绘出糖原代谢在产热性转变中的多层次转录调控网络，拓展了对白脂肪棕化及代谢重编程的理解。其主要贡献在于整合信号通路、共激活因子与核受体的交互作用，但研究仍主要基于小鼠模型，后续验证其在人类代谢调控中的普适性将更具意义。

---

## 91. 用于超声可激活先天免疫调控与癌症疫苗治疗的多肽声佐剂。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402324)
**期刊：** Nature communications
**PMID：** 41402324
**DOI：** 10.1038/s41467-025-66976-2

### 第一部分 原文与翻译

**英文原标题：** Polypeptide sono-adjuvant for ultrasound-activatable regulation of innate immunity and cancer vaccination therapy.

> **英文摘要：**
> Spatiotemporally-controllable regulation of innate immunity in lymph node remains a critical challenge to implement effective cancer vaccination. Here we report an ultrasound-activatable strategy to precisely stimulate innate immunity activation in vivo. Mechanistically, ultrasound-triggered mechanical and oxidative forces synchronously activate innate immune pathways in antigen-presenting cells via calcium ion influx and mitochondria DNA release. We next design a polypeptide sono-adjuvant (SONA) library with adjustable physicochemical properties for lymph node-targeting delivery. The top-performed SONA specifically activates robust and durable innate immune responses in lymph node upon localized ultrasound stimulation. The combination of SONA-based vaccine with ultrasound stimulation induces about 3.0-fold higher antigen-specific T cell responses than conventional adjuvant-based vaccines. Moreover, in syngeneic mouse models of orthotopic breast and liver tumors, the combination of SONA-based neoantigen vaccine with ultrasound stimulation markedly boosts immune checkpoint blockade therapy to suppress tumor growth and distant metastasis. Collectively, the polypeptide sono-adjuvant offers great promise for precise regulation of innate immunity and cancer vaccine therapy.

> **中文摘要：**
> 在淋巴结中实现时空可控的先天免疫调节仍是实现有效癌症疫苗接种的关键挑战。本文报道了一种可被超声激活的策略，以在体内精确刺激先天免疫的激活机制。从机制上看，超声触发的机械力和氧化应力通过诱导钙离子内流和线粒体DNA释放，同步激活树突状抗原呈递细胞中的先天免疫通路。随后，研究者设计了一套具有可调理化性质、能靶向淋巴结递送的多肽声佐剂（SONA）文库。在局部超声刺激下，表现最佳的SONA可在淋巴结中特异性诱导强烈且持久的先天免疫反应。将基于SONA的疫苗与超声刺激结合应用，诱导的抗原特异性T细胞应答约为传统佐剂疫苗的3倍。此外，在同源小鼠的原位乳腺癌和肝癌模型中，基于SONA的新抗原疫苗与超声刺激联合能够显著增强免疫检查点抑制疗法的抗肿瘤作用，抑制肿瘤生长及远处转移。总体而言，多肽声佐剂为精准调控先天免疫和癌症疫苗治疗提供了重要潜力。

### 第二部分 AI 大师评价

本研究开发了一种可被超声激活的多肽声佐剂，用于精确调控淋巴结内的先天免疫，从而显著提升癌症疫苗的免疫效力。该方法结合超声机械与氧化应力，诱导抗原呈递细胞的免疫通路激活，在动物模型中表现出强效的T细胞免疫应答与抗肿瘤作用。研究创新性地将物理刺激与生物佐剂设计相结合，为个体化癌症疫苗提供新的可控策略。其局限性在于尚需进一步验证在大型动物及临床中的安全性与效果。

---

## 92. 转移性激素敏感性前列腺癌中早期良性前列腺特异抗原反应的预测。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402322)
**期刊：** Nature communications
**PMID：** 41402322
**DOI：** 10.1038/s41467-025-67298-z

### 第一部分 原文与翻译

**英文原标题：** Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

> **英文摘要：**
> There is an unmet need for a tool that could predict early favorable prostate-specific antigen (PSA) response in metastatic hormone sensitive prostate cancer (mHSPC) patients receiving androgen receptor pathway inhibitor (ARPI). Here, we train and validate a multivariable logistic regression model to predict early favorable PSA response (≤0.2 ng/mL by 6 months) in these patients. Patients randomly allocated to the ARPI arms of the LATITUDE (abiraterone), TITAN (apalutamide), and ARASENS (darolutamide) trials, are split 60:40 into training (n = 1030) and internal validation (n = 688) cohorts. The locked model is validated in an independent external validation cohort - the enzalutamide arm of the ENZAMET trial (n = 540). The area under curve and Brier score for the locked model in the external validation cohort are 0.82 (95% confidence interval [CI] = 0.78-0.85) and 0.16, respectively. Stratification by predicted probability tertiles show PSA response rates of 92% (95% CI = 88-96), 74% (95% CI = 68-81), and 39% (95% CI = 32-47), respectively. Pending prospective validation, our model predicts early favorable PSA response supporting its potential role in guiding treatment decisions.

> **中文摘要：**
> 针对接受雄激素受体通路抑制剂（ARPI）治疗的转移性激素敏感性前列腺癌（mHSPC）患者，目前亟需一种能够预测早期良性前列腺特异抗原（PSA）反应的工具。在本研究中，我们建立并验证了一个多变量逻辑回归模型，用于预测这些患者在6个月内实现早期良性PSA反应（PSA ≤ 0.2 ng/mL）。从LATITUDE（阿比特龙）、TITAN（阿帕他胺）和ARASENS（达罗他胺）等临床试验中随机分配至ARPI组的患者被按6:4比例划分为训练队列（n=1030）和内部验证队列（n=688）。锁定后的模型在一个独立的外部验证队列——ENZAMET试验的恩杂鲁胺治疗组（n=540）中进行了验证。在外部验证队列中，该锁定模型的曲线下面积（AUC）为0.82（95%置信区间[CI]=0.78–0.85），布里尔得分为0.16。按预测概率三分位分层分析的PSA反应率分别为92%（95% CI=88–96）、74%（95% CI=68–81）和39%（95% CI=32–47）。在有待前瞻性验证的情况下，我们的模型能够预测早期良性PSA反应，显示出其在指导治疗决策中的潜在作用。

### 第二部分 AI 大师评价

该研究旨在开发并验证一项基于多变量逻辑回归的预测模型，以便在接受ARPI治疗的mHSPC患者中预判早期良性PSA反应。研究整合了多项大型临床试验数据，并在独立外部队列中验证了模型的稳健性，表现出较高的辨识度（AUC=0.82）和较好的校准度。结果显示该模型能够有效区分不同PSA反应概率人群，为个体化治疗决策提供依据。其创新性在于多试验、多药物数据的整合应用，但尚需进一步的前瞻性研究以确认其临床实用价值。

---

## 93. XPF-ERCC1复合物靶向SLX4依赖性DNA修复通路的分子基础

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402316)
**期刊：** Nature communications
**PMID：** 41402316
**DOI：** 10.1038/s41467-025-67216-3

### 第一部分 原文与翻译

**英文原标题：** Molecular basis of XPF-ERCC1 targeting to SLX4-dependent DNA repair pathways.

> **英文摘要：**
> The preservation and faithful propagation of genetic information is essential for all life forms and depends on cellular pathways that enable replication, recombination, and repair of DNA. The multifunctional XPF-ERCC1 DNA endonuclease complex acts in several DNA repair pathways and interacts with numerous partner proteins and large DNA repair assemblies, including the nucleotide excision repair machinery and the SMX tri-endonuclease complex. Here, we report structures of XPF-ERCC1 in complex with the DNA repair factors SLX4 and SLX4IP, thereby identifying key residues responsible for direct interactions with XPF-ERCC1. When introduced into human cells, point mutations in these interfaces impair the interactions between XPF-ERCC1 and SLX4 or SLX4IP, and disruption of the XPF-SLX4IP interface leads to cis-platin sensitivity. Furthermore, our data reveal the structure of the human XPF-ERCC1-SLX4IP-SLX4 complex with DNA bound at its active site, and they complete the structural characterisation of molecular interactions required to assemble the SMX complex.

> **中文摘要：**
> 遗传信息的保存与忠实传递对于所有生命形式都是至关重要的，这一过程依赖于细胞内能够实现DNA复制、重组与修复的通路。多功能的XPF-ERCC1 DNA核酸内切酶复合物在多种DNA修复通路中发挥作用，并与众多伴侣蛋白和大型DNA修复复合体相互作用，其中包括核苷酸切除修复机制以及SMX三内切酶复合体。在本研究中，我们报道了XPF-ERCC1与DNA修复因子SLX4和SLX4IP复合的结构，从而识别出介导XPF-ERCC1直接相互作用的关键氨基酸残基。当这些界面突变点被引入人细胞后，XPF-ERCC1与SLX4或SLX4IP之间的相互作用受损，而破坏XPF-SLX4IP界面会导致顺铂敏感性。此外，我们的数据揭示了人源XPF-ERCC1-SLX4IP-SLX4复合物在其活性位点结合DNA的结构，从而完善了组装SMX复合体所需分子相互作用的结构特征化。

### 第二部分 AI 大师评价

本研究通过解析XPF-ERCC1与SLX4及SLX4IP复合物的高分辨率结构，揭示了XPF-ERCC1靶向SLX4依赖性DNA修复通路的分子机制。研究者鉴定出关键界面残基，并通过突变实验验证这些相互作用对复合体稳定性及顺铂敏感性的重要性。该工作在结构层面完善了SMX复合体组装机制的认识，为理解多通路DNA修复的整合调控提供了新的分子基础。其创新之处在于完成了人类SMX复合体的结构特征化，但仍需进一步探究这些结构特征在细胞动态修复过程中的功能意义。

---

## 94. 代谢综合征通过油酸介导的多胺积聚促进子宫内膜癌发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402312)
**期刊：** Nature communications
**PMID：** 41402312
**DOI：** 10.1038/s41467-025-67083-y

### 第一部分 原文与翻译

**英文原标题：** Metabolic syndrome promotes endometrial cancer by Oleic acid-mediated polyamine accumulation.

> **英文摘要：**
> Metabolic syndrome increases the risk of endometrial cancer development and progression, but the mechanism remains unclear. We find that polyamine metabolites are notably elevated in the sera and tumor tissues of endometrial cancer patients with metabolic syndrome. Oleic acid, one of the many components in hyperlipidemia, is the key factor for upregulating Ornithine Decarboxylase 1 (ODC1) (the rate-limiting enzyme in polyamine metabolism) and downstream polyamines. Mechanistically, Oleic acid binds to and stabilizes Homeobox B9 (HOXB9) by inhibiting the binding of HOXB9 to E3 ligase Praja2. Stable HOXB9 then competes with OAZ1 and combines with ODC1 to block ODC1 degradation. Targeting HOXB9 or ODC1 reduces polyamine levels and suppresses tumor growth/spread. Oleic acid-HOXB9-ODC1 stable cascading axis then is confirmed in patient tissues, and ODC1 inhibitors boost patient-derived tumor cells' chemosensitivity. This study links fatty acids to polyamine buildup, reveals a mechanism for metabolic syndrome-driven endometrial cancer, and points to HOXB9 and ODC1 as potential therapeutic targets.

> **中文摘要：**
> 代谢综合征会增加子宫内膜癌的发生和进展风险，但其机制尚不明确。我们发现，在伴有代谢综合征的子宫内膜癌患者的血清和肿瘤组织中，多胺代谢物显著升高。油酸是高脂血症中众多成分之一，是上调鸟氨酸脱羧酶1（ODC1，作为多胺代谢的限速酶）及其下游多胺的关键因素。在机制上，油酸通过抑制HOXB9与E3连接酶Praja2的结合，从而与HOXB9结合并稳定HOXB9。稳定的HOXB9随后与OAZ1竞争并结合ODC1，以阻止ODC1降解。靶向HOXB9或ODC1可降低多胺水平，并抑制肿瘤的生长和扩散。该研究在患者组织中证实了油酸-HOXB9-ODC1稳定级联通路，并发现ODC1抑制剂可增强患者来源肿瘤细胞的化疗敏感性。本研究揭示了脂肪酸与多胺积聚之间的联系，阐明了代谢综合征驱动子宫内膜癌的分子机制，并指出HOXB9和ODC1可能作为潜在治疗靶点。

### 第二部分 AI 大师评价

本研究揭示了代谢综合征促进子宫内膜癌发展的新机制，确定油酸通过HOXB9稳定作用介导ODC1上调和多胺积聚。研究将脂肪酸代谢与肿瘤代谢联系起来，发现HOXB9和ODC1在代谢综合征相关癌症中的关键作用。实验验证了油酸-HOXB9-ODC1通路在患者组织及肿瘤细胞中的稳定性，并显示靶向该通路能增强化疗敏感性。该研究具有较高创新性，为治疗代谢相关癌症提供了新靶点，但仍需临床验证其转化潜力。

---

## 95. 撤稿声明：纳米药物揭示PBOV1促进肝细胞癌发生的机制并助力有效的基因治疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402307)
**期刊：** Nature communications
**PMID：** 41402307
**DOI：** 10.1038/s41467-025-67606-7

### 第一部分 原文与翻译

**英文原标题：** Retraction Note: Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该文为一篇撤稿声明，涉及先前关于PBOV1在肝细胞癌中促癌作用研究的撤回。原研究利用纳米药物作为工具，探索基因治疗的新思路，但由于数据或结果原因被撤回。此撤稿提示科研可重复性与数据真实性在纳米医学与基因治疗领域的重要性，亦反映了学术期刊的自我纠错机制。

---

## 96. 半胱氨酰白三烯受体2的激动性变构调控的分子机制解析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402306)
**期刊：** Nature communications
**PMID：** 41402306
**DOI：** 10.1038/s41467-025-67630-7

### 第一部分 原文与翻译

**英文原标题：** Molecular insights into ago-allosteric modulation at cysteinyl leukotriene receptor 2.

> **英文摘要：**
> Cysteinyl leukotriene receptor CysLT2R, which is activated by the endogenous cysteinyl leukotrienes (CysLTs) LTC4, LTD4, and LTE4, has emerged as a potential therapeutic target due to the involvement in various inflammatory diseases. Accumulating evidence indicates that CysLT2R is also involved in the pathogenesis of cardiovascular diseases and contribute to tumor progression in cancer. However, the structural basis underlying the ligand recognition and the receptor activation remains to be elucidated. Here, we present two cryo-electron microscopy (cryo-EM) structures of the human CysLT2R-G complexes bound to LTC4 and LTD4. CysLTs are characterized as ago-allosteric modulators (ago-PAMs) of CysLT2R. Our structures reveal that CysLTs are recognized by a lipid-facing pocket above intracellular loop 2 (ICL2) near the cytoplasmic side of the receptor. Furthermore, a noncanonical activation mechanism exists between the allosteric binding pocket and the G-binding site. Our findings provide comprehensive insights into the recognition of CysLTs and G protein signaling transduction by CysLT2R, which may facilitate rational design of drugs.

> **中文摘要：**
> 内源性半胱氨酰白三烯（CysLTs）LTC4、LTD4 和 LTE4 可激活半胱氨酰白三烯受体 CysLT2R，由于其在多种炎症性疾病中的作用，CysLT2R 被认为是潜在的治疗靶点。越来越多的证据表明，CysLT2R 也参与心血管疾病的发病机制，并促进肿瘤的进展。然而，配体识别与受体激活的结构基础尚未明确。在本研究中，我们解析了两种结合 LTC4 和 LTD4 的人源 CysLT2R-G 复合物的冷冻电镜（cryo-EM）结构。CysLTs 被鉴定为 CysLT2R 的激动性变构调节剂（ago-PAMs）。结构分析显示，CysLTs 通过膜侧、位于受体胞质侧第二胞内环（ICL2）上方的口袋进行识别。此外，在变构结合口袋与 G 蛋白结合位点之间存在一种非典型的激活机制。我们的研究揭示了 CysLT2R 介导的 CysLTs 识别及 G 蛋白信号转导的全面分子机制，为理性药物设计提供了重要见解。

### 第二部分 AI 大师评价

该研究通过冷冻电镜揭示了半胱氨酰白三烯受体2在配体结合和G蛋白耦联过程中的高分辨率结构，明确了激动性变构调控的结构基础。研究发现CysLTs通过一个靠近第二胞内环的膜侧口袋进行识别，并揭示了非典型受体激活通路。这一成果为理解CysLT2R在炎症、心血管及肿瘤疾病中的作用提供了关键结构证据。研究具有较高创新性，但未来仍需结合功能实验验证其信号调控机制。

---

## 97. 构筑柔性亚纳米铁电催化剂以克服异相催化动力学障碍，增强催化与免疫治疗效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402300)
**期刊：** Nature communications
**PMID：** 41402300
**DOI：** 10.1038/s41467-025-67097-6

### 第一部分 原文与翻译

**英文原标题：** Constructing flexible sub-nanometer ferroelectric catalyst to overcome heterocatalytic kinetic barriers for enhanced catalytic and immuno-therapy.

> **英文摘要：**
> Piezoelectric catalysis enhances therapeutic outcomes in nanocatalysis but is limited by intrinsic catalysis mechanism. This study employs sub-nanometer HfZrO (HZO) nanowires as a piezoelectric catalyst to address these challenges. Oxygen K-edge X-ray absorption spectroscopy and spherical aberration-corrected transmission electron microscopy reveal the orthorhombic phase (Pca21) in HZO nanowires. This structure imparts polymer-like flexibility to HfZrO, improving its sensitivity to mechanical stress. Molecular dynamics and first-principles calculations demonstrate that ultrasonic stimulation increases the mobility of oxygen bridges, facilitating efficient ferroelectric polarization reversal. This mechanism breaks the "scaling relationship" between the low activation energy for reactant adsorption and the high activation energy for product desorption, enabling significant hydroxyl radical generation. Additionally, hydrogen produced during catalysis promotes pyroptosis, enhancing CD8 T cell infiltration and reversing tumor immunosuppression. This research underscores the potential of sub-nanoscale ferroelectric materials in anti-tumor applications.

> **中文摘要：**
> 压电催化可增强纳米催化中的治疗效果，但其受到固有催化机理的限制。本研究采用亚纳米级HfZrO（HZO）纳米线作为压电催化剂以应对这些挑战。氧K边X射线吸收光谱和球差校正透射电子显微镜揭示了HZO纳米线中存在斜方相（Pca21）。该结构赋予HfZrO类似聚合物的柔性，提高其对机械应力的敏感性。分子动力学模拟和第一性原理计算表明，超声刺激可增加氧桥的迁移性，从而促进高效的铁电极化反转。该机制打破了反应物吸附低活化能与产物脱附高活化能之间的“缩放关系”，实现了显著的羟基自由基生成。此外，催化过程中产生的氢气可促进细胞焦亡，增强CD8 T细胞浸润并逆转肿瘤免疫抑制。本研究强调了亚纳米尺度铁电材料在抗肿瘤应用中的潜力。

### 第二部分 AI 大师评价

该研究旨在通过构建柔性亚纳米级铁电HfZrO纳米线催化剂，克服传统异相催化的动力学瓶颈。作者利用先进表征技术确认材料的斜方相结构，并结合分子动力学与第一性原理计算揭示超声作用下的铁电极化反转机制。该机制有效突破了吸附和脱附能垒的耦合限制，显著提升了羟基自由基产量及免疫治疗协同效果。研究呈现出铁电-压电特性在肿瘤治疗催化系统中的创新潜力，但仍需进一步验证其生物安全性与可扩展性。

---

## 98. 血脑屏障打开后细胞外颗粒的动态释放可预测胶质母细胞瘤对紫杉醇的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402297)
**期刊：** Nature communications
**PMID：** 41402297
**DOI：** 10.1038/s41467-025-65681-4

### 第一部分 原文与翻译

**英文原标题：** Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.

> **英文摘要：**
> Liquid biopsies hold promise to improve the diagnosis, assessment of response to therapy, and ultimately guide the management of cancer patients. However, implementation of this approach in brain tumors has proven challenging due to the limited passage of molecules across the blood-brain barrier (BBB). We recently reported results from a phase I clinical trial in which the BBB was transiently opened in glioblastoma (GBM) patients using skull-implantable low-intensity pulsed ultrasound combined with microbubbles (LIPU/MB). In this study, treatment and BBB opening was performed every 3 weeks with paclitaxel administration until disease progression or up to 6 cycles (NCT04528680). As an exploratory objective of this trial, here we investigate extracellular vesicles and particles (EVPs/EPs) released into circulation in the context of tumor cell death as a potential biomarker for response to treatment. We develop and validate a microfluidic device designed to capture tumor-derived EVPs in glioblastoma patients (ExoChip). This approach leverages GBM-based expression of phosphatidylserine and Annexin-V chemistry that is traditionally used to measure apoptosis. EVPs are characterized using nanoparticle tracking analysis, proteomics, western blot, and scanning electron microscopy. Proteomic analysis of circulating EVPs isolated from GBM patients reveals distinct expression patterns to that of healthy individuals, and scRNA-seq analysis of these genes supported their tumoral origin within the GBM microenvironment. In vitro, paclitaxel-susceptible glioma cells treated with this drug exhibit apoptosis and dose-dependent EVP release. In concordance, we find changes in EVP release following the initiation of paclitaxel with LIPU/MB correlated with overall survival in GBM patients. Thus, our study introduces an efficient microfluidic platform for the capture of circulating GBM EVPs and demonstrates that release upon BBB opening is predictive of outcomes following paclitaxel treatment. This approach represents a real-time surrogate biomarker for treatment response for a disease where imaging-based assessment of response has not been shown to be reliable. Future prospective validation is warranted.

> **中文摘要：**
> 液体活检有望改善癌症患者的诊断、治疗反应评估，并最终指导其管理。然而，将这一方法应用于脑肿瘤面临挑战，因为分子穿越血脑屏障（BBB）的能力受限。我们最近报道了一项Ⅰ期临床试验的结果，在该试验中，通过颅骨可植入的低强度脉冲超声联合微泡（LIPU/MB），在胶质母细胞瘤（GBM）患者中实现了BBB的短暂开放。在本研究中，治疗及BBB开放每3周进行一次，同时给予紫杉醇，直至疾病进展或最多6个周期（NCT04528680）。作为本试验的探索性目标，我们研究了与肿瘤细胞死亡相关的循环中释放的细胞外囊泡及颗粒（EVPs/EPs），以评估其作为治疗反应潜在生物标志物的可能性。我们开发并验证了一种设计用于捕获GBM患者肿瘤来源EVPs的微流控装置（ExoChip）。该方法利用GBM细胞表达的磷脂酰丝氨酸及传统用于检测细胞凋亡的Annexin-V化学特性。我们采用纳米颗粒追踪分析、蛋白质组学、蛋白印迹及扫描电子显微镜对EVPs进行表征。从GBM患者血液中分离的循环EVPs的蛋白质组分析显示，其表达谱与健康个体显著不同，单细胞RNA测序分析进一步支持这些基因来源于GBM肿瘤微环境中的肿瘤成分。体外研究显示，对紫杉醇敏感的胶质瘤细胞经药物处理后发生凋亡，并呈剂量依赖性释放EVPs。与此一致，我们发现，在使用LIPU/MB联合紫杉醇治疗后，EVPs释放的变化与GBM患者的总体生存时间相关。因此，本研究提出了一种高效的微流控平台用于捕获GBM循环EVPs，并证明BBB开放后EVPs的释放可预测紫杉醇治疗结局。该方法为一种实时反映治疗反应的替代性生物标志物，尤其适用于传统影像学反应评估不可靠的疾病。未来仍需前瞻性验证。

### 第二部分 AI 大师评价

本研究旨在解决脑肿瘤液体活检受限于血脑屏障的难题，通过利用超声联合微泡暂时打开BBB，观察胶质母细胞瘤患者治疗后的细胞外囊泡释放变化。研究团队开发了基于微流控的ExoChip装置，实现了对肿瘤来源EVPs的捕获与多维度表征。结果显示，EVPs的释放量与紫杉醇治疗反应及生存期相关，具有预测价值。该研究创新性地提出了实时监测治疗反应的生物标志物策略，但仍需更大规模、前瞻性研究以验证其临床应用潜力。

---

## 99. 介导蛋白激酶通过调控蛋白质合成的转录作用构成MYC驱动型髓母细胞瘤的治疗脆弱性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402279)
**期刊：** Nature communications
**PMID：** 41402279
**DOI：** 10.1038/s41467-025-64937-3

### 第一部分 原文与翻译

**英文原标题：** Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma.

> **英文摘要：**
> MYC-driven medulloblastoma (MB) is a highly aggressive brain tumor with poor prognosis and limited treatment options. Through CRISPR-Cas9 screening, we identify the Mediator-associated kinase CDK8 as a critical regulator of MYC-driven MB. Both genetic loss and pharmacological inhibition of CDK8 impair MB tumor growth. Moreover, we find that CDK8 cooperates with MYC to sustain the MYC-mediated translational program, as CDK8 depletion induces pronounced transcriptional changes in translation-associated gene sets, reduces ribosome biogenesis, and impairs protein synthesis. Mechanistically, CDK8 regulates the occupancy of RNA polymerase II at specific chromatin loci, facilitating epigenetic alterations that promote the transcription of ribosomal genes. Furthermore, combined inhibition of CDK8 and mTOR synergistically enhances therapeutic efficacy in vivo, leading to more pronounced tumor growth suppression. Overall, our findings establish a functional link between CDK8-mediated transcriptional regulation and mRNA translation, suggesting a promising therapeutic approach targeting protein synthesis for MYC-driven MB.

> **中文摘要：**
> MYC驱动的髓母细胞瘤（MB）是一种侵袭性极强、预后不良且治疗选择有限的脑肿瘤。通过CRISPR-Cas9筛选，我们鉴定出Mediator复合体相关激酶CDK8是MYC驱动型MB的关键调控因子。无论是CDK8的遗传性缺失还是药理学抑制，均可削弱MB肿瘤的生长。此外，我们发现CDK8与MYC协同维持由MYC介导的翻译程序，因为CDK8的耗减会引起与翻译相关基因集的显著转录变化、减少核糖体生物发生并损害蛋白质合成。在机制上，CDK8通过调控RNA聚合酶II在特定染色质位点的结合，促进有利于核糖体基因转录的表观遗传改变。此外，联合抑制CDK8与mTOR可在体内表现出协同增强的治疗效果，导致肿瘤生长被更加显著地抑制。总体而言，我们的研究确立了CDK8介导的转录调控与mRNA翻译之间的功能联系，并提示针对蛋白质合成的治疗策略可能成为MYC驱动型MB的有前景的新方法。

### 第二部分 AI 大师评价

本文揭示了CDK8在MYC驱动型髓母细胞瘤中的关键作用，指出该激酶通过调控转录进而影响蛋白质合成，从而维持肿瘤生长。研究利用CRISPR-Cas9筛选、分子机制分析及联合靶向实验，系统阐明了CDK8调控核糖体基因表达及其与MYC的协同关系。联合抑制CDK8和mTOR显示出显著的协同抗肿瘤效应，突显潜在的治疗价值。该研究创新性在于明确了一个新的转录-翻译调控轴，但后续仍需在临床前模型和安全性方面进一步验证。

---

## 100. 在情境丰富且动态的场景中情感线索的整合在个体间存在差异

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402276)
**期刊：** Nature communications
**PMID：** 41402276
**DOI：** 10.1038/s41467-025-67466-1

### 第一部分 原文与翻译

**英文原标题：** Integration of affective cues in context-rich and dynamic scenes varies across individuals.

> **英文摘要：**
> Humans need to make rapid and accurate judgments of others' emotions to understand and navigate the social world around them. To do so, humans combine multiple sources of emotional information from facial expressions and contextual information. However, it is not well understood how different sources of information are integrated, let alone how observers assess which signals should be combined. Across three studies (n = 944) using data from new and previously collected datasets, we investigate whether affective inferences follow a Bayesian framework where information is optimally weighted based on its ambiguity and then combined. We compare this model to a more parsimonious Heuristic integration model that averages cues without considering cue ambiguity. We find that the Bayesian model best predicts individual observers' inferences of affect, but there are significant individual differences in integration strategies, with some individual observers adopting a Heuristic strategy. We also find that integration models that use stable weights instead of dynamic weights, as well as non-integration models, fail to predict observers' affective judgments. Our findings suggest that there are significant idiosyncratic differences in how humans combine affective cues, where some observers use a Bayesian framework to weigh individual cues before integration, while others use efficient but less optimal strategies.

> **中文摘要：**
> 人类需要对他人的情绪进行快速且准确的判断，以理解并应对周围的社会世界。为此，人类会将面部表情和情境信息等多种情绪信息来源加以整合。然而，目前尚不清楚不同信息来源是如何被整合的，更不清楚观察者如何判断哪些信号应当被结合。在三项研究（n=944）中，使用新数据集和既有数据集的数据，我们探讨情感推断是否遵循贝叶斯框架，即根据信息的模糊性对其进行最优加权后再整合。我们将该模型与一种更为简约的启发式整合模型进行比较，后者在整合时不考虑线索模糊性，而是简单取平均。结果发现，贝叶斯模型最能预测个体观察者的情感推断，但整合策略存在显著个体差异，一些观察者采用了启发式策略。我们还发现，使用固定权重（而非动态权重）的整合模型以及非整合模型均无法准确预测观察者的情感判断。研究结果表明，人类在整合情感线索的方式上存在显著的个体化差异，其中部分观察者在整合前采用贝叶斯框架对单个线索进行加权，而另一些则采用更高效但相对次优的策略。

### 第二部分 AI 大师评价

该研究旨在揭示人类如何在复杂情境中整合多源情绪线索，采用了基于新旧数据集的三项研究设计，以贝叶斯模型与启发式模型进行比较。结果显示，大多数个体倾向于按照贝叶斯原理对信息进行加权整合，但也存在显著的个体差异，一些人使用更简化的启发式策略。该研究突出了人类情感加工策略的多样性，为理解社会认知差异提供了新的理论框架。其局限性在于模型仍为实验性推断，需通过真实情境验证。

---

## 101. 基于既往慢性镇痛药使用及焦虑或抑郁持续时间的癌症诊断分期分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402270)
**期刊：** Nature communications
**PMID：** 41402270
**DOI：** 10.1038/s41467-025-66334-2

### 第一部分 原文与翻译

**英文原标题：** Cancer stage at diagnosis by duration of pre-existing chronic analgesic use and anxiety or depression.

> **英文摘要：**
> Pre-existing chronic diseases may delay or expedite cancer diagnosis. Here, we examine variations in cancer stage at diagnosis based on duration and type of common chronic conditions. We identify lung and colon cancers diagnosed 2012-2018 from national cancer registration, and pre-existing physical and mental-health conditions from linked primary care records. Using multivariable logistic regression, we explore associations between the most prevalent conditions (Anxiety/Depression and Chronic Analgesic Medication use), classified as "Recent-onset" (first recorded <12months pre-cancer) or "Persistent/Historic" (12-72 months pre-cancer), and cancer stage at diagnosis. We show that recent-onset Analgesic Medication use can be associated with increased odds of advanced stage lung or colon cancer diagnosis. Conversely, persistent/historic Chronic Analgesic Medication use can be associated with reduced odds of advanced stage lung cancer and persistent/historic Anxiety/Depression with reduced odds of advanced stage lung or colon cancer. Persistent or historic conditions may increase healthcare utilisation, offering opportunities for early cancer diagnosis. Recent-onset conditions may lead to delays through the alternative explanations or competing demands mechanisms.

> **中文摘要：**
> 既往存在的慢性疾病可能会延迟或加速癌症的诊断。在本研究中，我们基于常见慢性病的持续时间和类型，探讨诊断时癌症分期的差异。我们利用国家癌症注册数据，确定了2012年至2018年间诊断的肺癌和结肠癌病例，并从关联的初级保健记录中提取既往的身体和心理健康状况。通过多变量逻辑回归分析，我们研究了最常见的疾病（焦虑/抑郁与慢性镇痛药使用）与诊断时癌症分期之间的关联，这些疾病被分类为“近期发作”（首次记录时间在癌症诊断前不足12个月）或“持续/既往”（癌症诊断前12–72个月）。研究结果显示，近期发作的镇痛药使用可能与晚期肺癌或结肠癌诊断的可能性增加相关。相反，持续/既往的慢性镇痛药使用与肺癌晚期诊断的可能性降低相关，而持续/既往的焦虑或抑郁则与肺癌或结肠癌晚期诊断的可能性降低相关。持续或既往的疾病可能增加医疗服务利用，从而提供早期癌症诊断的机会；而近期发作的疾病可能通过替代解释或竞争需求机制导致诊断延迟。

### 第二部分 AI 大师评价

该研究旨在探讨既往慢性镇痛药使用及焦虑或抑郁与癌症诊断分期之间的关联，利用全国癌症注册和初级保健数据相结合的多变量逻辑回归方法进行分析。结果揭示了不同慢性病状态（近期发作与持续/既往）在癌症早诊或延误中的相反作用，具有重要的临床防控启示。其创新性在于将心理与药物使用因素同时纳入癌症早诊机制分析，但因观察性设计，无法完全排除混杂因素的影响。整体而言，该研究为理解慢性病管理与癌症早期发现之间的联系提供了新的证据基础。

---

## 102. 14种表观遗传时钟与174种新发疾病结局的无偏比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402269)
**期刊：** Nature communications
**PMID：** 41402269
**DOI：** 10.1038/s41467-025-66106-y

### 第一部分 原文与翻译

**英文原标题：** An unbiased comparison of 14 epigenetic clocks in relation to 174 incident disease outcomes.

> **英文摘要：**
> Epigenetic Clocks have been trained to predict chronological age, healthspan and lifespan. Such clocks are often analysed in relation to disease outcomes - typically using small datasets and a limited number of clocks. Here, we present a large-scale (n = 18,859), unbiased comparison of 14 widely used clocks as predictors of 174 incident disease outcomes and all-cause mortality over 10-years of follow up. Second- and third-generation clocks significantly outperform first-generation clocks, which have limited applications in disease settings. Of the 176 Bonferroni significant (P < 0.05/174) associations from fully-adjusted Cox regression models controlling for lifestyle and socioeconomic measures, there are 27 diseases (including primary lung cancer and diabetes) where the hazard ratio for the clock exceeds the clock's association with all-cause mortality. Furthermore, for 32 of the 176 findings, adding the clock to a null classification model with traditional risk factors significantly increases the classification accuracy by >1%. However, there is minimal evidence for interactions between the clocks and sex or smoking (ever/never) status. Second- and third-generation epigenetic clocks show promise for disease risk prediction, particularly in relation to respiratory and liver-based conditions.

> **中文摘要：**
> 表观遗传时钟已被训练用于预测实际年龄、健康寿命和总寿命。此类时钟常被用于分析与疾病结局的关系——但通常基于较小的数据集和有限数量的时钟。在本研究中，我们开展了一项大规模（n=18,859）的、无偏的比较研究，评估14种广泛使用的表观遗传时钟在10年随访期间预测174种新发疾病结局及全因死亡率的能力。第二代和第三代表观遗传时钟的表现显著优于第一代时钟，而后者在疾病研究中的应用有限。在针对生活方式和社会经济因素进行充分调整的Cox回归模型中，共发现176项经Bonferroni校正后的显著关联（P<0.05/174）。其中，27种疾病（包括原发性肺癌和糖尿病）中，时钟的风险比超过其与全因死亡率之间的关联。此外，在176项发现中的32项中，将时钟加入仅含传统风险因素的空分类模型后，可显著提高分类准确率超过1%。然而，几乎没有证据显示时钟与性别或吸烟（曾经/从未）状态之间存在交互作用。总体而言，第二代和第三代表观遗传时钟在疾病风险预测方面展现出应用潜力，尤其是在呼吸系统和肝脏相关疾病中。

### 第二部分 AI 大师评价

本研究通过大样本、系统性比较14种表观遗传时钟与174种疾病结局的关联，提供了迄今为止最全面的实证分析。结果显示第二代与第三代时钟在疾病风险预测和全因死亡率评估中显著优于第一代模型。研究还指出某些疾病中时钟的风险比甚至超过其对全因死亡率的预测，提示其潜在的特异性诊断价值。其创新在于无偏的大规模验证及功能层面比较，局限性则在于观察性设计及尚未明确的因果推断。

---

## 103. 一种广谱中和抗体通过抑制 gB 介导的膜融合对 α 皰疹病毒属提供跨属保护

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41402251)
**期刊：** Nature communications
**PMID：** 41402251
**DOI：** 10.1038/s41467-025-66099-8

### 第一部分 原文与翻译

**英文原标题：** A broadly neutralizing antibody confers cross-genus protection against alphaherpesviruses by inhibiting gB-mediated membrane fusion.

> **英文摘要：**
> The global prevalence and disease burden of alphaherpesviruses infections, including human-infecting viruses such as HSV-1, HSV-2, and VZV, as well as animal-infecting viruses like PRV, BHV, CHV, and FHV, highlight the unmet need for more effective and universal antiviral strategies. However, there has been no significant progress in developing broad-spectrum interventions against herpesvirus. Here we report the identification of a broadly neutralizing antibody against alphaherpesviruses, 16F9, which targets the glycoprotein B (gB) of alphaherpesviruses and offers cross-protection against multiple viruses such as HSV-1, HSV-2, and PRV in mice. 16F9 demonstrated robust therapeutic efficacy in various female mouse models of herpesvirus diseases including PRV-induced viral encephalitis, HSV-1-induced viral encephalitis, viral keratitis, cutaneous herpes, and neonatal herpesvirus infections. High-resolution cryo-electron microscopy structures revealed that 16F9 binds a conserved site of vulnerability on Domain I of gB. The binding of 16F9 disrupts the interaction between pre-gB and gHgL complex, thereby preventing viral membrane fusion and blocking viral infection. This study provides a foundation for advancing antiviral strategies and underscores the potential of gB-targeted interventions for combating herpesvirus infections.

> **中文摘要：**
> α 皰疹病毒感染在全球范围内的流行及其造成的疾病负担——包括可感染人类的 HSV-1、HSV-2 和 VZV，以及感染动物的 PRV、BHV、CHV 和 FHV——凸显了开发更有效且普适的抗病毒策略的迫切需求。然而，目前在开发针对皰疹病毒的广谱干预措施方面尚无显著进展。本研究报告了针对 α 皰疹病毒的一种广谱中和抗体 16F9 的发现，该抗体可识别 α 皰疹病毒糖蛋白 B（gB），并在小鼠中对多种病毒（包括 HSV-1、HSV-2 和 PRV）提供交叉保护。16F9 在多种雌性小鼠皰疹病毒疾病模型中表现出强大的治疗效果，这些模型包括 PRV 诱导的病毒性脑炎、HSV-1 诱导的病毒性脑炎、病毒性角膜炎、皮肤皰疹和新生鼠皰疹病毒感染。高分辨率冷冻电子显微镜结构显示，16F9 结合于 gB 域 I 上一个保守的易感位点。16F9 的结合会破坏前体 gB 与 gHgL 复合物之间的相互作用，从而阻止病毒膜融合并阻断病毒感染。本研究为推进抗病毒策略奠定了基础，并强调了针对 gB 的干预在抗击皰疹病毒感染中的潜力。

### 第二部分 AI 大师评价

本研究发现了一种可跨 α 皰疹病毒属发挥作用的广谱中和抗体 16F9，通过靶向病毒糖蛋白 gB 并阻断其与 gHgL 复合物的相互作用，抑制膜融合。研究利用多种小鼠模型验证了其在多种病毒感染中的治疗效果，并通过冷冻电镜解析了关键结构结合位点。该成果揭示了 gB 作为广谱抗皰疹病毒靶点的可行性，为未来开发通用性抗病毒药物提供了理论基础。然而，后续仍需在人类系统和不同宿主中验证其有效性与安全性。

---

## 104. B7-H3 作为实体瘤治疗的普适靶点：临床前景与生物学复杂性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41401407)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41401407
**DOI：** 10.1200/JCO-25-02487

### 第一部分 原文与翻译

**英文原标题：** B7-H3 as a Universal Target for Solid Tumor Therapy: Clinical Promise and Biological Complexity.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该论文聚焦于免疫检查点分子 B7-H3 在实体瘤治疗中的潜力，探讨其作为通用治疗靶点的科学依据与临床应用前景。标题暗示作者可能系统综述了 B7-H3 的表达谱、生物学功能以及其在免疫逃逸、肿瘤微环境调控中的作用。研究的创新性在于将 B7-H3 提升为跨肿瘤类型的治疗靶点，但也面临生物学机制复杂及安全性评估等挑战。总体而言，该工作为未来开发广谱抗肿瘤免疫疗法提供了重要方向。

---

## 105. 评估肿瘤学中专科姑息治疗的获益：重新思考临床试验设计

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41401402)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41401402
**DOI：** 10.1200/JCO-25-02206

### 第一部分 原文与翻译

**英文原标题：** Assessing the Benefit of Specialist Palliative Care in Oncology: Rethinking Clinical Trial Design.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究旨在探讨如何更科学和有效地评估专科姑息治疗在肿瘤学中的临床获益。标题暗示作者关注的是传统临床试验设计在该领域可能存在的局限，并尝试提出新的研究框架或方法学思考。其创新点在于从设计层面重新定义疗效评估指标，可能强调患者生活质量与多维度结局指标的整合。尽管具体方法与数据尚未披露，但该研究方向具有重要的临床意义与研究价值。

---

## 106. 更正：“ETV4介导的肿瘤相关中性粒细胞浸润促进膀胱癌的淋巴管生成和淋巴转移”

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41401362)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41401362
**DOI：** 10.1002/advs.73278

### 第一部分 原文与翻译

**英文原标题：** Correction to "ETV4 Mediated Tumor-Associated Neutrophil Infiltration Facilitates Lymphangiogenesis and Lymphatic Metastasis of Bladder Cancer".

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

这篇文章为原研究“ETV4介导的肿瘤相关中性粒细胞浸润促进膀胱癌淋巴管生成和淋巴转移”的更正说明，可能针对实验数据或图表中的细节进行修订。虽然未提供具体摘要，但更正类论文通常反映研究团队对结果准确性和可重复性的重视。整体上，这体现了学术严谨性和对科学诚信的维护。

---

## 107. 分解脂肪，发现疾病：质子密度脂肪分数（PDFF）在代谢相关脂肪性肝病（MASLD）诊断中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400864)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41400864
**DOI：** 10.1097/HEP.0000000000001603

### 第一部分 原文与翻译

**英文原标题：** Fraction the fat, find the disease: Proton density fat fraction (PDFF) in MASLD diagnosis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献聚焦于质子密度脂肪分数（PDFF）在代谢相关脂肪性肝病（MASLD）诊断中的潜力，标题暗示作者探讨了PDFF如何定量化区分脂肪分布并辅助疾病识别。尽管未提供摘要，推测其重点在于PDFF在影像诊断中的敏感性与特异性比较。研究可能具有影像生物标志物验证价值，但仍需更多临床验证以确定其诊断阈值与标准化可行性。

---

## 108. 心肾代谢综合征与代谢功能障碍相关脂肪性肝病（MASLD）中肝纤维化进展及肝相关事件风险的关系

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400631)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41400631
**DOI：** 10.1097/HEP.0000000000001645

### 第一部分 原文与翻译

**英文原标题：** Cardiovascular-Kidney-Metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD.

> **英文摘要：**
> BACKGROUND: Cardio-kidney-metabolic (CKM) syndrome, a new framework integrating cardiovascular, renal, and metabolic dysfunction, remains inadequately characterized in metabolic dysfunction-associated steatotic liver disease (MASLD).
> 
> OBJECTIVE: We investigated the relationships between CKM stages and liver fibrosis severity, progression, and the risk of liver-related events (LREs) in MASLD.
> 
> DESIGN: Patients with MASLD from the VCTE-Prognosis cohort were stratified according to CKM stages. Outcomes included the prevalence of advanced liver fibrosis (LSM ≥10 kPa), liver stiffness progression (≥20% increase and Baveno category upshift), and incident LREs. Associations were assessed using multivariable logistic regression and Cox proportional hazards models.
> 
> RESULTS: Among 12,097 patients with MASLD, the prevalence of advanced liver fibrosis increased across CKM stages at baseline: 9.6% (CKM stage 0-1), 18.0% (CKM stage 2), and 31.6% (CKM stage 3-4). CKM stage 2 (adjusted-OR=1.663, 95%CI 1.444-1.915) and CKM stage 3-4 (adjusted-OR=2.575, 95%CI 2.109-3.144) were independently associated with advanced fibrosis. During a 4.5-year median follow-up, 716 patients (6.1%) experienced progression of liver stiffness and 352 patients (1.7%) developed LRE. Compared to CKM stage 0-1, the risk of liver stiffness progression was higher in CKM stage 2 (adjusted-HR=1.321, 95%CI 1.050-1.662; p=0.018) and CKM stage 3-4 (adjusted-HR=1.767, 95%CI 1.339-2.330; p<0.001). In contrast, only CKM stage 3-4 was significantly associated with an increased risk of LREs (adjusted-HR=1.975, 95%CI 1.245-3.133; p=0.004).
> 
> CONCLUSION: CKM stages are independently associated with the severity and progression of liver fibrosis in MASLD. CKM stage 2 significantly increases liver stiffness progression without excess LRE risk, while CKM stage 3-4 confers the highest risk for liver-related outcomes.

> **中文摘要：**
> 背景：心肾代谢（CKM）综合征是一个整合心血管、肾脏和代谢功能障碍的新框架，其在代谢功能障碍相关脂肪性肝病（MASLD）中的特征尚未得到充分阐明。
> 
> 目的：我们研究了MASLD中不同CKM分期与肝纤维化严重程度、进展以及肝相关事件（LREs）风险之间的关系。
> 
> 设计：来自VCTE-Prognosis队列的MASLD患者根据CKM分期进行分层。研究终点包括高级肝纤维化的患病率（LSM≥10 kPa）、肝硬度进展（肝硬度增加≥20%且Baveno分级上移）以及新发LREs。通过多变量逻辑回归和Cox比例风险模型评估相关性。
> 
> 结果：在12,097例MASLD患者中，基线时高级肝纤维化的患病率随CKM分期升高而增加：9.6%（CKM 0-1期）、18.0%（CKM 2期）和31.6%（CKM 3-4期）。CKM 2期（校正比值比=1.663，95%置信区间1.444–1.915）和CKM 3-4期（校正比值比=2.575，95%置信区间2.109–3.144）与高级肝纤维化独立相关。在中位随访4.5年期间，716例（6.1%）患者出现肝硬度进展，352例（1.7%）患者发生LRE。与CKM 0-1期相比，CKM 2期患者肝硬度进展风险较高（校正风险比=1.321，95%置信区间1.050–1.662，p=0.018），CKM 3-4期风险进一步升高（校正风险比=1.767，95%置信区间1.339–2.330，p<0.001）。相反，只有CKM 3-4期与LRE风险显著升高相关（校正风险比=1.975，95%置信区间1.245–3.133，p=0.004）。
> 
> 结论：CKM分期与MASLD中肝纤维化的严重程度和进展独立相关。CKM 2期显著增加肝硬度进展风险，但未增加LRE风险，而CKM 3-4期则带来最高的肝相关结局风险。

### 第二部分 AI 大师评价

该研究基于大规模MASLD队列系统评估了心肾代谢综合征（CKM）分期与肝纤维化及肝相关事件之间的关系，具有显著的临床意义。通过多变量模型分析，研究揭示CKM分期与肝纤维化严重程度和进展风险呈独立正相关。尤其是CKM 2期即可显著促进肝硬度进展，而CKM 3-4期则显著增加肝事件风险。研究创新地将CKM框架应用于MASLD领域，但其观察性设计可能限制因果推论。总体而言，该研究为代谢共病背景下MASLD分层管理提供了数据支持。

---

## 109. 基于大规模人群内镜液体活检的胃液DNA含量揭示其作为胃癌候选肿瘤生物标志物的潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400466)
**期刊：** eLife
**PMID：** 41400466
**DOI：** 10.7554/eLife.107103

### 第一部分 原文与翻译

**英文原标题：** Endoscopic liquid biopsies of gastric fluid in a large human patient cohort reveal DNA content as a candidate tumor biomarker in gastric cancer.

> **英文摘要：**
> Gastric cancer remains a diagnostic and therapeutic challenge worldwide. Improved prognostic biomarkers could aid treatment planning across surgical, neoadjuvant, and adjuvant settings. We evaluated a novel liquid-biopsy approach integrated with esophagogastroduodenoscopy (EGD) by analyzing gastric fluid DNA (gfDNA) from a large cohort (n=1056) to assess its diagnostic utility and prognostic value in gastric cancer. In this exploratory study, gfDNA concentration was measured in patients with normal gastric mucosa, peptic diseases, preneoplastic conditions, or cancer. Variables included sex, gastric fluid pH, proton-pump inhibitor use, tumor subtype, stage, and outcomes. gfDNA levels were significantly higher in gastric cancer than in all comparison groups (mean 26.86 ng/µL; 95% CI 20.05-33.79; p=3.61 × 10e) and as compared to non-malignant controls (mean 10.77 ng/µL; 95% CI 9.23-12.33; p=9.55 × 10e) and preneoplastic states (mean 10.10 ng/µL; 95% CI 7.59-12.60; p=1.10 × 10e). Advanced tumors (T3) exhibited higher gfDNA than earlier stages (T2 or below; mean 25.66 vs 15.12 ng/µL; p=5.97 × 10e). In a subset of gastric cancer patients, gfDNA >1.28 ng/µL associated with longer progression-free survival (p=0.009) and correlated with increased tumor-infiltrating immune cells (p=0.001); this association remained after adjusting for stage (p=0.014). Elevated gfDNA supports gastric cancer presence in the general human population and may inform disease management when combined with tissue biopsies. Importantly, gfDNA shows prognostic potential in established gastric cancer, where higher gfDNA content may paradoxically relate to better outcomes, potentially linked to immune-cell infiltration. These findings warrant further validation and integration with complementary diagnostic modalities to enhance accuracy and clinical utility.

> **中文摘要：**
> 胃癌在全球范围内仍然是诊断和治疗方面的重大挑战。改进的预后生物标志物可能有助于在手术、术前新辅助及术后辅助治疗中进行更优的治疗规划。我们评估了一种与食管胃十二指肠镜（EGD）整合的新型液体活检方法，通过分析来自大规模人群队列（n=1056）的胃液DNA（gfDNA），以评估其在胃癌中的诊断效用及预后价值。在这项探索性研究中，我们测定了正常胃黏膜、消化性疾病、癌前病变及癌症患者的gfDNA浓度。分析变量包括性别、胃液pH值、质子泵抑制剂使用、肿瘤亚型、分期及结局。结果显示，胃癌患者的gfDNA水平显著高于所有比较组（均值26.86 ng/µL；95% CI 20.05–33.79；p=3.61 × 10e），亦显著高于非恶性对照组（均值10.77 ng/µL；95% CI 9.23–12.33；p=9.55 × 10e）及癌前病变组（均值10.10 ng/µL；95% CI 7.59–12.60；p=1.10 × 10e）。进展期肿瘤（T3）的gfDNA水平高于早期分期（T2及以下）（均值25.66 vs 15.12 ng/µL；p=5.97 × 10e）。在胃癌患者的一个子集中，gfDNA >1.28 ng/µL与更长的无进展生存期相关（p=0.009），并与更多的肿瘤浸润免疫细胞相关（p=0.001）；在校正分期后，该相关性仍然存在（p=0.014）。总体而言，升高的gfDNA支持在人群中识别胃癌的可能性，当与组织活检结合时，可能有助于疾病管理。值得注意的是，gfDNA在已确诊胃癌中显示出预后潜力，其较高含量可能反常地与更好的预后相关，可能与免疫细胞浸润有关。这些发现需要进一步验证，并与互补的诊断手段整合，以提高准确性和临床实用性。

### 第二部分 AI 大师评价

该研究旨在评估通过内镜采集的胃液DNA作为液体活检标志物在胃癌中的诊断及预后价值。研究基于超过千例受试者队列，发现胃液DNA浓度在胃癌患者中显著升高，并与病理分期及免疫细胞浸润呈相关。更高的胃液DNA水平在部分病例中反而提示更佳的预后，提示其潜在的免疫机制关联。研究创新之处在于将液体活检与内镜操作融合，揭示非传统体液中DNA指标的临床意义，但其机制及可重复性仍需进一步验证。

---

## 110. 人嗜铬细胞瘤和副神经节瘤的转录亚型对免疫微环境及术后复发和转移预测的影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400463)
**期刊：** eLife
**PMID：** 41400463
**DOI：** 10.7554/eLife.107108

### 第一部分 原文与翻译

**英文原标题：** Transcriptional subtypes on immune microenvironment and predicting postoperative recurrence and metastasis in human pheochromocytoma and paraganglioma.

> **英文摘要：**
> Human pheochromocytomas and paragangliomas (PPGLs) exhibit substantial molecular and immune heterogeneity, complicating risk assessment and treatment. Here, we define three distinct tumor transcriptional subtypes (C1, C2, and C3) in a clinically annotated cohort of PPGL patients through integrative transcriptomic and immunogenomic profiling. C1 is characterized by hypoxia-driven pathways and an immunosuppressive microenvironment, correlating with poor prognosis. C2 exhibits a highly inflamed immune landscape with robust CD8 T cell infiltration, suggesting potential sensitivity to immunotherapy. C3 is enriched in metabolic reprogramming pathways and displays intermediate clinical outcomes. Genetic analysis reveals subtype-specific mutational patterns, with pseudohypoxic driver mutations (, , , and ) predominant in C1 and C3, while kinase pathway alterations ( and ) define C2. Single-nucleus RNA sequencing of human PPGL tumors further delineates immune ecosystem diversity. Notably, we identify , , and  as key subtype-specific biomarkers, with  driving tumor progression in C1 and emerging as a potential therapeutic target. Our findings provide a refined molecular classification integrating immune and genomic features in human PPGLs, offering a framework for improved prognostication and precision therapies in this rare neuroendocrine tumor type.

> **中文摘要：**
> 人类嗜铬细胞瘤和副神经节瘤（PPGLs）表现出显著的分子及免疫异质性，导致风险评估和治疗变得复杂。在本研究中，研究者通过整合转录组和免疫基因组特征分析，在一具备临床注释的PPGL患者队列中定义了三种截然不同的肿瘤转录亚型（C1、C2和C3）。C1的特征为缺氧驱动的通路及免疫抑制性微环境，与预后不良相关。C2表现出高度炎症性的免疫特征，并伴随强烈的CD8 T细胞浸润，提示其可能对免疫治疗具有敏感性。C3富集于代谢重编程通路，临床结局处于中间水平。遗传学分析揭示了亚型特异性突变模式，伪缺氧驱动基因突变（……等）主要见于C1和C3，而激酶信号通路改变（……等）定义了C2。对人PPGL肿瘤的单核RNA测序进一步描绘了免疫生态系统的多样性。值得注意的是，研究者鉴定出……等关键亚型特异性生物标志物，其中……在C1中驱动肿瘤进展，并成为潜在的治疗靶点。本研究提出了一种整合免疫和基因组特征的精细分子分型，为改善该类罕见神经内分泌肿瘤的预后评估与精准治疗提供了新框架。

### 第二部分 AI 大师评价

本研究通过转录组与免疫组学整合分析，揭示了嗜铬细胞瘤和副神经节瘤存在三种具有显著生物学差异的转录亚型。研究细致刻画了不同亚型的免疫景观、代谢特征及基因突变模式，并通过单核RNA测序进一步解析了免疫微环境多样性。其成果为PPGL的分子分型和个体化治疗提供了新的生物学依据，尤其在免疫治疗敏感性预测方面具有潜在应用价值。但目前部分机制仍有待功能性验证，且样本量的扩展将进一步增强结论的可靠性。

---

## 111. 超高灵敏度ctDNA动态分析在接受免疫治疗的实体瘤中的广泛应用价值

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400436)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41400436
**DOI：** 10.1158/1078-0432.CCR-25-2312

### 第一部分 原文与翻译

**英文原标题：** Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.

> **英文摘要：**
> PURPOSE: Prior studies have suggested the biomarker potential of plasma-derived ctDNA in patients with cancer treated with immune checkpoint inhibitors. This study investigated the ability of ctDNA to predict progression-free and overall survival in a cohort of patients with advanced cancer treated with immunotherapies.
> 
> EXPERIMENTAL DESIGN: In order to characterize the potential role of ultrasensitive ctDNA detection in the management of these patients, we have performed tumor whole-genome sequencing-informed, ultrasensitive ctDNA analysis-tracking approximately 1,800 tumor-specific mutations per patient-in a retrospective cohort (n = 136) and a prospective validation cohort (n = 66) across 24 cancer types treated with immune checkpoint inhibitors alone or in combination with bispecific antibodies or immune cell engagers.
> 
> RESULTS: Analyzing 1,455 longitudinal samples, we found that ctDNA molecular response measured as early as 3 weeks after treatment initiation correlated with improved progression-free and overall survival, whereas ctDNA clearance at any time strongly correlated with radiologic response and prolonged survival. Additionally, ctDNA dynamics distinguished true progression from pseudoprogression and predicted outcomes in patients receiving continued immunotherapy beyond initial progression.
> 
> CONCLUSIONS: This study highlights the broader applicability of ultrasensitive ctDNA as a biomarker across cancer types and immunotherapy modalities.

> **中文摘要：**
> 研究目的：既往研究提示，血浆来源的循环肿瘤DNA（ctDNA）在接受免疫检查点抑制剂治疗的癌症患者中具有作为生物标志物的潜力。本研究探讨ctDNA在预测接受免疫治疗的晚期癌症患者无进展生存期和总体生存期方面的能力。
> 
> 实验设计：为阐明超高灵敏度ctDNA检测在患者管理中的潜在作用，我们基于肿瘤全基因组测序信息进行了超敏ctDNA分析——每位患者追踪约1,800个肿瘤特异性突变，并在回顾性队列（n=136）和前瞻性验证队列（n=66）中开展研究，涵盖24种癌症类型。这些患者接受了单用免疫检查点抑制剂或与双特异性抗体、免疫细胞激活剂联合的免疫治疗。
> 
> 研究结果：通过分析1,455份纵向样本，我们发现，在治疗开始后早至3周时测得的ctDNA分子反应与更好的无进展生存期和总体生存期相关；而在任意时间实现ctDNA清除均与影像学反应及更长生存期显著相关。此外，ctDNA动态可区分真实进展与假性进展，并能预测继续接受免疫治疗超过初始进展患者的预后。
> 
> 研究结论：本研究强调，超高灵敏度ctDNA作为生物标志物在多种癌症类型和免疫治疗方案中具有更广泛的应用性。

### 第二部分 AI 大师评价

该研究系统评估了超高灵敏度ctDNA检测在多种免疫治疗相关癌症中的预后预测价值，采用全基因组信息指导的精确突变追踪策略，覆盖多癌种、多治疗方案。结果显示，早期ctDNA动态变化可高效预测疗效及生存，并能识别假性进展等临床关键情境。其创新性在于以大规模、多队列、超灵敏度技术验证ctDNA跨癌种应用的可行性。局限性可能包括回顾性分析部分样本偏倚及成本与检测普及性问题。

---

## 112. 丙酮酸命运通过调节细胞氧化还原电位决定细胞生长。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400249)
**期刊：** eLife
**PMID：** 41400249
**DOI：** 10.7554/eLife.103705

### 第一部分 原文与翻译

**英文原标题：** The fate of pyruvate dictates cell growth by modulating cellular redox potential.

> **英文摘要：**
> Pyruvate occupies a central node in carbohydrate metabolism such that how it is produced and consumed can optimize a cell for energy production or biosynthetic capacity. This has been primarily studied in proliferating cells, but observations from the post-mitotic  fat body led us to hypothesize that pyruvate fate might dictate the rapid cell growth observed in this organ during development. Indeed, we demonstrate that augmented mitochondrial pyruvate import prevented cell growth in fat body cells in vivo as well as in cultured mammalian hepatocytes and human hepatocyte-derived cells in vitro. We hypothesize that this effect on cell size was caused by an increase in the NADH/NAD ratio, which rewired metabolism toward gluconeogenesis and suppressed the biomass-supporting glycolytic pathway. Amino acid synthesis was decreased, and the resulting loss of protein synthesis prevented cell growth. Surprisingly, this all occurred in the face of activated pro-growth signaling pathways, including mTORC1, Myc, and PI3K/Akt. These observations highlight the evolutionarily conserved role of pyruvate metabolism in setting the balance between energy extraction and biomass production in specialized post-mitotic cells.

> **中文摘要：**
> 丙酮酸在碳水化合物代谢中处于核心节点，其生成和消耗方式可使细胞在能量产生或生物合成能力之间实现最优平衡。这一过程主要在增殖细胞中得到研究，但来自终末分化脂肪体的观察引导我们假设，丙酮酸的代谢命运可能决定该器官在发育过程中出现的快速细胞生长。事实上，我们证实，增强的线粒体丙酮酸摄入在体内的脂肪体细胞中以及体外培养的哺乳动物肝细胞与人源肝细胞系中均会抑制细胞生长。我们推测，这种对细胞体积的影响是由于 NADH/NAD 比值上升所致，后者将代谢重定向至糖异生，并抑制了支持生物质积累的糖酵解途径。氨基酸合成减少，随之而来的蛋白质合成降低，最终阻碍了细胞生长。令人意外的是，这些现象出现在多种促生长信号通路（包括 mTORC1、Myc 和 PI3K/Akt）均被激活的背景下。这些发现凸显了丙酮酸代谢在进化上保守的作用，即在专化的终末分化细胞中维持能量获取与生物质生成之间的代谢平衡。

### 第二部分 AI 大师评价

本研究旨在探讨丙酮酸代谢命运对细胞生长的调控机制。作者通过体内外模型发现，加强线粒体丙酮酸输入会抑制细胞生长，其机制可能与 NADH/NAD 比值上升引起的代谢重编程有关。研究揭示，即使在促生长信号通路活跃的条件下，代谢状态仍可主导细胞体积与合成活动。这一发现深化了对能量代谢与生物合成平衡之间关系的理解，提示丙酮酸代谢在终末分化细胞中的进化保守性。研究的创新性在于揭示代谢命运如何独立于经典信号通路调控细胞生长，但其局限在于主要依赖模型系统验证，仍需在更多生理背景中证实。

---

## 113. 撤稿声明：microRNA-7 上调死亡受体 5 并使耐药性脑肿瘤对半胱天冬酶介导的凋亡敏感。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400142)
**期刊：** Neuro-oncology
**PMID：** 41400142
**DOI：** 10.1093/neuonc/noaf260

### 第一部分 原文与翻译

**英文原标题：** Retraction of: microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该条目为撤稿声明，表明原始研究关于 microRNA-7 通过上调死亡受体 5 增强脑肿瘤细胞对凋亡反应的结论已不再可信。尽管该研究主题在分子肿瘤学领域具有高潜在价值，但撤稿反映了研究方法、数据或伦理层面的可能问题。此事件提示科研工作中重复验证与数据透明的重要性。

---

## 114. Pirin通过调控PLA2G4A转录并重塑脂质谱以抑制结直肠癌中的铁死亡。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400081)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41400081
**DOI：** 10.1002/advs.202516385

### 第一部分 原文与翻译

**英文原标题：** Pirin Transcriptionally Regulates PLA2G4A To Inhibit Ferroptosis in Colorectal Cancer via Lipid Profile Remodeling.

> **英文摘要：**
> Ferroptosis, an iron-dependent cell death driven by lipid peroxidation, is a promising therapeutic target in colorectal cancer (CRC); however, its regulation remains unclear. Here, Pirin (PIR) is recognized as a ferroptosis suppressor that acts through lipid remodeling. PIR is upregulated in CRC tissues, correlating with reduced ferroptosis sensitivity and enhanced tumor growth, whereas PIR loss restricts CRC progression in vivo and in vitro. Intestinal epithelium-specific PIR deletion limits AOM/DSS-induced tumorigenesis by increasing lipid peroxidation and promoting ferroptosis. Mechanistically, ferroptosis triggers a compensatory NRF2-PIR axis, in which NRF2 binds to the PIR promoter to induce its expression. PIR deficiency downregulates PLA2G4A (encoding cPLA2α), a key arachidonic-acid-metabolizing enzyme involved in ferroptosis control. Lipidomics has shown that PIR loss increases polyunsaturated fatty acid (PUFA)-containing phospholipids and decreases monounsaturated (MUFA) and saturated (SFA) species, shifting membranes toward a ferroptosis-permissive state. Restoration of PLA2G4A rescues ferroptosis resistance in PIR-deficient cells. Targeting this pathway, either by pharmacologic inhibition of PLA2G4A with AACOCF3 or by genetic disruption of the PIR-PLA2G4A axis, enhances the efficacy of ferroptosis inducers and suppresses CRC progression. This study defines an NRF2-PIR-PLA2G4A circuit that governs ferroptosis susceptibility via lipidome remodeling and highlights its therapeutic potential in CRC.

> **中文摘要：**
> 铁死亡是一种依赖铁、由脂质过氧化驱动的细胞死亡形式，是结直肠癌（CRC）的潜在治疗靶点；然而，其调控机制仍不清楚。本研究发现，Pirin（PIR）被鉴定为一种通过脂质重塑发挥作用的铁死亡抑制因子。PIR在CRC组织中上调，与铁死亡敏感性降低和肿瘤生长增强相关，而缺失PIR可在体内和体外限制CRC的进展。肠上皮特异性PIR缺失可通过增加脂质过氧化并促进铁死亡来限制AOM/DSS诱导的肿瘤发生。在机制上，铁死亡可诱导补偿性的NRF2-PIR轴，其中NRF2结合到PIR启动子上以促进其表达。PIR缺陷会下调PLA2G4A（编码cPLA2α），该酶是参与铁死亡调控的关键花生四烯酸代谢酶。脂质组学分析显示，PIR缺失导致含多不饱和脂肪酸（PUFA）的磷脂增加，而单不饱和脂肪酸（MUFA）及饱和脂肪酸（SFA）种类减少，使细胞膜向更易发生铁死亡的状态转变。恢复PLA2G4A表达可在PIR缺陷细胞中挽救铁死亡抵抗。通过药物AACOCF3抑制PLA2G4A或遗传学破坏PIR-PLA2G4A轴，均可增强铁死亡诱导剂的疗效并抑制CRC进展。本研究定义了一个通过脂质组重塑调控铁死亡敏感性的NRF2-PIR-PLA2G4A信号环路，并强调了其在结直肠癌中的治疗潜能。

### 第二部分 AI 大师评价

本研究旨在揭示铁死亡调控的分子机制，聚焦Pirin及其下游通路在结直肠癌中的作用。作者通过分子生物学实验、动物模型及脂质组学分析，系统阐明了NRF2-PIR-PLA2G4A轴在铁死亡敏感性调控中的关键作用。研究发现PIR通过调控脂质组成来抑制铁死亡，从而促进肿瘤进展；破坏该通路可增强铁死亡诱导剂效果，具有潜在的治疗价值。其创新性在于明确了脂质重塑与铁死亡之间的可调控联系，但仍需进一步研究其在临床应用中的安全性与普适性。

---

## 115. 受软药物启发的 MnSTF 纳米佐剂用于肿瘤免疫治疗中安全且协同的 cGAS-STING 通路激活

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41400033)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41400033
**DOI：** 10.1002/advs.202515432

### 第一部分 原文与翻译

**英文原标题：** Soft-Drug-Inspired MnSTF Nano-Adjuvant for Safe and Synergistic cGAS-STING Activation in Tumor Immunotherapy.

> **英文摘要：**
> The activation of the stimulator of interferon genes (STING) pathway is a cutting-edge strategy in tumor immunotherapy and has shown transformative potential in preclinical studies by inducing a type I interferon cascade and remodeling the tumor immune microenvironment. However, current STING agonists are limited by a narrow therapeutic window and substantial systemic toxicity, which significantly impedes their translational potential. To overcome these challenges, a novel self-assembling nanoadjuvant, MnSTF, grounded in the soft-drug design paradigm is designed. MnSTF is assembled through multidentate coordination between manganese ions (Mn), which exhibit moderate STING-activating activity, and the ENPP1 inhibitor STF-1623, thereby achieving synergistic activation of the cGAS-STING signaling axis. In contrast to conventional small-molecule STING agonists, MnSTF elicits no systemic inflammatory response at either therapeutic or supratherapeutic doses, demonstrating outstanding safety and biocompatibility. Furthermore, MnSTF profoundly reprograms the tumor immune microenvironment and, when coadministered with radiotherapy, mRNA vaccines, or protein antigens, induces robust antigen-specific T cell responses and marked antitumor efficacy. Accordingly, by combining soft-drug design with a dual-targeted immunomodulatory mechanism, MnSTF effectively reconciles the efficacy-safety trade-off of STING agonists in preclinical settings and expands the potential for precise immunoregulation via the STING pathway.

> **中文摘要：**
> 干扰素基因刺激因子（STING）通路的激活是肿瘤免疫治疗中的前沿策略，在临床前研究中已表现出通过诱导I型干扰素级联反应并重塑肿瘤免疫微环境的变革性潜力。然而，现有的STING激动剂受到治疗窗口狭窄和系统毒性显著的限制，这严重阻碍了其转化潜力。为克服这些挑战，研究者设计了一种基于软药物设计范式的全新自组装纳米佐剂MnSTF。MnSTF通过具有中等STING激活活性的锰离子（Mn）与ENPP1抑制剂STF-1623之间的多齿配位作用组装而成，从而实现cGAS-STING信号轴的协同激活。与传统的小分子STING激动剂相比，MnSTF在治疗剂量或过量剂量下均不会引起系统性炎症反应，显示出优异的安全性和生物相容性。此外，MnSTF可深度重塑肿瘤免疫微环境，并在与放疗、mRNA疫苗或蛋白抗原联合给药时，诱导强有力的抗原特异性T细胞反应及显著的抗肿瘤效应。因此，通过结合软药物设计与双靶点免疫调节机制，MnSTF在临床前模型中有效平衡了STING激动剂的疗效与安全性，为基于STING通路的精准免疫调控拓展了新的潜力。

### 第二部分 AI 大师评价

本文旨在构建一种新型软药物理念指导的MnSTF纳米佐剂，以安全、协同地激活cGAS-STING通路用于肿瘤免疫治疗。研究展示了MnSTF通过锰离子与STF-1623的配位实现信号协同放大并显著改善了传统STING激动剂的毒性与治疗窗口。实验表明该纳米体系在体内具备优异的安全性、免疫微环境重塑能力及抗肿瘤效应。研究创新性地将软药物化学与免疫信号靶向策略结合，为高安全性STING免疫调节的开发提供了新方向，但仍需进一步临床验证其长期安全性与疗效。

---

## 116. 芯片上乳腺肿瘤类器官的布里渊显微成像：对微流控诱导快速变形的力学与转录反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41399996)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41399996
**DOI：** 10.1002/advs.202513153

### 第一部分 原文与翻译

**英文原标题：** Brillouin Microscopy of Breast tumor Spheroids On-a-Chip: Mechanical and Transcriptional Responses to Microfluidic-Induced Rapid Deformations.

> **英文摘要：**
> Pioneering a novel integrated photonic platform, Brillouin-Raman Microspectroscopy on-a-Chip is presented, which enables real-time, high resolution analysis of mechano-chemical dynamics in complex 3D biological systems under controlled deformation. This contact-free, all-optical method seamlessly combines Brillouin and Raman microscopy within microfluidic devices, providing a unique correlative approach to overcome current limitations in probing cellular mechanics and biochemical responses in live multicellular models. This innovative platform, when applied to breast tumor spheroids, revealed that rapid, cyclical mechanical deformations, mimicking in vivo stresses, profoundly impacts tumor physiology. These findings demonstrate that controlled deformations trigger rapid nuclear shape changes and robust transcriptional reprogramming, marked by a significant (48-fold) upregulation of the early stress response regulator ATF3. These responses are accompanied by global spheroid stiffening, as precisely quantified by Brillouin spectroscopy. Remarkably, repeated deformation imprints a form of mechanical memory in these collective systems, which culminates in enhanced collagen invasion over 24 h. The label-free methodology sets a new benchmark in biophotonics, unlocking a new class of experiments to probe and modulate physiological and pathological processes with transformative potential for cancer research, broader mechanobiology, and the study of mechanical memory in organoids and other complex 3D models.

> **中文摘要：**
> 本研究开创性地提出了一种新型集成光子平台——芯片上布里渊-拉曼显微光谱技术，可在受控变形条件下实现对复杂三维生物系统中力学-化学动态的实时、高分辨率分析。这一非接触、全光学方法将布里渊显微与拉曼显微无缝整合于微流控装置中，提供了一种独特的相关性研究手段，以克服当前在活体多细胞模型中探测细胞力学及生化反应的局限性。当该创新平台应用于乳腺肿瘤类球体时，结果显示快速、周期性的机械变形（模拟体内应力）会显著影响肿瘤生理。研究发现，受控变形可诱发细胞核形态的快速变化和显著的转录程序重塑，其中早期应激反应调控因子ATF3表现出高达48倍的上调。这些反应伴随类球体整体刚度的增加，并通过布里渊光谱实现精确量化。值得注意的是，重复变形在这些集体系统中留下了一种“力学记忆”，并在24小时内导致更强的胶原侵袭能力。这种无需标记的方法为生物光子学设立了新的基准，开辟了一类全新的实验途径，用以探测和调控生理与病理过程，对癌症研究、更广泛的力学生物学以及类器官及其他复杂三维模型中力学记忆的研究具有变革性潜力。

### 第二部分 AI 大师评价

该研究构建了芯片级布里渊-拉曼显微平台，实现非接触、实时、多维度解析肿瘤类器官的力学与分子反应。通过微流控诱导快速变形，研究发现机械刺激可触发核结构变化、应激转录激活及类球体刚度增强，并产生“力学记忆”现象。该平台创新性地融合光子技术与微流控，推动了力学生物学与癌症机制研究的新方向。虽然机制细节尚需进一步验证，但其无标记、高精度特性展示出广阔的应用潜力。

---

## 117. 上皮性 WNT 分泌驱动发育中胃癌的生态位逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41398956)
**期刊：** Molecular cancer
**PMID：** 41398956
**DOI：** 10.1186/s12943-025-02543-z

### 第一部分 原文与翻译

**英文原标题：** Epithelial WNT secretion drives niche escape of developing gastric cancer.

> **英文摘要：**
> BACKGROUND: WNT signaling plays a key role in maintaining the gastric epithelium and promoting tumorigenesis. However, how gastric tumors achieve WNT niche independence remains unclear, as mutations on APC or CTNNB1-common mechanisms of ligand-independent WNT activation in colorectal cancer-are infrequent in gastric cancer. Understanding how WNT self-sufficiency is acquired in the stomach is therefore critical.
> 
> METHODS: We analyzed mouse gastric organoids harboring oncogenic KRAS with or without RNF43/ZNRF3 (RZ) or CDH1/TP53 (CP) mutations, along with corresponding in vivo mouse models. Niche independence was assessed through growth factor withdrawal, Porcupine and pathway-specific inhibitor treatments, and WNT rescue assays. We performed single-nucleus multiome sequencing (RNA + ATAC) to investigate transcriptional and chromatin dynamics. Findings from mouse models were validated using patient-derived gastric cancer organoids, and pan-cancer cell line datasets were analyzed to evaluate clinical and cross-tissue relevance.
> 
> RESULTS: Gastric fibroblasts secreted canonical WNT2B to maintain the homeostatic gastric epithelium. Upon KRAS activation, epithelial cells were reprogrammed to secrete WNT ligands independently of additional mutations. Single-nucleus multiome analysis revealed that KRAS-driven MAPK signaling opened SMAD2/3-bound enhancers at the WNT7B locus, leading to the emergence of WNT7B-expressing subpopulations. Inhibition of SMAD2/3 phosphorylation suppressed both organoid growth and WNT7B transcription, whereas exogenous WNT restored organoid proliferation. Patient-derived organoids with HER2 amplification, KRAS amplification, or WNT2 copy-number gain exhibited Porcupine inhibitor-sensitive growth, indicating dependence on WNT secretion from the organoids. Analysis of public transcriptomic datasets further demonstrated that the KRAS-MAPK-WNT7B axis is conserved across other cancer types, including lung cancer.
> 
> CONCLUSIONS: Gastric tumors can bypass niche dependence by acquiring KRAS-MAPK-SMAD2/3-driven epithelial WNT secretion. Targeting this axis-through MAPK inhibition, SMAD2/3 blockade, or suppression of WNT secretion-may represent a therapeutic vulnerability in gastric cancer and other KRAS-high malignancies.

> **中文摘要：**
> 背景：WNT 信号在维持胃上皮稳态和促进肿瘤发生中起关键作用。然而，胃肿瘤如何实现对 WNT 生态位的独立性仍不清楚，因为在结直肠癌中常见的配体非依赖性 WNT 激活机制——APC 或 CTNNB1 突变——在胃癌中较为罕见。因此，阐明胃组织如何获得 WNT 自主性的机制具有重要意义。
> 
> 方法：我们分析了携带致癌 KRAS、伴或不伴 RNF43/ZNRF3（RZ）或 CDH1/TP53（CP）突变的小鼠胃类器官，并结合相应的体内小鼠模型。通过生长因子撤除、Porcupine 及通路特异性抑制剂处理，以及 WNT 拯救实验评估其生态位独立性。我们进行了单核多组学测序（RNA + ATAC），以研究转录和染色质动力学。来自小鼠模型的发现通过患者来源的胃癌类器官加以验证，并利用泛癌细胞系数据集评估其临床与跨组织相关性。
> 
> 结果：胃成纤维细胞分泌经典的 WNT2B 以维持胃上皮稳态。KRAS 激活后，上皮细胞被重编程，可独立于其他突变而分泌 WNT 配体。单核多组学分析显示，KRAS 驱动的 MAPK 信号打开了 WNT7B 基因座处由 SMAD2/3 结合的增强子，导致表达 WNT7B 的亚群出现。抑制 SMAD2/3 磷酸化可同时抑制类器官生长及 WNT7B 转录，而外源性 WNT 能恢复类器官增殖。患者来源的类器官中，存在 HER2 扩增、KRAS 扩增或 WNT2 拷贝数增加者对 Porcupine 抑制剂敏感，提示其依赖于类器官自身的 WNT 分泌。公共转录组数据集分析进一步表明，KRAS-MAPK-WNT7B 轴在包括肺癌在内的其他癌种中同样保守存在。
> 
> 结论：胃肿瘤可通过获得由 KRAS-MAPK-SMAD2/3 驱动的上皮性 WNT 分泌机制以摆脱对生态位的依赖。针对该信号轴——通过 MAPK 抑制、SMAD2/3 阻断或 WNT 分泌抑制——可能为胃癌及其他 KRAS 高表达恶性肿瘤提供新的治疗脆弱点。

### 第二部分 AI 大师评价

该研究揭示了胃癌在缺乏常见 WNT 激活突变的情况下，通过 KRAS-MAPK-SMAD2/3 信号轴诱导上皮性 WNT 分泌，从而实现对 WNT 生态位的独立性。作者利用小鼠类器官模型、单核多组学测序及患者来源类器官实验，系统解析了信号重编程机制。研究还发现，该 KRAS-MAPK-WNT7B 轴在多种癌症中具有保守性，提示临床广泛意义。该工作创新性地揭示了肿瘤自给自足的信号机制，但在转化为临床治疗策略方面仍需进一步验证。

---

## 118. 伴发的PIK3CA突变通过炎症信号在EGFR突变型肺癌中促进恶病质发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41398174)
**期刊：** Nature communications
**PMID：** 41398174
**DOI：** 10.1038/s41467-025-67345-9

### 第一部分 原文与翻译

**英文原标题：** Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer.

> **英文摘要：**
> PIK3CA mutation is frequently concurrent with known oncogenic drivers such as EGFR mutation in lung cancer, raising an interesting question about its real function. Cachexia is a systemic disease arising from tumor-organ crosstalk, significantly contributing to cancer-related mortality. Through integrative study of genetically engineered mouse models (GEMMs) and clinical data, we find concurrent PIK3CA mutant preferentially drives cachexia in EGFR-mutant lung cancer, promoting malignant progression instead of cancer initiation. PIK3CA mutant-mediated cachexia can be overcome by osimertinib (Osi) treatment in Osi-sensitive GEMM. In contrast, chemotherapy, routinely used in clinic for those relapsed from Osi therapy, fails to ameliorate cachexia in Osi-resistant GEMM despite notable tumor suppression. PIK3CA mutant-driven cachexia is mediated through NF-κB activation and can be dampened by combined aspirin treatment. This work provides insights into PIK3CA mutant biological function and mechanisms behind its clinical impacts, and proposes a potential strategy for clinical management.

> **中文摘要：**
> PIK3CA突变在肺癌中常与已知的致癌驱动基因（如EGFR突变）同时存在，引发了其真实生物学功能的有趣问题。恶病质是一种源于肿瘤与器官间相互作用的全身性疾病，对癌症相关死亡率有显著贡献。通过对基因工程小鼠模型（GEMMs）和临床数据的综合研究，我们发现，伴发的PIK3CA突变在EGFR突变型肺癌中倾向于驱动恶病质的发生，促进恶性进展而非肿瘤起始。 在奥希替尼（Osi）敏感的GEMM中，奥希替尼治疗可以克服由PIK3CA突变介导的恶病质。 相反，对于奥希替尼治疗失败后接受常规化疗的病例，虽然化疗能显著抑制肿瘤，但在Osi耐药GEMM模型中并不能改善恶病质。 PIK3CA突变驱动的恶病质是通过NF-κB激活介导的，并可通过联合使用阿司匹林治疗而减弱。 本研究揭示了PIK3CA突变的生物学功能及其临床影响背后的机制，并提出了一种潜在的临床管理策略。

### 第二部分 AI 大师评价

本研究聚焦于PIK3CA与EGFR突变肺癌共存时的生物学效应，揭示了其通过炎症信号通路诱导恶病质的新机制。作者利用遗传工程小鼠模型和临床数据综合分析，明确了PIK3CA突变驱动恶病质的过程及其NF-κB依赖性。研究还发现，奥希替尼可在敏感模型中抑制该过程，而耐药状态下常规化疗无效，联合阿司匹林有望缓解相关症状。该工作深化了对癌症恶病质分子基础的理解，并为临床综合干预提供了新方向，但仍需进一步验证其在人类患者中的可行性与长期疗效。

---

## 119. 长链非编码RNA CISTR-ACT 通过调控 FOSL2 来调节人类和小鼠的细胞大小

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41397992)
**期刊：** Nature communications
**PMID：** 41397992
**DOI：** 10.1038/s41467-025-67591-x

### 第一部分 原文与翻译

**英文原标题：** LncRNA CISTR-ACT regulates cell size in human and mouse by guiding FOSL2.

> **英文摘要：**
> Organisms regulate cell size and shape to function efficiently. Aberrant cell morphogenesis is commonly associated with disease, yet gene-regulatory mechanisms remain unknown. CISTR-ACT was the first lncRNA involved in inter-chromosomal proximities and Mendelian disease, and it is associated with mean corpuscular volume (red blood cell size). Here, functional dissection of CISTR-ACT's DNA- and RNA-encoded mechanisms by in vitro and in vivo perturbations reveals that CISTR-ACT regulates cell size across cell types and species. CISTR-ACT's locus is embedded in a stable inter-chromosomal environment which contains cell size genes that are regulated by CISTR-ACT in trans. CISTR-ACT's RNA also has function and directly interacts with transcription factor FOSL2 to guide its regulation of cell morphogenesis and cell-cell adhesion genes. In the absence of CISTR-ACT, the FOSL2-chromatin binding is perturbed. Our study exemplifies how a functionally conserved lncRNA regulates cell size with multiple modes of action and ultimately contributes to clinically relevant phenotypes.

> **中文摘要：**
> 生物体通过调控细胞的大小和形状以实现高效功能。异常的细胞形态发生常与疾病相关，但基因调控机制仍不清楚。CISTR-ACT 是首个被发现参与染色体间近邻作用及孟德尔遗传病的长链非编码 RNA，并且与平均红细胞体积（红细胞大小）相关。在此，我们通过体内和体外扰动实验对 CISTR-ACT 的 DNA 编码与 RNA 编码机制进行了功能解析，结果表明 CISTR-ACT 可在不同细胞类型及物种间调节细胞大小。CISTR-ACT 的基因位点嵌入在一个稳定的染色体间环境中，该环境包含多个由 CISTR-ACT 以反式方式调控的细胞大小相关基因。CISTR-ACT 的 RNA 也具有功能，并可直接与转录因子 FOSL2 相互作用，以引导其对细胞形态发生及细胞间黏附基因的调控。在缺失 CISTR-ACT 的情况下，FOSL2 与染色质的结合受到扰动。我们的研究揭示了一种功能保守的 lncRNA 如何通过多种作用模式调控细胞大小，并最终影响临床相关表型。

### 第二部分 AI 大师评价

该研究揭示了长链非编码RNA CISTR-ACT 在细胞大小调控中的跨物种、跨细胞类型功能。通过结合体内外扰动实验，作者阐明了 CISTR-ACT 同时通过 DNA 编码位点和 RNA 分子层面参与调控，特别是其与转录因子 FOSL2 的直接相互作用机制。研究展示了 lncRNA 在染色质三维结构与基因表达网络间的协调作用，为理解细胞形态与疾病表型的分子基础提供了新视角。尽管尚需进一步解析其在不同组织及病理状态下的动态调控，但该工作具有重要的机制与转化研究价值。

---

## 120. 卵巢癌向人类网膜的转移破坏器官稳态并诱导根本性的组织重编程

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41397972)
**期刊：** Nature communications
**PMID：** 41397972
**DOI：** 10.1038/s41467-025-67557-z

### 第一部分 原文与翻译

**英文原标题：** Ovarian cancer metastasis to the human omentum disrupts organ homeostasis and induces fundamental tissue reprogramming.

> **英文摘要：**
> The omentum, a visceral adipose tissue with critical metabolic, immunological, and stem cell functions is the preferred site for ovarian cancer metastasis. However, its role in maintaining homeostasis and its responses to metastatic colonization remain incompletely understood. Using single-cell transcriptomics, we profile different anatomical regions of the omentum in patients with benign conditions and metastasis. We catalog the benign omentum and observe a stable cell type composition and a preserved stem and progenitor niche. Upon metastatic colonization, we report on increased immune heterogeneity and a concomitant reduction of mesothelial and progenitor cells. The lesser omentum, which is not routinely removed during surgical debulking, is identified as a premetastatic niche characterized by neutrophil infiltration, extracellular trap formation, and the presence of micrometastases. At established metastatic sites, resident cells exhibit cancer-associated phenotypes with regulatory, anti-adipogenic, and immunosuppressive properties. Cellular reprogramming across the omentum is associated with signaling profiles of tumor cells, suggesting potential influences on both proximal and distal tissue regions. This cell atlas illuminates the cellular and molecular determinants of organ homeostasis and reveals a high degree of plasticity and cellular reprogramming promoted by cancer colonization.

> **中文摘要：**
> 网膜是一种具有关键代谢、免疫和干细胞功能的内脏脂肪组织，是卵巢癌转移的首选部位。然而，它在维持稳态及对转移性定植的响应方面仍未得到完全了解。通过单细胞转录组学，我们分析了患有良性疾病和转移的患者网膜不同解剖区域的细胞特征。我们建立了良性网膜的细胞目录，观察到其细胞类型组成稳定，并保留了干细胞和祖细胞生态位。在转移性定植后，我们报告免疫异质性增加，同时间皮细胞和祖细胞数量减少。通常在减瘤手术过程中不会常规切除的小网膜，被确定为一种前转移生态位，其特征包括中性粒细胞浸润、细胞外陷阱形成以及微转移灶的存在。在已建立的转移病灶处，驻留细胞表现出与癌症相关的表型，具有调节性、抗脂生成及免抑制特征。整个网膜的细胞重编程与肿瘤细胞的信号传导模式相关，提示其可能同时影响近端和远端组织区域。该细胞图谱揭示了器官稳态的细胞与分子决定因素，并显示了由癌症定殖促进的高度可塑性与细胞重编程。

### 第二部分 AI 大师评价

本研究利用单细胞转录组学系统解析了卵巢癌转移对人类网膜的细胞组成与功能稳态的影响。研究发现，癌细胞定殖导致网膜免疫细胞异质性显著增加，同时干细胞及间皮细胞显著减少。小网膜被识别为前转移生态位，提示转移前微环境重塑的重要性。该工作揭示了癌症驱动的全器官细胞重编程机制，为理解卵巢癌器官特异性转移的病理基础提供了新见解。其局限在于样本量和空间分辨深度，未来研究可结合空间组学进一步验证发现。

---

## 121. 利用 PASTA 精确推补空间转录组中通路特异性基因表达

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41397970)
**期刊：** Nature communications
**PMID：** 41397970
**DOI：** 10.1038/s41467-025-67421-0

### 第一部分 原文与翻译

**英文原标题：** Accurate imputation of pathway-specific gene expression in spatial transcriptomics with PASTA.

> **英文摘要：**
> Mapping the entire transcriptome at single-cell resolution under its natural spatial context is essential for investigating the oncogenesis and progression of diseases. The recently emerged targeted in-situ technologies retain the spatial organization of cells at high resolution, although they remain limited in the number of genes that can be simultaneously measured. To overcome this obstacle, numerous computational methods have been developed to predict unmeasured gene expression in spatial transcriptomics data by leveraging scRNA-seq data. Most of these methods focus on the expression of individual genes and usually generate highly variable predictions. In this study, we introduce PASTA (PAthway-oriented Spatial gene impuTAtion), a spatial pathway expression imputation method that leverages cell type and spatial proximity to enhance prediction accuracy. PASTA assumes that nearby cells and cells of the same type exhibit similar expression patterns, along with pathway information integrated into the imputation process, which improves prediction robustness and enhances biological relevance in spatial transcriptomics data. We demonstrate PASTA's superior performance across both simulated and real-world datasets, highlighting its ability to impute pathway gene expression with improved stability and biological significance.

> **中文摘要：**
> 在自然空间背景下以单细胞分辨率绘制整个转录组，对于研究肿瘤发生和疾病进展至关重要。近期出现的靶向原位技术能够在高分辨率下保留细胞的空间组织结构，但同时可测量的基因数量仍然有限。为克服这一限制，已开发出多种计算方法，利用单细胞 RNA 测序（scRNA-seq）数据预测空间转录组数据中未测量的基因表达。这些方法大多关注单个基因的表达，往往导致预测结果高度可变。在本研究中，我们提出了 PASTA（PAthway-oriented Spatial gene impuTAtion），一种用于空间通路表达推补的方法，该方法利用细胞类型和空间邻近性以提高预测准确性。PASTA 假设彼此邻近的细胞及相同类型的细胞具有相似的表达模式，并在推补过程中整合通路信息，从而提升预测的稳健性并增强空间转录组数据的生物学相关性。我们在模拟和真实数据集中均展示了 PASTA 的优越性能，突显其在更高稳定性和生物学意义下推补通路基因表达的能力。

### 第二部分 AI 大师评价

该研究旨在解决空间转录组测序中基因检测数量受限的问题，提出了结合细胞类型、空间邻近性及通路信息的 PASTA 方法。与传统单基因预测方式相比，PASTA 引入通路层面的表达推补策略，提高了预测的稳健性和生物学相关性。作者通过多种数据验证了其在模拟和真实场景中的优越性能，表明该方法能更准确地恢复空间通路表达格局。研究创新性在于将通路信息融入空间转录组推补框架，但实际应用仍可能受限于通路注释质量与计算复杂度。

---

## 122. 单剂量HPV疫苗与双剂量的非劣效性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41337735)
**期刊：** The New England journal of medicine
**PMID：** 41337735
**DOI：** 10.1056/NEJMoa2506765

### 第一部分 原文与翻译

**英文原标题：** Noninferiority of One HPV Vaccine Dose to Two Doses.

> **英文摘要：**
> BACKGROUND: Multidose human papillomavirus (HPV) vaccination is efficacious, yet the vaccine has been underused globally. Emerging data suggest that a single dose may provide protection. Whether a single dose of HPV vaccine would provide similar protection to two doses is uncertain.
> 
> METHODS: In this trial, we assessed whether one dose of an HPV vaccine was noninferior to two doses. Girls 12 to 16 years of age were randomly assigned, in a 1:1:1:1 ratio, to receive one or two doses of a bivalent HPV vaccine or one or two doses of a nonavalent HPV vaccine. The primary end point was new HPV type 16 or 18 infection occurring from month 12 to month 60 and persisting for at least 6 months. The prespecified noninferiority margin was 1.25 infections per 100 participants. We also assessed vaccine effectiveness by comparing HPV16 or HPV18 infection among the trial participants with that among girls and women enrolled in a nonrandomized survey.
> 
> RESULTS: A total of 20,330 participants were enrolled and underwent randomization, and 3005 unvaccinated participants were enrolled in the survey. The noninferiority analysis showed that one vaccine dose was noninferior to two doses in preventing HPV16 or HPV18 infection. The rate difference between one and two doses of the bivalent vaccine was -0.13 infections per 100 participants (95% confidence interval [CI], -0.45 to 0.15; P<0.001 for noninferiority), and the difference between one and two doses of the nonavalent vaccine was 0.21 infections per 100 participants (95% CI, -0.09 to 0.51; P<0.001 for noninferiority). The vaccine effectiveness was at least 97% in each of the four trial groups. No safety concerns were identified.
> 
> CONCLUSIONS: One dose of either a bivalent or nonavalent HPV vaccine provided protection against HPV16 or HPV18 infection and was not inferior to two doses. (Funded by the National Cancer Institute and others; ESCUDDO ClinicalTrials.gov number, NCT03180034.).

> **中文摘要：**
> 背景：多剂量人乳头瘤病毒（HPV）疫苗接种已被证明有效，但在全球范围内使用不足。新兴数据提示，单剂量可能即可产生保护作用。单剂量HPV疫苗能否提供与双剂量相当的保护尚不确定。
> 
> 方法：在本试验中，我们评估单剂量HPV疫苗是否不劣于双剂量。12至16岁的女孩以1:1:1:1比例随机分配，分别接种双价HPV疫苗的一剂或两剂，或九价HPV疫苗的一剂或两剂。主要终点为第12个月至第60个月期间新发的HPV 16型或18型感染，并且持续至少6个月。预设的非劣效界限为每100名参与者1.25例感染。我们还通过比较试验参与者与一项非随机调查中女孩和女性的HPV16或HPV18感染率来评估疫苗有效性。
> 
> 结果：共有20,330名参与者入组并随机化，另有3,005名未接种疫苗的参与者入选调查。非劣效性分析显示，在预防HPV16或HPV18感染方面，单剂量不劣于双剂量。双价疫苗单剂与双剂的感染率差异为每100名参与者-0.13例（95%置信区间[CI]，-0.45至0.15；非劣效性检验P<0.001），九价疫苗单剂与双剂的差异为0.21例（95% CI，-0.09至0.51；P<0.001）。四个试验组的疫苗有效性均在97%以上。未发现安全性问题。
> 
> 结论：单剂双价或九价HPV疫苗均可对HPV16和HPV18感染提供保护，且不劣于双剂量。（本研究由美国国家癌症研究所及其他机构资助；ESCUDDO试验，ClinicalTrials.gov编号NCT03180034。）

### 第二部分 AI 大师评价

本研究通过大规模随机对照试验验证了单剂量HPV疫苗在预防HPV16及18型感染方面的非劣效性，结果显示单剂接种的保护效果与双剂相当，疫苗有效率均超过97%，且未发现安全隐患。这一发现对全球疫苗接种策略尤其是资源有限地区的实施具有重要意义。研究的创新点在于以严格的非劣效性设计为基础，直接比较不同剂量的效果。局限性可能包括后续长期保护效力及不同人群差异性仍需进一步观察。

---

## 123. 砷暴露减少与慢性疾病死亡率的关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41247717)
**期刊：** JAMA
**PMID：** 41247717
**DOI：** 10.1001/jama.2025.19161

### 第一部分 原文与翻译

**英文原标题：** Arsenic Exposure Reduction and Chronic Disease Mortality.

> **英文摘要：**
> IMPORTANCE: Chronic exposure to arsenic in drinking water has been associated with increased chronic disease mortality. However, there is limited evidence on associations between reduced exposure and mortality risk.
> 
> OBJECTIVE: To examine whether reductions in arsenic exposure, measured using urinary arsenic levels, are associated with lower mortality from chronic diseases, including cancer and cardiovascular disease (CVD).
> 
> DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort of 11 746 adults was enrolled between 2000 and 2002 in Araihazar, Bangladesh, with levels of well-water arsenic ranging from less than 1 µg/L to 864 µg/L (mean, 102 µg/L), exceeding the Bangladesh standard of 50 µg/L. Arsenic levels declined over time as a result of community mitigation. Mortality was tracked through 2022. Analyses included 10 977 participants with calculable changes in urinary arsenic levels.
> 
> EXPOSURES: Urinary arsenic levels were measured up to 5 times per participant through 2018. Participants were categorized based on changes in urinary arsenic levels.
> 
> MAIN OUTCOMES AND MEASURES: Adjusted hazard ratios (aHRs) and 95% CIs for mortality from chronic diseases, including cancer and CVD.
> 
> RESULTS: Among 10 977 participants (57% female; mean age, 37.0 [SD, 10.1] years), mean urinary arsenic levels declined from 283 (SD, 314) to 132 (SD, 161) µg/g creatinine from 2000 to 2018. Each IQR decrease in urinary arsenic (197 µg/g creatinine) was associated with 22% lower chronic disease mortality (aHR, 0.78 [95% CI, 0.75-0.82]), 20% lower cancer mortality (aHR, 0.80 [95% CI, 0.73-0.87]), and 23% lower CVD mortality (aHR, 0.77 [95% CI, 0.73-0.81]). Time-varying Cox and restricted cubic spline analyses showed larger reductions were associated with lower mortality, while increases were linked to higher risk. Compared with participants with consistently high urinary arsenic levels (above the baseline median of 199 µg/g creatinine [n = 1757]), those whose levels declined below the median (n = 3757) had lower mortality from chronic diseases (aHR, 0.46 [95% CI, 0.39-0.53]), including cancer (aHR, 0.51 [95% CI, 0.35-0.73]) and CVD (aHR, 0.43 [95% CI, 0.34-0.53]), similar to those consistently below the median (n = 4959) (aHR, 0.43-0.49). Findings were similar in propensity score-matched analyses.
> 
> CONCLUSIONS AND RELEVANCE: These findings support an association between reduced arsenic exposure and improved health outcomes in populations exposed to contaminated drinking water.

> **中文摘要：**
> 重要性：长期饮用水中砷暴露与慢性疾病死亡率升高相关。然而，关于暴露降低与死亡风险之间关系的证据有限。
> 
> 研究目的：探讨以尿砷水平衡量的砷暴露减少是否与慢性疾病（包括癌症和心血管疾病［CVD］）死亡率降低相关。
> 
> 研究设计、场所与参与者：在孟加拉国阿赖哈扎尔地区于2000年至2002年间纳入11,746名成年人组成前瞻性队列，井水砷浓度范围从<1 µg/L至864 µg/L（平均102 µg/L），高于孟加拉国标准50 µg/L。因社区干预，砷水平随时间下降。研究随访至2022年，分析纳入能计算尿砷变化的10,977名参与者。
> 
> 暴露因素：截至2018年，每名参与者最多测定5次尿砷水平。根据尿砷水平变化对参与者进行分类。
> 
> 主要结局与测量指标：调整后的慢性病死亡（包括癌症及CVD）风险比（aHR）及其95%置信区间（CI）。
> 
> 结果：在10,977名参与者中（57%为女性；平均年龄37.0岁［标准差10.1］），2000年至2018年尿砷平均水平由283（标准差314）降至132（标准差161）µg/g肌酐。尿砷每下降一个四分位距（197 µg/g肌酐），慢性疾病死亡率降低22%（aHR 0.78［95% CI, 0.75–0.82］），癌症死亡率降低20%（aHR 0.80［95% CI, 0.73–0.87］），CVD死亡率降低23%（aHR 0.77［95% CI, 0.73–0.81］）。时变Cox回归及受限三次样条分析显示，较大幅度的下降与更低死亡率相关，而水平升高与更高风险相关。与持续高尿砷组（基线中位数199 µg/g肌酐以上，n=1757）相比，尿砷水平降至中位数以下者（n=3757）慢性疾病死亡率更低（aHR 0.46［95% CI, 0.39–0.53］），包括癌症（aHR 0.51［95% CI, 0.35–0.73］）及CVD（aHR 0.43［95% CI, 0.34–0.53］），与始终维持较低水平者（n=4959；aHR 0.43–0.49）相似。倾向评分匹配分析结果一致。
> 
> 结论与意义：本研究结果支持在受砷污染饮水暴露人群中，减少砷暴露与改善健康结局之间存在关联。

### 第二部分 AI 大师评价

本研究通过孟加拉国长期队列，系统评估了饮水中砷暴露水平下降与慢性疾病死亡风险之间的关联。利用连续尿砷测量和时变Cox模型，研究发现砷暴露降低显著减少癌症和心血管死亡率，且存在剂量反应关系。结果为公共卫生干预减少饮水砷污染的长远健康获益提供了强有力证据。研究优势在于长期随访与高质量暴露评估，但仍可能受未测混杂因素影响。

---

## 124. GenBioPro诉Raynes案后各州对米非司酮的监管

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41143830)
**期刊：** JAMA
**PMID：** 41143830
**DOI：** 10.1001/jama.2025.19752

### 第一部分 原文与翻译

**英文原标题：** State Mifepristone Regulation Following GenBioPro v Raynes.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

这篇刊登于《JAMA》的文章聚焦于GenBioPro诉Raynes案件之后，美国各州对米非司酮（药物流产药物）的监管变化。虽然本文暂无摘要，但根据标题可推测研究探讨了该司法判决对州级生殖健康法规的影响。主题具有高度的政策与公共卫生意义，有助于理解法律裁决与药品可及性之间的互动。然而，若缺乏实证数据或比较分析，其结论的普适性可能受限。

---

## 125. ctDNA引导的肌层浸润性膀胱癌辅助用阿替利珠单抗治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41124204)
**期刊：** The New England journal of medicine
**PMID：** 41124204
**DOI：** 10.1056/NEJMoa2511885

### 第一部分 原文与翻译

**英文原标题：** ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

> **英文摘要：**
> BACKGROUND: Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)-based detection of molecular residual disease may identify patients at high risk for recurrence after cystectomy who can benefit from adjuvant immunotherapy, thus sparing patients at lower risk from unnecessary treatment burden.
> 
> METHODS: In a phase 3, double-blind, randomized trial, we used serial ctDNA testing to monitor (for up to 1 year) patients with muscle-invasive bladder cancer and no radiographic evidence of disease after surgery. Eligible patients who tested ctDNA-positive during surveillance were randomly assigned in a 2:1 ratio to receive intravenous atezolizumab or placebo every 4 weeks for up to 1 year. The primary end point was investigator-assessed disease-free survival. Overall survival was a secondary end point that was assessed in a hierarchical fashion to control for alpha. Patients who persistently tested ctDNA-negative did not receive atezolizumab or placebo.
> 
> RESULTS: A total of 761 patients were enrolled; 250 eligible patients who tested ctDNA-positive underwent randomization (167 to the atezolizumab group and 83 to the placebo group). The median disease-free survival was 9.9 months with atezolizumab, as compared with 4.8 months with placebo (hazard ratio for first event of disease recurrence or death, 0.64; 95% confidence interval [CI], 0.47 to 0.87; P = 0.005). The median overall survival was 32.8 months with atezolizumab, as compared with 21.1 months with placebo (hazard ratio for death, 0.59; 95% CI, 0.39 to 0.90; P = 0.01). A total of 28% of the patients who received atezolizumab and 22% of those who received placebo had adverse events of grade 3 or 4 (related to atezolizumab or placebo in 7% vs. 4%); 3% and 2% of the patients, respectively, had fatal adverse events (related to atezolizumab or placebo in 2% vs. none). Among 357 patients with persistent ctDNA-negative status, disease-free survival was 95% at the end of the 1-year monitoring period and 88% at 2 years.
> 
> CONCLUSIONS: Among patients with muscle-invasive bladder cancer, ctDNA-guided adjuvant therapy with atezolizumab led to significantly longer disease-free survival and overall survival than placebo. (Funded by F. Hoffmann-La Roche; IMvigor011 ClinicalTrials.gov number, NCT04660344.).

> **中文摘要：**
> 背景：肌层浸润性膀胱癌患者在行膀胱切除术后的预后差异较大。基于循环肿瘤DNA（ctDNA）的分子残留病灶检测可以识别出术后复发高风险患者，这些患者可从辅助免疫治疗中获益，从而避免低风险患者承担不必要的治疗负担。
> 
> 方法：在一项Ⅲ期、双盲、随机对照试验中，我们使用连续ctDNA检测对术后无影像学疾病证据的肌层浸润性膀胱癌患者进行最长1年的监测。监测期间ctDNA检测呈阳性的合格患者以2:1的比例随机分配，接受静脉注射阿替利珠单抗或安慰剂，每4周一次，最长1年。主要终点为研究者评估的无病生存期。总生存期为次要终点，采用层级方式控制α错误。持续ctDNA阴性的患者未接受阿替利珠单抗或安慰剂治疗。
> 
> 结果：共入组761例患者；其中250例ctDNA阳性患者被随机分配（阿替利珠单抗组167例，安慰剂组83例）。阿替利珠单抗组的中位无病生存期为9.9个月，安慰剂组为4.8个月（首次疾病复发或死亡的风险比为0.64；95%置信区间[CI]，0.47–0.87；P＝0.005）。阿替利珠单抗组的中位总生存期为32.8个月，而安慰剂组为21.1个月（死亡风险比为0.59；95% CI，0.39–0.90；P＝0.01）。分别有28%的阿替利珠单抗组患者和22%的安慰剂组患者出现3或4级不良事件（与研究药物相关者分别为7%与4%）；致死性不良事件发生率分别为3%与2%（药物相关者为2%与0%）。在357例持续ctDNA阴性患者中，监测1年结束时无病生存率为95%，2年时为88%。
> 
> 结论：在肌层浸润性膀胱癌患者中，ctDNA引导的阿替利珠单抗辅助治疗较安慰剂显著延长了无病生存期和总生存期。（由F. Hoffmann-La Roche资助；IMvigor011试验，ClinicalTrials.gov编号NCT04660344。）

### 第二部分 AI 大师评价

本研究通过Ⅲ期随机、双盲试验验证了ctDNA在术后分层指导辅助免疫治疗中的应用价值。研究显示，对于ctDNA阳性的肌层浸润性膀胱癌患者，阿替利珠单抗可显著改善无病生存期和总生存期，证明ctDNA可作为分子残留病灶的精准生物标志物。该策略有助于将免疫治疗精准用于复发高风险人群，减少低风险患者不必要的治疗负担。尽管结果令人鼓舞，但长期疗效、安全性及成本效应仍需后续研究进一步验证。

---

速递结束，祝您工作愉快！